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Insulin resistance is the main risk factor for the development of type-2 diabetes (T2D). It is described 
as perturbed insulin signalling in the peripheral target tissues (which include the liver, skeletal muscle 
and adipose tissue), resulting in deficient insulin action. In the liver, this leads to the inability of insulin 
to regulate glucose metabolism by decreasing hepatic glucose production (HGP), and thus decrease 
blood glucose concentrations, aiding in the progression to T2D. Numerous factors contribute to the 
development of insulin resistance, such as stress and obesity, however inflammation is known to play 
a key role. An increased inflammatory state is associated with enhanced production of acute phase 
proteins (APPs). Increased serum levels of APPs, such as plasminogen activator inhibitor-1 (PAI-1), 
serum amyloid A (SAA), and C-reactive protein (CRP) have additionally been associated with T2D and 
are commonly used as biological markers for this disease state. However, whether these APPs are more 
than just biological markers for T2D and could contribute to the development of insulin resistance has 
not yet been established. Although some studies support the possibility that PAI-1, SAA, and CRP 
impair insulin signalling, their role in the development of hepatic insulin resistance requires 
investigation. The aim of this study was thus to investigate the effect of PAI-1, SAA, and CRP on 
hepatic insulin signalling by investigating key proteins in the insulin signalling pathway which, 
comprise the insulin receptor (IR), insulin receptor substrate-2 (IRS-2), and the central protein, Akt, in 
a murine hepatoma and human liver carcinoma cell line, BWTG3 and HepG2, respectively. 
Additionally, HGP was investigated as well as the transcriptional regulation of G6Pase and PEPCK, 
two key enzymes involved in gluconeogenesis, which is an important process contributing to HGP. The 
overall results in this study showed that all three APPs impair hepatic insulin signalling in both liver 
cell models although to different degrees depending on the dose and length of exposure. Specifically, 
CRP was most effective in modulating the activation of key proteins (the IR and Akt) in the insulin 
signalling pathway, which subsequently correlated to its ability to increase G6Pase and PEPCK mRNA 
levels as well as HGP. The length of exposure played an integral role in this study as pro-longed 
exposure to PAI-1 and CRP enhanced their inhibitory effect on insulin signalling. This was not shown 
for SAA, which rather displayed dose-dependent effects. As far as could be determined, the results in 
this study is the first to support the role of PAI-1, SAA, and CRP in the development of hepatic insulin 
resistance as well as to directly compare the effects of these three APPs in the same experimental model. 
Although the molecular mechanism of these observed effects require further investigations, the findings 




Insulienweerstandigheid is die hoof-risikofaktor vir die ontwikkeling van tipe-2 diabetes (T2D). Dit 
word beskryf as versteurde insulien-seintransduksie in die perifere teikenweefsel (waaronder die lewer, 
skeletale spiere en adipose weefsel), wat tot ’n tekort aan insulien-aksie lei. In die lewer lei dit tot die 
onvermoë van insulien om glukose-metabolisme te reguleer deur die hepatiese glukose-produksie 
(HGP) te verminder, en gevolglik bloedglukosekonsentrasie verminder, wat die progressie van T2D 
aanhelp. Talle faktore dra by tot die ontwikkeling van insulienweerstandigheid, soos stres en vetsug, 
maar dit is bekend dat inflammasie ’n sleutelrol speel. ’n Verhoogde inflammatoriese staat word verbind 
met versterkte produksie van akute fase-proteïene (APP’s). Verhoogde serumvlakke van APP’s, soos 
plasminogeenaktivator-remmer-1 (PAI-1), serum amiloïed A (SAA), en C-reaktiewe proteïene (CRP) 
is bykomend ook geassosieer met T2D en meer algemeen gebruik as biologiese merkers vir hierdie 
siektetoestand. Maar of hierdie APP’s meer is as slegs biologiese merkers vir T2D en kan bydra tot die 
ontwikkeling van insulienweerstandigheid is nog nie bevind nie. Al het sommige studies die 
moontlikheid ondersteun dat PAI-1, SAA en CRP insulien-seintransduksie benadeel, vereis hul rol in 
die ontwikkeling van hepatiese insulienweerstandigheid verdere ondersoek. Die doel van hierdie studie 
was dus om die effek van PAI-1, SAA en CRP op hepatiese insulien-seintransduksie te ondersoek deur 
ondersoek in te stel na die sleutelproteïene in die insulien-seintransduksie-weg, wat bestaan uit die 
insulienreseptor (IR), insulienreseptor subtraat-2 (IRS-2), en die sentrale proteïen, Akt, in ’n muriene 
hepatoom en menslik lewer karsinoom-sellyn, onderskeidelik BWTG3 en HepG2. Daarby is HGP 
ondersoek, asook die transkripsionele regulering van G6Pase en PEPCK, twee sleutel-ensieme betrokke 
in glukoneogenese, wat ’n belangrike proses is wat bydra tot HGP. Die algehele resultate in hierdie 
studie wys dat al drie APP’s benadeel hepatiese insulien-seintransduksie in albei lewerselmodelle, maar 
tot ’n ander graad afhangend van die dosis en lengte van blootstelling. Spesifiek CRP was die mees 
effektiewe in die modulering van die aktivering van sleutelproteïene (die IR en Akt) in die insulien-
seintransduksie-weg, wat gevolglik gekorreleer het met sy vermoë om G6Pase en PEPCK mRNA-
vlakke te verhoog, asook HGP. Die lengte van blootstelling speel ’n integrale rol in hierdie studie omdat 
langdurige blootstelling aan PAI-1 en CRP hul inhiberende effek van insulien-seintransduksie te 
vergroot. Dit is nie vir SAA getoon nie, wat aan die ander kant dosis-afhanklike effekte getoon het. So 
ver vasgestel kon word, is die resultate in hierdie studie die eerste om die rol van PAI-1, SAA en CRP 
te ondersteun in die ontwikkeling van hepatiese insulienweerstandigheid, asook om direk die effekte 
van hierdie drie APP’s te vergelyk in dieselfde eksperimentele model. Al verg die molekulêre 
meganismes van hierdie waargeneemde effekte verdere ondersoek, bied die bevindings in hierdie studie 
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Diabetes Mellitus (DM), a common disease in western society, is described as a metabolic disorder, 
characterized by a dysfunction in glucose metabolism, which is normally regulated by insulin secreted 
from pancreatic β-cells (1). DM can be classified into two categories, namely type-I (T1D) and type-II 
diabetes (T2D). T1D, also referred to as “insulin-dependent DM”, occurs when the pancreas fails to 
produce sufficient insulin leading to insulin deficiency (2). This type accounts for 5-10% of individuals 
with DM (3). Type-II diabetes (T2D), however, which is also known as “non-insulin dependent DM”, 
is the most common type accounting for more than 90% of patients with DM (2, 4), with resistance to 
the effects of insulin the main causative factor, which sets the stage for the development of the disease. 
Insulin resistance is defined as the inability of peripheral target tissues (which includes the liver, skeletal 
muscle, and adipose tissue) to respond normally to insulin, resulting in chronic increases in blood 
glucose levels (hyperglycaemia), a key characteristic of T2D (4, 5). Despite increasing knowledge 
concerning the risk factors for T2D, the incidence and prevalence of the disease continues to rise 
globally (2, 4, 6). In 2017, it was estimated by the International Diabetes Federation that 451 million 
people live with DM worldwide (2, 4) and this number is expected to increase to 693 million by the 
year 2045 (7). Additionally, the burden of non-communicable diseases, which include T2D and 
cardiovascular disease, continues to rise in South Africa (SA), in addition to being one of the leading 
causes of death in SA adults (8, 9). Therefore, a better understanding of the pathophysiology of the 
disease is of great importance. Although current treatments for T2D, including drugs such as metformin 
and thiazolidinediones (TZDs), which aim to decrease blood glucose levels and increase insulin 
sensitivity, are often effective, these drugs are linked to gastrointestinal side effects and increased 
cardiovascular complications, respectively (10, 11). Therefore, novel therapeutic approaches are 
warranted.  
As insulin resistance is the main risk factor for T2D, an understanding of the pathophysiology of an 
insulin-resistant state would be beneficial. The molecular mechanism of insulin resistance is not well 
understood, but involves the insulin signalling pathway, an integrated network of signalling proteins 
and secondary messengers. A defect or disruption to any of the signalling proteins or production of 
secondary messengers results in deficient insulin action, which sets the scene for the development of 
T2D (12, 13). Insulin mainly targets the liver, adipose tissue, and skeletal muscle, all of which can 
become resistant to insulin. The liver especially is of interest as not only is it the first organ reached by 
secreted insulin, it is also a major contributor to hyperglycaemia observed in T2D (10). Furthermore, it 
has been reported that insulin resistance is initiated firstly in the liver before the skeletal muscle and 
adipose tissue is affected (14, 15), establishing the liver as an important gate-keeper to the onset of 
insulin resistance and T2D (16). Several factors are known to contribute to insulin resistance and affect 




glucocorticoids), and chronic inflammation (17–19). Approximately 60% of patients with T2D are 
obese (2) and one of the possible mechanisms linking obesity to the development of T2D, is increased 
inflammation, amongst other factors (19–21). Additionally, it has been shown that pro-inflammatory 
cytokines such as tumour necrosis-alpha (TNF-α) and interleukin-6 (IL-6), which are increased in 
response to obesity, induce insulin resistance at a molecular level by modulating the insulin signalling 
pathway (22–25). These pro-inflammatory cytokines together with glucocorticoids (GCs) induce the 
expression of several acute phase proteins (APPs), including plasminogen activator inhibitor-1 (PAI-
1), serum amyloid A (SAA), and C-reactive protein (CRP) (26–33). These APPs are used routinely as 
biological markers for T2D as their levels are significantly increased in the serum of T2D patients (34–
41). However, whether these APPs could lead to the development of T2D remains to be elucidated. 
Some studies have shown an association between PAI-1, SAA, and CRP in the development of insulin 
resistance, therefore it is possible that these APPs may be the correlative link between inflammation 
and insulin resistance, however, evidence supporting this hypothesis is limited and requires more 
attention.   
The aim of this review is to highlight the importance of the insulin signalling pathway and insulin action 
in the liver, which regulates glucose metabolism. In addition, the molecular mechanism of insulin 
resistance and the development thereof will be discussed, as well as the important role inflammation 
plays in this process. Finally, the association of APPs with insulin resistance will be reviewed as a novel 




 The liver: a key role player in glucose homeostasis 
“The dynamic regulation of glucose metabolism is essential for systemic carbohydrate 
homeostasis and organism survival.” – Titchenell, P et al., 2015 (42). 
The liver is widely described as an essential metabolic organ that governs whole-body energy 
metabolism. It specifically plays a key role in glucose metabolism by maintaining a balance between 
glucose production and glucose storage in the form of glycogen (10, 11, 43). After a meal, there is an 
increase in blood glucose, free fatty acids (FFAs), and amino acids, which are transported to the liver 
where they are metabolized. Blood glucose enters the liver via a plasma glucose transporter (GLUT), 
which exists as four isoforms (GLUT1-4). GLUT2, a bi-directional glucose transporter, is mainly 
expressed in hepatocytes (the main cell type in the liver (~80%)) (43). Once glucose enters the liver, 
via GLUT2, various processes regulating the breakdown and storage of glucose in the form of glycogen 
occurs to facilitate decreasing blood glucose concentrations (11, 43). These processes include glycolysis 
(which involves the breakdown of glucose to produce energy in the form of ATP) and glycogen 
synthesis (the production of glycogen using glucose as a substrate) (43) (Table 1.1). Upon entrance to 
the liver, glucose is phosphorylated to glucose-6 phosphate (G6P) by a liver specific hexokinase, known 
as glucokinase (10, 43). G6P can no longer be exported and is thus retained in hepatocytes (10, 44), 
where it can either be catabolised via the glycolytic pathway, or alternatively converted to glycogen. 
Under fasting conditions, when nutrients are scarce, the opposite occurs and the liver releases glucose 
in to the blood by increasing the metabolic pathways involved in hepatic glucose production (HGP), 
which will be discussed later in this section (43, 45). These processes are tightly regulated by hormones 
such as insulin and dysregulation of this process can cause hyperglycaemia, leading to the progression 
of T2D (11).  
HGP involves two metabolic reactions: the breakdown of glycogen to form glucose (known as 
glycogenolysis) and de novo glucose synthesis (gluconeogenesis) (43). Both of these processes are 
suppressed by insulin in the fed state (11, 46, 47) (Table 1.1). However, under fasting conditions, when 
the plasma glucose levels are relatively low, the liver produces glucose to meet energy demands. The 
contribution of glycogenolysis and gluconeogenesis to the supply of glucose is approximately 
equivalent, however, over time the glycogen content in the liver becomes limited and gluconeogenesis 
becomes the principal source of glucose (10, 45, 48).  
The process of gluconeogenesis involves the formation of glucose from substrates such as pyruvate, 
lactate, glycerol, and amino acids like alanine and glutamine (43, 44, 46, 49), which together account 
for approximately 90% of gluconeogenic substrates (44). This process involves a biochemical pathway, 
which is essentially the inverse of the glycolytic pathway, but requires four additional enzymes (45, 46). 
Two of these enzymes, phosphoenolpyruvate carboxykinase (PEPCK), which catalyses one of the rate-




(G6Pase) that catalyses the hydrolysis of G6P to free glucose, the final step of gluconeogenesis, are 
considered key enzymes of gluconeogenesis (46). The first step in the breakdown of glycogen is 
catalyzed by the enzyme glycogen phosphorylase, which is responsible for the production of G6P 
(10, 43). The final step in glycogen synthesis, which is catalyzed by glycogen synthase, can be regulated 
by glycogen synthase kinase 3 (GSK3), which phosphorylates and thereby inactivates glycogen 
synthase (10, 43, 50). As previously mentioned, all these enzymatic processes can be regulated by 
insulin, which is secreted from the pancreatic β-cells in response to increasing blood glucose 
concentrations. The ability of insulin to regulate HGP is imperative to maintain glucose homeostasis, 
as a defect in this process can result in the hyperglycaemia observed in T2D. Therefore, the molecular 
mechanisms through which insulin regulates glucose metabolism in the liver will be discussed in the 
following section.  
 Insulin action in the liver 
As mentioned previously, one of the main aims of insulin is to decrease blood glucose concentrations. 
In addition, it also prevents blood glucose from increasing by directly inhibiting HGP, by suppressing 
gluconeogenesis and glycogenolysis, amongst other processes. Insulin rather promotes the utilization 
and storage of glucose in the liver, by upregulating glycolysis and glycogen synthesis (11, 43) (Table 
1.1). It acts directly on HGP by two mechanisms: acute changes to metabolic pathways, which is 
controlled by modifications to proteins or allosteric effectors, and long-term alterations in gene 
expression of the key enzymes involved (10, 42). The effect of insulin on glycogen synthesis is acute, 
involving post-translational modifications of GSK3, the main regulatory enzyme of glycogen synthase, 
that entails an inhibitory phosphorylation that essentially results in the activation of glycogen synthase 
(Table 1.1) (43). Additionally, insulin mediates a more long-term effect on the direct regulation of 
hepatic gluconeogenesis. Unlike most metabolic enzymes, the two key gluconeogenic enzymes, PEPCK 
and G6Pase, are not regulated allosterically or via posttranslational modifications, but instead at a 
transcriptional level (46, 49), which is supported by the presence of multiple binding sites for 
hormonally responsive transcription factors in the promoter of the genes encoding for these enzymes 
(46). Specifically, insulin suppresses the transcription of the G6Pase and PEPCK genes, by influencing 
their regulatory transcription factors via its signalling cascade (44, 46, 51, 52).  
In addition to directly affecting gluconeogenesis through the transcriptional regulation of key 
gluconeogenic enzymes, as described above, insulin also indirectly affects gluconeogenesis via 
extrahepatic tissues (42) (Table 1.1). Insulin can decrease lipolysis and proteolysis in adipose tissue and 
skeletal muscle, respectively, thus reducing the levels of FFAs, glycerol, and amino acids made 
available as substrates for gluconeogenesis (43, 44, 47, 53). Additionally, an increase in circulating 
insulin levels results in a decrease in glucagon secretion from pancreatic α-cells, which is known to 




regulation of gluconeogenesis is sufficient to maintain normal glucose metabolism (54). The direct 
effect of insulin was demonstrated in vivo, in canines, where portal plasma insulin suppressed HGP 
without changes observed in glucagon levels or gluconeogenic substrates (55, 56). In a mouse model, 
however, insulin was shown to be more effective in decreasing HGP via extrahepatic tissues i.e. 
indirectly (57), thus suggesting that both of these processes are needed to observe suppression of HGP.  
Gluconeogenesis is much less sensitive to acute changes in plasma insulin concentrations than 
glycogenolysis both in vitro and in vivo (58), with higher insulin concentrations over a longer period of 
time required to effect gluconeogenesis, which involves the transcriptional regulation of G6Pase and 
PEPCK genes (47, 59). In support of this phenomenon, excess insulin levels were demonstrated to 
suppress gluconeogenesis by 20%, while glycogenolysis was completely suppressed in healthy 
individuals (60). Nevertheless, since gluconeogenesis is a primary source of HGP in patients with T2D 
(11, 61), and its rate is increased in this disease (61, 62), it is important to better understand how insulin 
regulates this process, as individuals with insulin resistance fail to suppress HGP (11, 53). This might 
provide insight into the inability of the liver to respond to insulin, which will help to understand the 
pathophysiology of T2D (44). 
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 Insulin & the insulin signalling network 
Discovered in 1921 by Banting et al., (63), insulin is an endocrine anabolic peptide hormone that 
consists of 51 amino acids that controls whole-body metabolism, cell growth and differentiation (64). 
Insulin is active as a monomer, which consists of two polypeptide chains: a 21 amino acid residue (the 
“A”-chain) and 30 amino acid residue (the “B”-chain) bound by disulphide linkages (65). The 
conformational state of insulin is dependent on the insulin concentration and surrounding pH. The 
monomer tends to form dimers as the insulin concentration rises and forms hexamers at pH 6.0, which 
is consequently the storage form of insulin (66).   
Insulin is produced in the β-cells of the Islets of Langerhans in the pancreas. Initially, insulin is 
synthesized as prepoinsulin, then processed to the precursor – proinsulin – which is then converted to 
insulin and a C-peptide and stored in secretory “granules” awaiting to be secreted in response to nutrient 
availability (66). Insulin secretion is triggered by a series of events which include an increase in 
circulating plasma glucose levels and involves the fusion of the granules with the β-cell membrane and 
subsequent exocytosis. The concentration of insulin stored in the β-granules is roughly 40 nM (66). 
Insulin secretion consists of two phases – a transient first phase, which in humans peak at 1.4 nM/min 
when glucose levels are ~7 mM and lasts for ~10 minutes (66). The sustained second phase displays a 
secretion rate of 0.4 nM/min. This biphasic pattern is less prominent in mice than in rats and humans, 
due to the relatively higher plasma insulin levels in mice (8-9 nM in mice vs 4-5 nM in rats and humans) 
(66). After secretion, insulin travels via the bloodstream to its peripheral target tissues (liver, adipose 
tissue, and skeletal muscle) to regulate cell metabolism through the activation of the insulin signalling 
pathway.  
 Insulin signalling pathway 
The insulin signalling pathway is a large multicomplex network, which can be branched into three major 
pathways that are activated by insulin. The phosphatidylinositol-3-kinase (PI3K)/Akt pathway mediates 
the metabolic effects of insulin such as the regulation of glucose, lipid, and protein metabolism in 
peripheral target tissues. The mitogen-activated protein kinase (MAPK) pathway controls the 
mitogenic, growth, and cell differentiation effects and the CAP/Cb1/Tc10 (Cb1-associated 
protein/cannabinoid receptor type-1/G-binding protein TC-10) pathway mediates the membrane 
translocation of glucose transporter 4 (GLUT4) in muscle and adipose tissue, which aids in glucose 
uptake in these cells (67–71). For the purpose of investigating the metabolic signal of the insulin 
signalling pathway, this study will focus on the PI3K/Akt pathway (depicted in Fig.1.3). This signalling 
cascade differs between the three peripheral target tissues, resulting in different metabolic outcomes. 
For instance, regulation of glucose metabolism is the most important outcome of insulin signalling in 




adipose tissue and skeletal muscle, which account for ~70% of glucose uptake (71–73). Additionally, 
lipid and protein metabolism are mainly regulated in adipose tissue and skeletal muscle, respectively 
(68, 74).  
In the following section, the PI3K/Akt pathway will be reviewed according to three of its main 
components: the insulin receptor, insulin receptor substrates, and the central protein Akt. Additionally, 
the downstream effects as a result of this pathway as well as its regulation will be discussed.  
1.3.1.1 Insulin Receptor 
The insulin receptor as a mediator for the biological effects of insulin was first reported  by Freychet 
and colleagues in 1971 (75). Subsequently, throughout the 1980’s, the structural and functional 
properties of the insulin receptor was characterized (76–79). The insulin receptor is a member of a 
superfamily of receptor tyrosine kinases (RTK), which are single transmembrane polypeptide chains 
that exert their signalling effect through tyrosine kinase activity (80, 81). Within the superfamily of 
RTK, the insulin receptor subfamily exists, which consists of the insulin receptor (IR), the insulin-like 
growth factor receptor (IGF-R), and the orphan insulin related receptor (IRR) (80, 82). All three 
receptors are expressed in most mammalian tissues, especially in the peripheral target tissues (67, 82). 
The insulin receptor is tetrameric and consists of two extracellular α-subunits (135 kDa) and two 
intracellular β-subunits (95 kDa) that are covalently linked by disulphide bonds, as depicted in Fig.1.1. 
The IR, IGF-R and IRR are unique from the other members of the RTK superfamily in that they are 
maintained as a covalent dimer in the absence of ligand (80, 83). The extracellular α-subunits contain 
the insulin binding site and the β-subunits possess  three compartmentalized regions - the extracellular, 
transmembrane, and cytosolic domains (Fig.1.1) (80, 84, 85). The cytosolic tyrosine kinase domain 
contains the ATP binding consensus sequence and three clusters of tyrosine residues that can be 
phosphorylated in response to insulin, as first described in 1982 (76–78, 80, 84). The IR exists as two 
isoforms, IR-A and IR-B, which is formed when the IR mRNA undergoes alternative splicing at exon 
11 and only differs by the absence (IR-A) or presence (IR-B) of 12 amino acids at the carboxy terminal 
of the α-subunit (84, 86, 87). These isoforms are differentially expressed in tissue, with IR-B expressed 
in abundance in peripheral target tissues. Nonetheless, insulin binds both isoforms with similar affinity 
(87).  
Prior to insulin binding, the α-subunits exhibit an inhibitory effect on the β-subunits (88). Upon binding 
of insulin, the IR undergoes a conformational change that relieves the inhibitory effect. The mechanism 
of relief has been extensively investigated and a number of models have been proposed (89–92), all 
resulting  in the autophosphorylation of at least five distinct sites in the β-subunits (93). Phosphorylation 
of a cluster of residues (Tyr1158, Tyr1162, Tyr1163) within the kinase domain has been shown to be 
necessary for activation of the kinase allowing it to recognise other substrates (85, 94, 95) (Fig.1.1). 




major sites of phosphorylation (80, 96–98). Finally, phosphorylation of Tyr960 in the juxtamembrane 
region is required for receptor internalization and binding of the phosphotyrosine-binding (PTB) 
domain of insulin receptor substrate (IRS) proteins for subsequent phosphorylation on tyrosine residues 
(98, 99), which will be discussed later (Section 1.3.1.2).  
The importance of the IR in insulin signalling in peripheral target tissues was demonstrated with tissue-
specific knockout studies (100). IR knockout of the pancreatic β cell resulted in dysfunction of insulin 
secretion and impaired glucose tolerance (101). Additionally, liver-specific deletion of the IR led to 
severe insulin resistance and dysregulation of glucose metabolism (102), however when Okamoto and 
colleagues (103) partially restored hepatic IR expression in IR knockout mice, insulin signalling in the 
liver was restored, but hepatic insulin action in vivo i.e. the ability of insulin to decrease HGP, was not. 
Interestingly, muscle-specific deletion of the IR did not alter glucose tolerance, although insulin 
signalling in the muscle was abolished (104). Muscle-specific deletion of both the IR and IGF1-R 
displayed enhanced basal glucose uptake, suggesting that other tyrosine kinases that activate the insulin 
signalling pathway may be enhanced in the absence of the IR and IGF-1R (105). Finally, adipocyte-
specific IR knockout mice were protected from age-related obesity and its subsequent metabolic 
abnormalities (106). Together these studies suggest that the IR plays a significant role in insulin 
signalling and insulin action in the liver.  
   
 
Figure 1.1. Schematic illustration of the structure of the insulin receptor. The insulin receptor, present in the 
plasma membrane as a dimer, consists of two extracellular α-subunits and two intracellular β-subunits that are 
covalently linked by disulphide bonds. The α-subunit contains the insulin binding domain and intracellular β-
subunit contains tyrosine residues that regulate the kinase activity upon insulin binding. Image was redrawn and 





1.3.1.2 Insulin Receptor Substrates (IRS) 
Activation of the insulin receptor results in the recruitment of intracellular substrates containing 
phosphotyrosine binding (PTB) domains, of which the best described is the insulin receptor substrate 
(IRS) family. These proteins act as scaffolds to mediate the binding of intracellular effectors (68, 82) 
that amplify the insulin signal. The main role of the IRS proteins in the insulin signalling pathway is to 
convert the tyrosine phosphorylation signal into a lipid kinase signal (64), of which the mechanism will 
be discussed later in this section (Section 1.3.1.3). The IRS family consists of six isoforms (IRS-1-6), 
of which IRS-1 and IRS-2 mediate the metabolic effects of the IR. IRS proteins have NH2-terminal 
pleckstrin homology (PH) domains, allowing these proteins to bind to phosphoinositides with high 
affinity and specificity (107), and PTB domains (~100 residues) that target them to the activated IR 
(Fig.1.2A). Additionally, their COOH-terminal tail contains multiple tyrosine and serine/threonine 
phosphorylation sites that act as “on” and “off” switches, respectively (68). IRS-1 and 2 contain 
common functional domains, however there are some differences. A review by White (108) details that 
IRS-1 contains 21 putative tyrosine phosphorylation sites (not all are shown in Fig.1.2A), of which 14 
of these sites are conserved in IRS-2, three sites from IRS-1 are not found in IRS-2 and four novel sites 
exist in IRS-2. Additionally, unique to IRS-2 is the existence of a kinase regulatory loop binding region 
(KRLB) (residues 591-733), which interacts with the tyrosine kinase domain of the IR (109) (Fig.1.2A). 
Detailed studies of IRS-1 phosphorylation upon insulin stimulation demonstrated that at least 8 tyrosine 
residues on IRS-1 that undergo phosphorylation including Tyr608, Tyr628, Tyr939, and Tyr987 (108). 
The proposed mechanism of IRS binding to the IR is shown in Fig.1.2B. The PTB domain of the IRS 
protein attracts and associates with the juxtamembrane region of the IR (residues Tyr972 (68) and 
Tyr960 (98, 108) has been described), resulting in the phosphorylation and further activation of multiple 
IRS tyrosine residues.  
Results from different knockout studies, summarised in Table 1.2, have shown that different IRS 
proteins appear to have specific roles in different tissues (67, 110). IRS-1-deficient mice show growth 
retardation and mild insulin resistance, especially in the muscle, but did not develop T2D due to 
increased insulin secretion by pancreatic β-cells to compensate for the mild-resistance (111, 112). These 
mice also displayed normal glucose tolerance. Additionally, pre-adipocytes of IRS-1 deficient mice 
showed defects in adipocyte differentiation (113). In contrast, IRS-2 deficient mice displayed defective 
insulin signalling in the liver and inadequate compensatory insulin secretion resulting in 
hyperglycaemia and the development of T2D (111, 114–116) These studies illustrate that IRS-1 seems 
to be the key mediator of insulin signalling in skeletal muscle, adipose tissue and pancreatic β-cells 
whereas IRS-2 is important for liver metabolism (67, 110). The latter is supported by Rother and 
colleagues (117) who demonstrated in mice lacking the IR in hepatocytes, a reduction in IRS-2, and not 




metabolism (117). Therefore, in summary the activation of IRS-1 or IRS-2 will result in different 
metabolic effects in peripheral target tissues, with IRS-2 showing importance in the regulation of HGP.  
 
  
Figure 1.2. Schematic illustration of the structure of IRS-1 and 2 (A) and binding of the IRS protein to the 
activated IR (B). (A) The IRS-1 and IRS-2 proteins have structural similarity, pertaining to the NH2-terminal PH and 
PTB domains (which consists of ~100 amino acids). On the right is shown the COOH-terminal with phosphorylated 
tyrosine residues (conserved residues lacking evidence of phosphorylation are shown in parentheses). Tyrosine residues 
that recruits intracellular effectors which include PI3K, are shown by red bars. The unique kinase regulatory loop 
binding region (KRLB), which modulates interaction with the IR, in IRS-2 is also shown. (B) It is proposed that the 
PTB domain of the IRS attracts and associates with the juxtamembrane region of the IR, resulting in the phosphorylation 
of multiple IRS tyrosine residues and thus further activation by the IR. Images redrawn and adapted from Copps & 
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1.3.1.3 Protein Kinase B/Akt 
Protein kinase B/Akt is the central protein in the insulin signalling pathway. The PI3K/Akt pathway is 
a critical link between IRS proteins and the metabolic actions of insulin. As mentioned in section 
1.3.1.2, activated IRS proteins recruit phosphoinositides to the plasma membrane with high affinity and 
specificity through their PH domains. Phosphatidylinositol 3-kinase (PI3K) is a class of heterodimers 
that consist of a regulatory (p85α) and catalytic subunit (p110) (Fig.1.3). These proteins contain a 
sequence-specific phosphotyrosine binding module in their regulatory subunits, known as Src 
homology-2 (SH2) domains, that allows them to recognize and dock to phosphorylated tyrosine residues 
on other proteins. Consequently, activation of the catalytic subunit occurs, which rapidly 
phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2), thus generating the lipid messenger, 
phosphatidylinositol (3,4,5)-triphosphate (PIP3) (82, 119, 120). This results in the recruitment of 3-
phosphoinositide-dependent protein kinase 1 (PDK1) that mediates the metabolic effects of PI3K 
through the recruitment and activation of Akt. PDK1 contains a PH domain that binds to the membrane-
 





bound PIP3, triggering its own activation, and subsequently activates the central protein Akt by 
phosphorylating Thr308 residue in its activation loop as described by Alessi and colleagues in 1993 
(121) and Stephens and colleagues in 1998 (122).  
Akt is a serine/threonine kinase that contains both a Thr308 and Ser473 residue required for full 
activation of the protein (121, 123–125). The Ser473 residue is situated in the carboxyl-terminal 
hydrophobic motif of the protein and identity of the kinase responsible for its phosphorylation has been 
debated in literature (125–127). Several candidates were proposed, including PDK1, integrin-linked 
kinase (ILK) (127) and Akt itself (125). Finally, the identity of this mystery kinase, referred to as 
“PDK2”, was solved by Sarbassov and colleagues in 2005 (123) when they demonstrated that Akt 
becomes phosphorylated at its Ser473 residue by a unique complex of the mammalian target of 
rapamycin (mTOR) kinase. mTOR is a large protein kinase that exists in two distinct forms: a raptor-
containing complex that is sensitive to the drug rapamycin (mTORC1) and regulates cell growth in part 
by phosphorylating S6K1 (a negative regulator of the insulin signalling pathway), and a rictor-
containing complex (mTORC2) that is not sensitive to rapamycin and its cellular function is not entirely 
understood (123). Once it was established that Akt phosphorylation at the Ser473 residue is not sensitive 
to acute rapamycin treatment, Sarbassov (123) demonstrated that mTORC2 is responsible for Akt 
Ser473 phosphorylation using RNA interference in cultured Drosophila cells.  
Overall, Akt phosphorylation at Ser473 is the most commonly used marker of cellular insulin action 
(68, 128) as it indicates final activation of the protein, increasing its kinase activity and resulting in 
subsequent downstream signals.  
1.3.1.4 Downstream of Akt 
Akt phosphorylates various downstream targets of the insulin signalling pathway, which either activates 
or inhibits its substrates (Fig.1.3). As described in Table 1.1, this results in the regulation of 
carbohydrate metabolism in the liver. Insulin-stimulated Akt acts upon two downstream targets that 
inhibits HGP (44, 47, 129). The first target involves the transcription factors of the Forkhead box O 
(FoxO) family that control the expression of gluconeogenic and lipogenic genes (82). Active, nuclear 
FoxO1 binds the transcriptional co-activator peroxisome proliferative activated receptor-γ coactivator 
1-α (PGC1-α) to coordinate the transcription of the gluconeogenic genes, G6Pase and PEPCK (68). 
Three residues of FoxO1: Thr24, Ser256, and Ser319, is phosphorylated by Akt, which provides 
docking sites for binding proteins leading to the nuclear exclusion of FoxO1, thus attenuating its 
transcriptional activity (46, 82, 130), resulting in insulin-induced downregulation of gluconeogenic 
genes. The second target of Akt is glycogen synthase kinase 3 (GSK3), a serine/threonine kinase that 
regulates glycogen synthesis by phosphorylating and inhibiting glycogen synthase (Section 1.2) (46, 
68). GSK3 exists as two isoforms, GSK3α and GSK3β that are structurally and functionally similar 




GSK3α (Ser21) and GSK3β (Ser9) (130). Phosphorylation at these sites results in the inhibition of the 
protein, which favours dephosphorylation of glycogen synthase, thereby contributing to insulin 
stimulation of glycogen synthase activity and an increase in glycogen synthesis (68, 130). 
Additionally, Akt also targets and upregulates the lipogenic transcriptional regulator, sterol regulatory 
element binding protein 1c (SREBP-1c), which promotes de novo lipogenesis by enhancing the 
transcription of several lipogenic enzymes (44, 68). SREBP-1c upregulation occurs primarily through 
transcription, but also through cleavage and nuclear translocation (68).  
Akt targets a vast array of proteins, with only some mentioned in this section, that forms part of the 
insulin signal transduction network and is responsible the for action of insulin in the cell. In addition, 
some targets are involved in the negative regulation of the insulin signalling pathway itself (64, 68, 82). 
Dysregulation of any of these Akt target proteins have the potential to play a significant role in the 





Figure 1.3. Schematic illustration of the PI3K/Akt pathway activated by insulin and the downstream targets of Akt in the liver. Insulin binding 
to the IR results in activation of the protein and subsequent recruitment and activation of IRS-1 and 2. Activated IRS-1 and 2 recruits the kinase PI3K, 
which catalyses the conversion of PIP2 to the lipid messenger, PIP3. This is followed by the recruitment of PDK1 that phosphorylates the central 
protein Akt, at its Thr308 residue. Additionally, mTORC2 phosphorylates Akt at Ser473 resulting in the full activation of the protein. Akt acts upon 
various downstream targets such as FoxO1, GSK3, mTORC1, S6K and SREBP1 that results in the regulation of glucose, lipid and protein metabolism. 




1.3.1.5 Regulation of the insulin signalling pathway 
The insulin signalling pathway is tightly controlled by various mechanisms of regulation as summarised 
in Fig.1.4. In this section, the regulation of the IR and IRS proteins and additionally Akt will be 
discussed. As mentioned above, the IR and IRS become activated via tyrosine phosphorylation, 
therefore tyrosine phosphatases can act as negative regulators of the insulin signalling pathway. Protein 
tyrosine phosphatase 1B (PTP1B), a very well-studied tyrosine phosphatase, acts by dephosphorylating 
the tyrosine residues on activated IR and IRS proteins (64, 82, 131). PTP1B is an essential protein that 
opposes insulin action (82, 131). The importance of PTP1B in regulating insulin sensitivity was 
demonstrated in PTP1B-knockout mice, which showed increased IR phosphorylation in muscle and 
liver tissues. Additionally, these mice were resistant to high fat diet-induced obesity and associated 
insulin resistance (131–133). The role of PTP1B in hepatic metabolism has also been extensively 
studied (134–138). Over-expression of PTP1B in Fao hepatoma cells, impaired insulin-stimulated 
glucose metabolism (137). Inversely, the reduction of PTP1B in these cells increased insulin signalling 
(134). Additionally, Gum et al., (138) demonstrated an increase in IRS1/2 tyrosine phosphorylation and 
Akt activation in response to insulin in the liver of obese mice in which PTP1B expression was reduced 
by 60%. Another study, performed by Gonzalez-Rodriguez et al., in 2007 (135), showed an increase in 
insulin sensitivity in hepatocytes from adult PTP1B-deficient mice, that specifically affected the 
insulin-mediated Akt/FoxO1 signalling pathway. Finally, a study from diabetic IRS-2 deficient mice 
show increased hepatic mRNA and protein levels of PTP1B, which resulted in impairment of the 
insulin-mediated Akt/FoxO1 pathway (136). These effects were reversed by PTP1B deletion in these 
mice, highlighting the important role of PTP1B in hepatic insulin signalling (136). 
Furthermore, the IR and IRS proteins contains in their kinase domains, many serine/threonine residues, 
that when phosphorylated results in their inhibition, therefore reducing the activated insulin signal. 
Serine phosphorylation of the IRS proteins results in failure of these proteins to associate with the 
activated PI3K, thus decreasing the downstream effect of Akt (68, 139). Increased Ser/Thr 
phosphorylation of IR and IRS1/2 occurs in response to cytokines, FAs, hyperglycaemia, mitochondrial 
dysfunction, ER stress, and insulin itself via activation of multiple kinases, including p38 MAP kinase, 
c-Jun amino-terminal kinase (JNK), inhibitor κB kinase (IKK), protein kinase C (PKC), and also the 
mTORC1/S6K signalling pathway (64, 82, 118). Increased IR serine phosphorylation associated with 
decreased tyrosine phosphorylation has been observed in insulin-resistance states in mice and humans 
(82, 140, 141). Additionally, PKC was shown to inhibit IR autophosphorylation by phosphorylating the 
Thr1160 residue in the activation loop, a mechanism caused by lipotoxicity (142). Phosphorylation of 
IRS-1 at its serine residues has been well studied (143–147). Although IRS-1 has many serine residues 
(118), the best studied is Ser307 in rats and Ser312 in humans, which is located near the PTB domain 
(143) and is phosphorylated via several mechanisms including insulin-stimulated kinases such as 




site of phosphorylation by JNK (144). Phosphorylation of IRS-1 at Ser307 by JNK disrupts the 
interaction between the PTB domain of IRS-1 and the catalytic domain of the IR (143). Aguirre et al., 
(143) demonstrated that IRS-1 phosphorylation at Ser307 inhibited insulin-stimulation of PI3K and 
MAPK cascades, suggesting that phosphorylation at this site might be a general mechanism to regulate 
insulin signalling. Pederson et al., (145) demonstrated that Ser/Thr phosphorylation of IRS-1 precedes 
through a rapamycin-dependent pathway (mTORC1 signalling), which is supported by Ueno and 
colleagues (146). Additionally, Ser307 (in rats, and Ser312 in humans) phosphorylation of IRS-1 is also 
induced by IKKβ, an enzyme which activates the transcription of NFκB (147). The serine 
phosphorylation of IRS-2 has not been as extensively studied (149, 150). Two serine residues of IRS-2 
were investigated in 2011, Ser675 and Ser907 (150), both of which are situated adjacent to the PI3K 
and Grb2 binding domains. It was shown in insulin-stimulated hepatoma cells, that phosphorylation of 
IRS-2 at Ser675 was promoted by mTORC1 and Ser907 by ERK1/2, however these sites did not 
regulate downstream PI3K or Grb2 activity but might be implicated in the mTOR- and ERK-mediated 
negative feedback control (150).  
Another site of regulation of the insulin signalling pathway is the recruitment and activation of Akt 
through PI3K via protein and lipid phosphatases. An example of a lipid phosphatase is phosphatase 
tensin homolog (PTEN), which is a 3’-phosphatase that converts PIP3 into its precursor PIP2, thus 
antagonizing PI3K signalling (64, 82). Deletion of PTEN in the liver of mice improved Akt signalling 
and enhanced insulin sensitivity (82, 151). A second lipid phosphatase, Src homology 2 (SH2)-
containing inositol 5’-phosphatase-2 (SHIP2), has the same function as PTEN and has been shown to 
negatively regulate insulin-stimulated Akt phosphorylation in mice (82, 152, 153). Furthermore, there 
are two protein phosphatases that regulate Akt phosphorylation. Firstly, pleckstrin homology domain 
and leucine-rich repeat protein phosphatase 1 (PHLPP), is an Akt Ser473 phosphatase (64). Secondly, 
protein phosphatase 2A (PP2A) is another serine/threonine phosphatase that dephosphorylates Akt at 
both the Thr308 and Ser473 residue (64). Both of these phosphatases are involved in the negative 
feedback loop of the insulin signalling pathway (64). 
In conclusion, multiple regulatory mechanisms as described in this section are in place to attenuate or 
terminate insulin signalling once activated. The ability to turn off the insulin signal is crucial for 
maintaining homeostasis, however dysfunction in the regulation of the insulin signalling pathway at its 





Figure 1.4. Negative regulation of the insulin signalling pathway. Overview of the various mechanisms that regulate the IR, IRS-1 and 2 proteins and Akt. The 
tyrosine phosphatase, PTP1B, dephosphorylates the tyrosine resides of the IR and IRS proteins. Phosphorylation of the IR and IRS at their Ser/Thr residues results in inhibition 
of the proteins. Protein kinase C (PKC) phosphorylates the IR at the Thr1160 residue. Inhibitor κB kinase (IKK), c-Jun amino-terminal kinase (JNK), S6K and mTOR 
phosphorylate IRS-1 and IRS-2 at their serine residues. Lipid phosphatases, PTEN and SHIP2, act by converting PIP3 to the precursor PIP2 thus antagonizing PI3K signalling. 
The protein phosphatases, PHLPP and PP2A act by dephosphorylating Akt at the Ser473 (PHLPP) or at both residues (PP2A). Image redrawn and adapted from Haeusler et 




 Insulin Resistance 
Insulin resistance is defined as the inability of the peripheral target tissues (liver, adipose tissue, skeletal 
muscle) to respond normally to the physiological concentrations of insulin secreted by the pancreatic 
β-cells. The attenuated effect of insulin in these peripheral tissues precedes the development of 
hyperglycaemia. Defective insulin action manifests itself as reduced glucose uptake in skeletal muscle 
and adipose tissue and increased glucose production in the liver amongst other outcomes (67, 71). This 
leads to the inability of insulin to decrease blood glucose concentrations. In order to compensate for 
this effect, the pancreatic β-cells increases the secretion of insulin, which results in the characteristic 
hyperinsulinemia (excess plasma insulin levels) observed in insulin-resistant states and is a primary 
contributor to the development of T2D (154–156), in addition to hyperglycaemia (discussed in section 
1.2) (11). Finally, when the β-cells fail to produce the excess amounts of insulin needed, due to β-cell 
dysfunction, T2D emerges (48, 157).  
At the molecular level, two underlying mechanisms of insulin resistance have been proposed, which 
involves a defective insulin signalling pathway (17, 68, 154). The first mechanism describes decreased 
activation of key nodes in the insulin signalling pathway, which include the IR, IRS proteins, and Akt. 
This is described in Table 1.2, which shows that knockout of the IR as well as IRS proteins led to 
dramatic insulin resistance, specifically in the liver (102, 110, 114–116). For example, studies whereby 
IR and IRS were knocked out (Table 1.2), in rodent livers lead to hepatic insulin resistance, resulting in 
hyperglycaemia and glucose intolerance, which subsequently lead to the development of T2D 
(102, 115, 116) . Additionally, reduced tyrosine phosphorylation of the IR and IRS proteins have been 
observed in insulin-resistant states (24, 25, 158, 159), and hepatic inactivation of PI3K, PDK1, and 
mTORC2, which results in the inactivation of Akt, also induced hyperglycaemia and hyperinsulinemia 
in mice (160–162). A second mechanism involves an imbalance between two pathways mediating 
insulin action: the PI3K/Akt pathway and the MAPK pathway. Under normal conditions, there is a 
balance in the regulation of the PI3K/Akt pathway, to attenuate the metabolic signal, which is controlled 
by components of the MAPK pathway (including p38, ERK1/2 and JNK). However, dysregulation of 
the insulin signalling pathway, due to deficient  IRS proteins shows an imbalance in this system 
(17, 154, 155, 163). Herein the PI3K/Akt pathway is inactivated, which disrupts nutrient homeostasis, 
while the activation of the MAPK pathway is sustained, promoting mitogenesis and overgrowth 
(17, 154). This results in increased Ser/Thr phosphorylation of the IRS proteins, leading to further 
inhibition of insulin signalling (67). This dysregulation can be caused by various additional factors, 
including the activation of inflammatory pathways, increased pro-inflammatory cytokines and FFAs as 
well as by stress and obesity (19, 23, 169–172, 24, 25, 159, 164–168). 
Furthermore, insulin resistance in the different peripheral target tissues presents with different 




well as other transcription factors regulating glucose and lipid metabolism (section 1.3.1.4) 
(67, 68, 154). In adipose tissue, fat cell development is retarded and there is an increase in lipolysis 
(17, 154). The excessive FFAs travels to the liver and skeletal muscle, promoting gluconeogenesis and 
inhibiting glucose uptake, respectively, thus worsening hyperglycaemia (17). Additionally, 
hyperlipidemia (increased triglycerides levels in the blood), which is a key feature of insulin resistance, 
develops as a result of altered lipid metabolism, specifically in the liver, in which lipogenesis is 
increased (17, 67). Overall, insulin resistance is multifaceted and involves cross-talk between the 
peripheral target tissues (173) as well as various nodes in the insulin signalling pathway. Various factors 
such as stress, obesity and inflammation contribute to tissues becoming insulin resistant and will be 
discussed in the next section.  
 Factors that contribute to insulin resistance 
1.4.1.1 Stress  
In response to stress, glucocorticoids (GCs), are released from the cortex of the adrenal gland (10) to 
mediate important physiological effects on metabolism, specifically glucose metabolism (174, 175). 
These steroid hormones act via binding to the glucocorticoid receptor (GR) resulting in the 
transcriptional activation of the key gluconeogenic enzymes, G6Pase and PEPCK (10, 175, 176). 
Additionally, GCs also promote proteolysis in skeletal muscle and lipolysis in adipose tissue, leading 
to an increase in gluconeogenic substrates to be used in the liver (10, 177, 178). Therefore, a principal 
effect of GCs is to oppose insulin action in the liver (177). 
GCs also exert immunosuppressive and anti-inflammatory actions, via the GR, by repressing the 
transcription of various pro-inflammatory genes (179). For this reason, synthetic GCs, such as 
prednisolone and dexamethasone (Dex) were developed to treat autoimmune and inflammatory diseases 
(175). However, it has been established that when present in excess, GCs, both synthetic and 
endogenous (cortisol, in humans, and corticosterone, in rodents) induce insulin resistance in the 
peripheral target tissues, due to their adverse metabolic effects (175, 176, 179, 180).  
Patients with Cushing’s syndrome, characterised by high circulating levels of endogenous GCs, are 
known to develop insulin resistance (178). This phenomenon stemming from this rare disease 
highlighted the role excess GCs play in insulin resistance. This is especially important since general 
chronic stress conditions will result in the activation of the hypothalamic-pituitary-adrenal (HPA) axis 
resulting in the increased production and secretion of endogenous GCs, which could affect insulin 
action similarly to what is observed in Cushing’s syndrome patients. Furthermore, exogenous or 
synthetic GCs such as Dex and prednisolone, which are commonly prescribed to patients with 
inflammatory disease, also affect key components of the insulin signalling pathway 




transcription of IRS-1, while increasing the transcription of PTP1B and p38 MAPK, two proteins that 
negatively affect insulin signalling (181, 182). Dex, on the other hand had a more pronounced effect on 
the insulin signalling pathway. For instance, Dex treatment decreased the insulin-stimulated 
phosphorylation status of the IR and IRS-1 in the liver and skeletal muscle as well as the association of 
IRS-1 with PI3K (167). Similarly, Sakoda et al., (171) showed that in 3T3-L1 adipocytes, Dex 
decreased the tyrosine phosphorylation and protein expression of IRS-1. Furthermore, at the centre of 
the pathway, Dex is able to decrease the phosphorylation of Akt at both Thr308 and Ser473 in skeletal 
muscle (168, 170) and adipocytes (168) as well as the phosphorylation of GSK3-β (170), a downstream 
target of Akt. Finally, insulin-stimulated glucose uptake in adipose tissue (168, 169) and skeletal 
muscle, as well as glycogen synthesis (170) was decreased in the presence of Dex. It is evident that 
GCs, known for their anti-inflammatory action, also induce insulin resistance by affecting various nodes 
in insulin signalling.  
1.4.1.2 Obesity 
Obesity, which is an underlying cause of insulin resistance, is characterized by adipose tissue expansion 
owing to the increase in adipose tissue number (known as hyperplasia) and size (hypertrophy) (183). 
Obesity is also characterized by excessive accumulation of white adipose tissue (WAT), resulting from 
both hypertrophy of pre-existing adipocytes and increased adipocyte differentiation (183, 184). Studies 
in humans have shown that that weight loss/gain is associated with a decrease/increase in insulin 
sensitivity, respectively, therefore suggesting that obesity and insulin resistance present a cause-and-
effect relationship (19, 185, 186). Mechanisms that associate the development of insulin resistance with 
obesity involve: FA metabolism and actions of adipokines (cytokines from adipose tissue).  
Plasma FA concentrations increase in obese individuals mainly due to increased FA release associated 
with fat mass expansion (19, 187). As discussed previously in this section, these FAs in circulation 
serve as an energy source for gluconeogenesis in the liver, thus promoting hyperglycaemia. 
Additionally, FAs can serve as signalling molecules that activate protein kinases (these include PKC, 
JNK, NFκB, and IKKβ as previously discussed in section 1.3.1.5) which induce the Ser/Thr 
phosphorylation of IRS proteins (19, 188). Furthermore, increased plasma FAs can induce a defect in 
the insulin-stimulated tyrosine phosphorylation of IRS-1 as well as PI3K activation and glucose uptake 
in rats, as shown by Yu et al. (189).  
In addition to increasing plasma FAs concentrations, obesity gives rise to a heightened state of 
inflammation (154, 165, 166). This was first shown by Hotamisligil et al.,(190) who showed a positive 
correlation between obesity and the mRNA levels of the pro-inflammatory cytokine, tumour necrosis 
factor (TNF-α), in mice. Subsequent experimental models of obesity also showed this effect along with 
an increase in TNF-α protein levels (159, 191–193). Furthermore, in the study performed by 




glucose transporter responsible for glucose uptake in adipocytes, thus affecting glucose metabolism. 
Moreover, in vitro studies have shown that in a variety of cell types including adipocytes (194), 
hepatoma cells (24), fibroblasts (172), and myeloid 32D cells (25), TNF-α caused a decrease in IR 
autophosphorylation and subsequent inhibition of IRS-1. Additionally, TNF-α also induced serine 
phosphorylation of IRS-1 in cultured adipocytes (25) and hepatoma cells (23), while mice lacking 
TNF-α were protected against the development of obesity-induced insulin resistance (159). Overall, 
these studies demonstrate how obesity-related inflammation can cause insulin resistance at a molecular 
level. 
In addition to TNF-α, other adipokines such as interleukin-6 (IL-6), adiponectin, and resistin play a role 
in the development of insulin resistance (154). IL-6 and resistin, which can induce insulin resistance in 
mice (195–197), are markedly increased in obesity (198). At the cellular level, IL-6 decreased the 
tyrosine phosphorylation of IRS-1 as well as activation of Akt and glycogen synthesis in HepG2 cells 
and primary mouse hepatocytes (22), while in vivo, mice lacking resistin showed improved glucose 
homeostasis (in part due to decreased expression of gluconeogenic enzymes) (199). Levels of 
adiponectin, on the other hand, are decreased in obesity, unlike TNF-α, IL-6, and resistin. Adiponectin 
enhances insulin sensitivity in the liver, decreases influx of FAs, and reduces hepatic glucose output 
(200). Thus in an obese state with lower concentrations of adiponectin, the development of hepatic 
insulin resistance is promoted (154, 201).  
Overall, obesity links inflammation to the development of insulin resistance, and causes biochemical 
abnormalities in adipose tissue, which can negatively affect the insulin signalling pathway, especially 
in the liver.  
1.4.1.3 Inflammation (chronic inflammation)  
As mentioned above inflammation as a result of obesity affects insulin resistance. Inflammation, more 
specific chronic inflammation of course does not only occur as a result of obesity. Thus a chronic 
inflammatory state as a result of various factors such as aging has the potential to induce insulin 
resistance (202). This was shown in mice, fed a high-fat diet, in which chronic inflammation was 
induced and essentially resulted in decreased insulin sensitivity in the liver, adipose tissue, and skeletal 
muscle (203). Indeed, protein expression of IRS-1, IRS-2, and Akt was decreased, as well as the 
phosphorylation of Akt at Thr308 (203). Subsequently, this resulted in hyperglycaemia and impaired 
β-cell function (203).  
As already mentioned, an obese state results in the release of pro-inflammatory cytokines, TNF-α and 
IL-6. These pro-inflammatory mediators induce insulin resistance on a molecular level by affecting 
insulin signalling (22–25, 166, 172, 190, 194). In addition to TNF-α and IL-6, another pro-inflammatory 




treatment with IL-1β decreased insulin-stimulated glucose uptake in 3T3-L1 adipocytes by decreasing 
the protein expression of GLUT4 as well as its translocation to the plasma membrane (204). This 
decrease was accompanied by an inhibition of IRS-1 protein expression as well as a decrease in insulin-
stimulated tyrosine phosphorylation of IRS-1 and Akt at Thr308 (204). In addition to affecting glucose 
uptake, IL-1β also decreased glycogen synthesis in primary cultured rat hepatocytes by inhibiting 
glycogen synthase activity (205). Furthermore, these pro-inflammatory cytokines exert their inhibitory 
effects, on IRS-1 specifically, via activation of MAPK pathway components such as JNK and ERK1/2 
(21, 154, 164, 204), which could mediate the cross-talk between inflammatory signalling and insulin 
resistance (19).  
Another factor linking chronic inflammation to insulin resistance, is the acute phase response (APR). 
A review by Pickup and Crooke (206) discussed how T2D can be considered a disease of the innate 
immune system. Herein, the authors proposed that T2D is an acute-phase disease, in which increased 
concentrations of pro-inflammatory cytokines and acute-phase proteins (APPs) are secreted, under the 
influence of various stimuli such as over nutrition (206, 207). This is supported by Rehman and Akash 
(202) who proposed that overnutrition is a major causative factor contributing to chronic inflammation 
in this disease state. APPs are evolutionary conserved proteins produced mainly in the liver in response 
to infection and inflammation (208) and their plasma levels have been associated with the complexities 
of T2D (39, 206, 207), leading to the question of whether they may play a role in development of the 
disease itself. Thus, in order to further understand this phenomenon, the importance of acute phase 




 Acute phase proteins  
 The importance of the acute-phase response 
The maintenance of homeostasis in mammals is ensured by a number of physiological mechanisms. 
When homeostasis is disturbed due to infection, trauma, tissue injury, surgery, or immunological 
disorders (206, 209, 210), the body responds by inducing a number of systemic and metabolic changes 
known as the acute phase response (APR) (211, 212).  
The APR is a manifestation of the innate immune system (213) that comprises two reactions: the local 
and systemic reaction, as described by Heinrich et al., (214) and shown in Fig.1.5. The local reaction is 
initiated at the site of invasion, which results in the release of pro-inflammatory cytokines, also known 
as early acute phase reactants (215). These include interleukin-6 (IL-6), interleukin-1 (IL-1), TNF-α, 
and interferon γ (IFNγ), of which IL-6 is considered the main regulator of the APR in the liver as shown 
in studies involving human hepatocytes (214, 216). The pro-inflammatory cytokines activate receptors 
on different target cells, which leads to intracellular signalling, resulting in the systemic reaction 
(Fig.1.5) characterized by a number of physiological responses in different tissues. These include fever, 
leucocytosis, increased levels of adrenocorticotrophic hormone (ACTH), and GCs, activation of 
complement, decrease in zinc and iron serum levels, changes in metabolism including increased 
gluconeogenesis, and finally synthesis of several plasma proteins, known as acute phase proteins 
(APPs), in the liver (209, 212, 214, 215). The concentrations of APPs can either be increased (known 
as positive APPs) or decreased (known as negative APPs) in response to inflammatory stimuli 
(209, 212). Positive APPs are further classified into three categories, dependent on the magnitude of 
their response (210). Major APPs increase 10-1000-fold in concentration within 48 hours, upon 
stimulation. This pronounced increase in concentration is followed by a rapid decline due to their short 
half-life (209, 210, 215). In contrast, the levels of moderate APPs increase by only 50% and minor 
APPs by 2-fold, and due to their longer half-life and depending on the stimuli have a prolonged duration 
(3-5 days) in circulation (209, 210, 215, 217). Thus, on average, the APR shows a rapid response that 
peaks within the first 48 hours but can last up to 3-5 days. The biological functions of the different 
positive APPs are vast (summarised in Table 1.3) and involve opsonization and trapping of 
microorganisms, activating the complement system, neutralizing enzymes, modulating the host’s 
immune response as well as wound healing and tissue repair (209, 213).  
Two major APPs, serum amyloid A (SAA) and C-reactive protein (CRP), have been extensively studied 
in literature due to their importance during the APR. This is reflected in their biological function, which 
involves processes in the host’s immediate response to infection (Table 1.3). Indeed, Gruys et al., (209) 
reports that their plasma concentrations become measurable within 4-5 hours after a single 




reported by Baumann (218) in 1989, peak levels of most APPs are observed at 24 hours, whereas SAA 
and CRP attain maximal levels at an earlier time point (8 to 12 hours). Importantly, SAA and CRP are 
sensitive markers of inflammation (215) and their plasma levels are routinely used to assess health in 
human patients and for diagnostic purposes (209, 219), because during situations of chronic 
inflammation (such as rheumatoid arthritis), their production is sustained (219). Their physiological 
concentrations reached during the APR have been investigated and will be discussed later (1.5.3 and 
1.5.4).  
The overall function of moderate and minor APPs involves processes important in healing, including 
antioxidant activity, the removal of enzymes released during tissue injury, and blood clotting, which is 
vital during tissue repair (Table 1.3). Unlike SAA and CRP, these proteins are not routinely used for 
clinical applications, yet they are still considered inflammatory markers in literature (210, 213, 217). 
Additionally, negative APPs, such as albumin and transferrin, decrease in concentration during the APR 
and for this reason is believed to not be as extensively studied (209). Their decrease allows for an 
increase in the unused pool of amino acids and hormones which can be used to generate positive APPs 
(210) and they are thus referred to as ”acute booster reactants” (209). Additionally, corticosteroid 
binding globulin (CBG), another negative APP, whose levels decrease during the APR, results in an 
increase in the concentration of free, biologically active GCs (220).   
Overall the APR is important to restore homeostasis (212) and lack of resolution of the inflammatory 
stimulus results in chronic inflammation (215). A chronic APR has various disease implications: 
including T2D, metabolic syndrome X, atherosclerosis (an inflammatory process that results in lipid 
accumulation in the vascular wall), and cardiovascular disease (221). Pickup et al., (206) in fact 
questioned whether or not T2D is an “acute phase disease”. In support of this, numerous studies have 
reported increased levels of APPs in diabetes (222, 223). The development of T2D as a result of a 
chronic APR is of special interest to this study, and therefore an overview of the significant APPs 
implicated in T2D, which include plasminogen activator inhibitor-1 (PAI-1), SAA, and CRP will be 





Figure 1.5. Illustration of the different phases that occur during the acute phase response. In response to various 
disturbances (infection, tissue injury, neoplastic growth and immunological disorders), the acute phase response is activated 
and results in two reactions: the local (1) and systemic (2) reaction. The local reaction results in the release of pro-inflammatory 
cytokines from the site of invasion or injury. The systemic reaction results in a number of physiological processes which, most 
importantly, includes the increase in the production of acute phase proteins in the liver. Image was redrawn and adapted from 





Table 1.3. Relevant positive acute phase proteins secreted in mammals and their physiological 
role in the APR 
Acute phase protein Role in the acute phase response 
Major (increase 10-1000 fold) 
C-Reactive Protein Opsonin, activation of complement, and 
immunomodulation. Enhances phagocytosis. 
(210, 213, 217). 
Serum Amyloid A Activation of leukocytes, chemotaxis and 
phagocytosis (210, 213, 217). 
Moderate (increase up to 50%) 
Fibrinogen Involved in tissue repair through endothelial-cell 
adhesion, spreading and proliferation. Promotes 
clot formation (210, 213, 217). 
Ceruloplasmin Scavenges free radicals (210). 
Haptoglobin Antioxidant that protects against reactive oxygen 
species (206, 217). Reduces oxidative damage 
associated with haemolysis (210). 
α1-acid glycoprotein Inhibits LPS activity (210). 
Plasminogen Activator Inhibitor-1 Inhibits the activation of plasminogen (thus 
inhibiting fibrinolysis) (213). 
Minor (increase 2-4 fold) 
α2-macroglobulin Protease inhibitors and removal of enzymes 
released during injury (210). 
 
 Plasminogen activator inhibitor-1 (PAI-1) 
The coagulation system plays an important role in the APR and the maintenance of homeostasis. It 
allows for blood flow to continuously be under surveillance and ensures rapid formation of blood clots 
at sites of injury, and thus prevents extreme blood loss from the circulation (224). Blood clots are 
stabilized by fibrin, which is formed from fibrinogen (224). In order to regulate this process of clot 
formation, an enzymatic system is in place, known as the fibrinolytic system, that is capable of 
dissolving blood clots (225). The fibrinolytic system comprises the formation of the active serine 
protease, plasmin, which can dissolve blood clots by cleaving multiple peptide bonds in the fibrin matrix 
(224, 225). An integral part of the fibrinolytic system is the formation of active plasmin from inactive 
plasminogen by the action of two plasminogen activators: tissue-type plasminogen activator (t-PA) and 
urokinase-type plasminogen activator (u-PA) (225–227), through their serine protease activity. PAI-1 
binds and inhibits these two plasminogen activators and thus serves as a checkpoint in the regulation of 
fibrinolysis (226). Additionally, plasmin is known to degrade extracellular matrix (ECM) components, 
and therefore PAI-1 indirectly regulates ECM degradation (228), which is an important factor to 
consider when understanding the role of PAI-1 in different disease states.  
PAI-1, also referred to as serpin E1, is a 45-kDa glycoprotein and a member of the serine protease 




most tissues and cell types of which the major sources include liver cells, adipocytes, vascular smooth 
muscle cells, and platelets (226–228). Additionally, under pathological conditions, PAI-1 is released 
from endothelial cells in response to inflammatory stimuli and other inflammation-activated cells 
including macrophages (227). Once synthesized, PAI-1 is released into the bloodstream where it 
spontaneously converts to a latent conformation and this process involves structural rearrangement of 
the protein (230). Active PAI-1 has a half-life of approximately 2 hours (226, 230), thereby indicating 
that this protein is fast-acting (231, 232). However, it can be stabilized through binding with vitronectin, 
a thermostable glycoprotein, which is able to convert PAI-1 into an active form (226, 230, 233). 
Therefore, the physiologically relevant form of PAI-1 is in complex with vitronectin (226, 227, 234). 
Additionally, a wide range PAI-1 levels in human plasma are observed: for instance, it was reported 
that physiological levels of PAI-1 range between 6 to 80 ng/ml, with a mean value of 24 ng/ml 
(225, 226). Furthermore, De Taeye et al., (234) stated that mean PAI-1 levels in healthy individuals 
ranged between 15 to 30 ng/ml, while several studies ranging from 1993 to 2006 reported mean PAI-1 
levels of 34 ng/ml (235), 9.4 ng/ml, (236), and 14.7 ng/ml (35). Although literature describes a variation 
in concentrations of PAI-1 in normal, healthy subjects, the levels of PAI-1 play an important role in 
understanding its role in disease. 
PAI-1 has been extensively studied in relation to obesity, insulin resistance, and T2D (studies 
summarised in Table 1.4). Elevated plasma PAI-1 levels are observed throughout the spectrum of 
insulin resistance, from obese subjects (237) to T2D patients (34, 35), and a strong correlation exists 
between body mass index (BMI) and plasma PAI-1 levels (234). The high expression levels of PAI-1 
in these disease states raises the question as to its contribution to the phenomenon. Indeed, PAI-1 was 
shown to be overexpressed in the adipose tissue of obese mice (238–240) and humans (228, 241). 
Therefore, it is considered a biological marker of obesity (234). However, whether this protein could 
contribute to the development of obesity is unclear?  
As described previously in section 1.4, obesity involves dynamic changes in adipose tissue mass and 
number. In addition, adipocyte differentiation plays an important role. During adipocyte differentiation, 
extensive ECM remodelling occurs. It is believed that the established role of PAI-1 in tissue 
remodelling, i.e. inhibition of ECM degradation, facilitates its role in the modulation of adipocyte 
differentiation (242). Indeed, several studies, most conducted in mice, support this hypothesis 
(242, 243). Liang and colleagues (242) demonstrated that overexpression of PAI-1 in mice inhibited 
murine adipocyte differentiation, while PAI-1 deficiency promoted it. In accordance with this, Lijnen 
et al., (243) showed that overexpression of PAI-1 in vivo impaired adipose tissue growth. Conversely, 
Crandall et al.,(244) showed that pharmacological inhibition of PAI-1 through a small molecule 
inhibitor, PAI-039, inhibited human pre-adipocyte differentiation. These studies indicate distinct 
differences in PAI-1-induced effects in murine versus human adipocytes. This study also demonstrated 




in reduced body weight, adipose tissue weight, and volume (244). In agreement with this result, two 
studies have shown that PAI-1 deficiency prevented fat accumulation and enhanced insulin sensitivity 
both in a genetic (245) and diet-induced (246) model of obesity, which suggests that PAI-1 protects 
against the development of obesity. Taken together, these findings suggest that PAI-1 plays a role in 
the development of obesity. Differences observed between these in vivo studies may be due to 
differences in age, fat composition of diet and genetic background of the mice (247).  
In addition to its role in obesity, it is well established that elevated plasma PAI-1 levels is a core feature 
of insulin resistance (228, 237, 248), which is of particular relevance to the current study. Increased 
plasma PAI-1 levels are observed in patients with insulin resistance and T2D (34, 35, 228, 248). Indeed, 
in the Insulin Resistance Atherosclerosis Study (IRAS) study, Festa and colleagues observed elevated 
levels of PAI-1 (±24 ng/ml) in patients that developed T2D, in comparison to the 16 ng/ml observed in 
non-diabetic healthy subjects (34) . Additionally, these authors showed that increased PAI-1 levels over 
time, in addition to high baseline levels (defined as 23.7 ng/ml), are associated with the onset of T2D 
(35, 249). Elevated PAI-1 levels and hyperinsulinemia are also correlated (248, 250). Hyperinsulinemia 
of course occurs as a result of peripheral insulin resistance as described in section 1.4. Clinically, 
improved control of hyperglycaemia in patients with T2D has been shown to decrease PAI-1 activity 
(173). Improving insulin resistance by diet, exercise, or oral antidiabetic drugs results in a decrease in 
plasma PAI-1 levels (173, 225). Troglitazone, an antidiabetic drug that improves insulin sensitivity, 
was shown to decrease plasma PAI-1 antigen levels and activity in diabetic patients (251). The in vitro 
study performed by Liang and colleagues (242) also showed that inhibition of PAI-1 in 3T3-L1 
adipocytes protected the cells against becoming resistant to insulin by blocking the effects of TNF-α on 
insulin sensitivity and glucose uptake. Therefore, PAI-1 may influence the development of obesity-
related insulin resistance through TNF-α. In agreement, PAI-1 was shown to inhibit insulin signalling 
in the hepatoma HepG2- (252) and endothelial cells isolated from aortic tissues in mice (253), by 
affecting the central protein of the insulin signalling pathway, Akt. Additionally, Tamura et al., (252) 
showed that PAI-1 affects hepatic glucose metabolism. The role of PAI-1 in developing insulin 
resistance was also demonstrated in vivo in mice lacking PAI-1, which showed improved 
hyperglycaemia and hyperinsulinemia associated with insulin resistance (245, 246), and also increased 
glucose uptake (254).  
In summary, in addition to being increased in response to insulin resistance, PAI-1 may also contribute 
to the development thereof. However, much work is still required to determine its contribution to the 




Table 1.4. Studies supporting the role of PAI-1 in the development of obesity, insulin resistance and type-2 diabetes. 
Disease 
state 
Model system Supporting data Reference 
Obesity 
In vivo 
Primary cultured adipocytes 
from PAI-1-deficient (PAI-/-) 
mice and overexpressed 
(PAI+/+) mice 
• PAI-1 deficiency enhanced adipocyte 
differentiation and insulin-stimulated 
glucose uptake.  
• Conversely, PAI-1 overexpression 
inhibited differentiation and reduced 
PPARγ expression.  
Liang et al. 
2006 (242) 
In vivo 
High-fat diet-induced obesity 
in PAI-1 knockout mice 
• Fat accumulation was prevented in PAI-
1 knockout mice, which additionally 
maintained PPARγ expression in 
adipocytes.  
Ma et al. 
2004 (246) 
In vivo 
Diet-induced obesity in mice, 




treated with the PAI-1 
inhibitor, PAI-039 
• Inhibition of PAI-1 attenuated dietary 
fat-induced obesity and showed lower 
glycemia and triglyceride level. 
 
• Inhibition of PAI-1 resulted in 






Genetic model of obesity and 
diabetic mice lacking the 
PAI-1 gene 
• PAI-1 deficiency reduced murine 
adiposity.  
Schäfer et al. 
2001 (245) 
In vivo 
Diet-induced obesity in PAI-
1 deficient mice 
• PAI-1 containing mice showed marked 
obesity. PAI-1 deficiency resulted in 





Transgenic mice with 
overexpression of PAI-1 in 
adipose tissue, administered 
the PAI-1 inhibitor, PAI-039 
• Overexpression of PAI-1 induced 
impaired adipose tissue growth. 
• Inhibition of PAI-1 did not affect 
adipose tissue development, but 
improved insulin sensitivity in mice. 
 





PAI-1 knockout mice fed a 
high-fat diet 
• PAI-1 deficiency decreased the plasma 
glucose, insulin and cholesterol levels 
that were markedly increased by the 
high fat diet 
Tamura et al. 
2014 (252) 
In vitro 
HepG2 cells were treated 
with 20 nM for 24 hours 
Treatment with PAI-1: 
• Affected hepatic insulin signalling and 
resulted in decreased insulin-induced 
glucose uptake.  
• Additionally, PAI-1 affected 
gluconeogenesis by increasing G6Pase 
and PEPCK mRNA levels 
Tamura et al. 
2015 (254) 
In vitro 
PAI-1 knockout endothelial 
cells treated with 10 ng/ml 
PAI-1 for 24 hours 
PAI-1 deficiency: 
• increased Akt activation 
Treatment with PAI-1: 
• decreased Akt activation  
Balsara et al. 
2006 (253) 
In vivo 
High-fat diet-induced obesity 
in PAI-1 knockout mice 
• PAI-1 knockout mice showed increased 
glucose uptake and maintained plasma 
glucose and insulin levels. 






Genetic model of obesity and 
diabetic mice lacking the 
PAI-1 gene 
• PAI-1 deficiency significantly improved 
the hyperglycaemia and hyperinsulinemia 
associated with insulin resistance.   





The IRAS study – measured 
PAI-1 levels in non-diabetic 
patients in relation to 
incident diabetes within 5 
years 
• Elevated levels of PAI-1 (±24 ng/ml) was 
associated with incident type-2 diabetes 
Festa et al. 
2002 (34) 
Epidemiological study 
Follow up study to Festa et al 
2002. 
• Increased PAI-1 levels over time, in 
addition to high baseline levels (23.7 
ng/ml), was associated with the onset of 
T2D 
Festa et al. 
2006 (35) 
 Serum Amyloid A (SAA) 
SAA is a well-characterized APP that is predominantly synthesized in the liver (213, 255). It is an 
apolipoprotein that can bind and transport lipids in the blood and is mainly associated with high-density 
lipoproteins (HDLs) (255, 256). The important functional role of SAA during the APR, in host defence, 
has made it a sensitive marker of inflammation, in addition to CRP (217, 219). Indeed, during the APR, 
the plasma levels of SAA increase up to 1000-fold (as discussed in section 1.5.1), from 1-5 µg/ml in 
healthy individuals, to an exceeding 1 mg/ml (256, 257). There are four different isoforms of the SAA 
genes (SAA1-4) of which SAA1 and SAA2 encode acute-phase SAA (A-SAA) proteins and SAA4 is 
a constitutively expressed protein (256–259). In humans, SAA3 is a pseudogene, but is functionally 
expressed in the adipose tissue of mice (259), particularly obese mice (260). A study by Lin et al., (261) 
found that SAA3 is expressed at very low levels in the liver of mice. Although, in humans, the liver is 
the main site of synthesis during the APR, a study by Sjoholm et al., (262) in 2005 showed that adipose 
tissue is the major expression site of A-SAA during non-acute phase conditions with the liver showing 
the second highest expression. In agreement with this result, Yang et al., (263) showed, in 2006, that 
A-SAA is highly expressed in human adipocytes.    
During the APR, A-SAA is secreted into circulation as a free protein and rapidly associates with HDLs, 
its physiological carrier (256). The amphipathic structure of SAA facilitates its binding to HDLs and its 
ubiquitous diffusion via the circulation to all organs and tissues, to perform its biological function (213). 
During the APR, SAA has immune-related functions that include acting as a chemoattractant for 
monocytes, leukocytes, and polymorphonuclear cells to inflammatory sites, resulting in the extension 
of inflammation (255, 259, 264). The immune-related functions of SAA are mediated by its ability to 
bind to various cell surface receptors (255, 265), which can result in the activation of various 
inflammatory signalling pathways, such as the MAPK and ERK1/2 pathways (discussed in section 




Like PAI-1, SAA is a marker of obesity (263) and has been extensively studied in relation to this 
inflammatory condition as summarised in Table 1.5. Increased circulating levels of SAA has been 
observed in obese individuals (263, 267, 268), which positively correlates with an increased BMI and 
decreased weight loss. The concentrations observed in the obese individuals ranged from approximately 
11-20 µg/ml (263, 267, 268). Poitou et al., (267) also observed increased levels of hSAA1 and hSAA2 
mRNA and protein expression in adipose tissue of these obese individuals. Additionally, like PAI-1, 
SAA has been shown to affect adipocyte differentiation in vitro by reducing the mRNA expression of 
two adipogenic transcription factors: PPARγ and C/EBPα (260, 269). Dysregulation of lipid 
metabolism (such as increased basal lipolysis and decreased lipid synthesis in adipose tissue) is also 
associated with obesity (263). It was shown by three independent studies that SAA increased lipolysis 
in vitro (260, 263, 269) and additionally reduced the mRNA expression of a transcription factor 
involved in lipid synthesis, namely SREPB-1c (269). Recently a study reported that mice fed a high-fat 
diet was protected from weight gain when treated with an anti-sense oligonucleotide that inhibits SAA 
mRNA expression (270). Furthermore, inhibiting SAA levels prevented adipose tissue expansion as 
well as macrophage infiltration into adipocytes, both of which are associated with obesity (270). Thus, 
not only are SAA levels increased during obesity, it appears to also play a role in the development 
thereof.  
In addition to obesity, SAA is also a marker of T2D and insulin resistance (271). Indeed, measurement 
of SAA concentrations in serum of patients with T2D showed significantly higher levels (38, 268, 272, 
273) (Table 1.5). SAA concentrations measured in T2D patients ranged from 2.1-24 µg/ml (38, 268, 
272, 273), comparable to levels observed in obese individuals. Additionally, elevated SAA levels (as 
well as other markers of inflammation including TNF-α, IL-6, and CRP) were observed in the plasma 
of previously healthy individuals, who presented with onset T2D (36, 37). Also in diabetic (ob/ob) mice, 
increased SAA mRNA levels strongly correlated with chronic hyperglycaemia observed in the mice 
(261). Treatment of T2D patients with the anti-diabetic drug, troglitazone, not only inhibited 
hyperglycaemia but also significantly reduced SAA levels (273). These findings raise the question of 
whether SAA is more than just a biological marker for T2D i.e. is an increase in SAA levels a result of 
T2D, or is T2D a result of an increase in SAA, or perhaps both scenarios are possible. Scheja and 
colleagues (271) investigated this hypothesis in both in vivo (insulin-resistance prone mouse model) 
and in vitro (3T3-L1 adipocytes) models. Insulin-resistance prone mice, which were fed a high-fat diet, 
showed a significant increase in SAA1 and SAA2 mRNA levels in the liver, and SAA3 mRNA levels 
in adipose tissue (271). The authors next treated 3T3-L1 adipocytes with SAA (12.5 µg/ml) which 
resulted in decreased IRS-1- and GLUT-4 mRNA expression (271). In accordance, Ye et al., (274) 
showed decreased tyrosine phosphorylation of the IRS-1 protein as well as decreased GLUT-4 protein 
expression in 3T3-L1 adipocytes treated with SAA (20 µg/ml). Additionally, SAA (10 and 20 µg/ml) 




Monteiro and colleagues, showed that treatment of 3T3-L1 adipocytes with SAA (5 and 10 µg/ml) 
significantly reduced insulin-stimulated glucose uptake as well as GLUT4 mRNA expression (260). 
Taken together, these studies support the hypothesis that SAA may play a role in the development of 
insulin resistance, which could consequently lead to T2D. However, most of the studies investigated 
the effect of SAA in adipose tissue, and little research exists on how the liver or skeletal muscle is 
affected by SAA. Not much is known about the effect of SAA on the development of hepatic insulin 
resistance, which plays a key role in the progression to T2D. Additionally, the effect of SAA on other 




Table 1.5. Studies supporting the role of SAA in the development of obesity, insulin resistance and type-2 diabetes 
Disease 
state 




• SAA decreased adipocyte 
differentiation, by decreasing 
adipogenic transcription factors 
(PPARγ, C/EBPα) 
• SAA significantly increased lipolysis 
Filippin-
Monteiro et al. 
2012 (260) 
In vivo  
SAA mRNA inhibition in mice 
fed a high-fat diet 
• Inhibition of SAA promoted a lack of 
adipose tissue expansion as well as 
macrophage infiltration into adipose 
tissue.  
De Oliveira et 
al. 2016 (270) 
In vivo  
Serum SAA levels in obese 
individuals  
In vitro 
Human adipocytes treated with 
SAA (2.34 µg/ml) for 24 hours  
• SAA levels increased in obese 
individuals 
• SAA levels decreased after weight loss 
 
• Treatment with SAA increased lipolysis  
Yang et al. 
2006 (263) 
In vitro 
Human adipocytes treated with 
SAA for 24 hours 
SAA treatment resulted in: 
• increased lipolysis 
• reduced mRNA expression of 
transcription factors involved in 
adipocyte differentiation (PPARγ, 
C/EBPα) and lipid synthesis (SREPB-
1c) 
Faty et al. 
2012 (269) 
In vivo 
Gene expression in obese 
individuals  
• Increased expression of SAA1 and 
SAA2 mRNA and protein expression in 
obese individuals 






• SAA significantly decreased insulin-
stimulated glucose uptake  
Filippin-




• SAA significantly decreased mRNA 
expression of Glut4 and IRS-1 




SAA significantly reduced: 
• insulin-stimulated glucose uptake 
• activation of IRS-1 
• GLUT4 expression 
Ye et al. 2009 
(274) 
In vivo  
SAA mRNA inhibition in mice 
fed a high-fat diet 
• Inhibition of SAA protected mice from 
weight gain and insulin resistance 
de Oliveira et 




Diabetic (ob/ob) mice. 
Measured SAA3 mRNA in 
adipose tissue 
• Isolated adipose tissue of T2D mice 
showed drastically increased SAA3 
mRNA levels  
Lin et al. 2001 
(261) 
Epidemiological study  
Patients with T2D who received 
daily treatment with troglitazone 
(anti-diabetic drug) 
• SAA levels were above the range for 
healthy subjects (approx. 6.2 µg/ml) 
• Troglitazone reduced SAA levels (by 25% 
down to 4.0 µg/ml) 
Ebeling et al. 
1999 (273) 
Epidemiological study  
Measured SAA levels in patients 
with impaired glucose tolerance 
• Plasma levels of SAA were significantly 
higher in patients with T2D and in those 
with impaired glucose tolerance (approx. 6 
µg/ml). 





in comparison to individuals with 
and without T2D 
Epidemiological study  
Measured SAA levels in non-
diabetic individuals who 
participated in a 7-year follow-up 
• SAA levels were significantly associated 
with the onset of T2D (approx. 4.0 µg/ml) 
Marzi et al. 
2013 (37) 
Epidemiological study  
Measured SAA levels in T2D 
patients 
• Insulin resistance and T2D was 
significantly correlated with SAA levels 
(approx. 24 µg/ml) 
Leinonen et al. 
2003 (38) 
 
 C-Reactive Protein (CRP) 
Discovered in 1930 in the serum of patients with acute pneumococcal pneumoniae (275), CRP was the 
first described APP. It was named for its capacity to bind the C polysaccharide of Streptococcus 
pneumoniae (209, 219, 276, 277) and subsequently played a significant role in the identification of the 
APR (277). CRP is primarily synthesized by hepatocytes in response to an inflammatory stimulus and 
its synthesis is mainly regulated by the pro-inflammatory cytokines TNF-α, IL-6, and IL-1 
(29, 278, 279). As a member of the pentraxin family of calcium-dependent ligand binding proteins 
(276), CRP is produced as a homopentameric protein, consisting of five identical subunits 
(Mr = 23 kDa) (209, 276, 280), which is termed native CRP (nCRP) (280). Additionally, this protein 
can irreversibly dissociate into its monomeric form (mCRP) which has been observed when the protein 
is exposed to harsh damaging conditions (276). In the presence of calcium, CRP binds to 
polysaccharides such as phosphocholine on microorganisms, with high affinity (276), and triggers the 
classical complement pathway of the innate immune system (280) (summarised in Table 1.3). The two 
isoforms have shown distinct functions in the inflammatory process with nCRP tending to exhibit more 
anti-inflammatory activities relative to the mCRP isoform (276, 280).  
The CRP levels in healthy individuals is generally below 2 mg/l (277), but can be as high as 10 mg/l 
(217, 219). This level can increase with illnesses such as rheumatoid arthritis or sepsis, in the first 6-8 
hours of the APR and can reach peak levels of 300 mg/l after 48 hours (277). Indeed, a review by 
Suffredini et al., (213) reported that during the APR, CRP increases from 1 mg/l up to 1000 mg/l in 
plasma. Additionally, CRP values between 2 and 10 mg/l may be seen with metabolic inflammatory 
states, such as uremia, cardiac ischemia, and other low non-infectious inflammatory conditions (219). 
Upon resolution of the inflammatory stimulus, CRP levels rapidly decline with a half-life on average 
of approximately 19 hours (276, 281). This is consistent under all conditions and disease states, 
therefore the sole determinant of circulating CRP concentrations is the synthesis rate (276). 
Additionally, few drugs affect the circulating levels of CRP unless they also affect the underlying 




In addition to PAI-1 and SAA, circulating levels of CRP have been studied in relation to insulin 
resistance and T2D, due to its role as a sensitive inflammatory marker (summarised in Table 1.6). This 
is important especially when establishing a link between inflammation and the development of insulin 
resistance and T2D. Several cross-sectional studies have shown that high sensitivity CRP levels 
(hsCRP) (CRP levels measured using high sensitivity immunoassays) are associated with obesity 
(282, 283), increased fasting blood sugar levels (283), and impaired insulin sensitivity (284, 285), all 
components of insulin resistance. These findings fuelled the speculation that elevated hsCRP levels 
might be able to identify individuals in a prediabetic, insulin resistant-state (286).  
In addition, significant epidemiological studies have shown that increased hsCRP levels may predict 
the development of future T2D. Firstly, the Women’s Healthy Study (WHS) (40) demonstrated an 
association between hsCRP and insulin-resistant states, showing that among healthy women, high levels 
of IL-6 and hsCRP were associated with an increased risk for the development of T2D. In addition, the 
Cardiovascular Health Study (CHS) (41) also demonstrated that in a population of elderly men and 
women, elevated baseline hsCRP levels predicted the development of T2D. Finally, the IRAS study 
performed by Festa and colleagues (34), showed that high hsCRP baseline levels (>2.4 mg/l) amongst 
patients diagnosed with insulin resistance were associated with a higher risk of developing T2D. In 
addition to this, in a later study by the same authors, a significant correlation between CRP and 
components of insulin resistance were recognised (39).  
In addition to establishing CRP as a predictive risk factor for insulin resistance and the development of 
T2D, numerous studies also investigated whether CRP could a play a role in the development of the 
disease state (summarised in Table 1.6). Alessandris and colleagues (287) demonstrated using rat 
skeletal muscle cells, that high concentration of CRP (10 mg/l) impaired insulin signalling by increasing 
the serine phosphorylation of IRS-1 and reducing the activation of Akt. Additionally, this resulted in 
reduced glycogen synthesis and glucose uptake, thus, showing that CRP has an overall effect on the 
regulation of glucose metabolism. In support of this study, Xu et al., (288) showed a similar effect of 
CRP on insulin signalling in endothelial cells. Treatment with concentrations of CRP (ranging from 1, 
5, 10, and 25 mg/l) increased serine phosphorylation of IRS-1 and decreased the activation of Akt (288). 
Furthermore, similar effects were observed on insulin signalling in primary cultured rat hepatocytes 
when treated with CRP (30 mg/l), which resulted in decreased tyrosine phosphorylation of IRS-1 and 
its association with PI3K, as well as increased serine phosphorylation of IRS-1 (289). Additionally, this 
study demonstrated the same effect in vivo in rats administered CRP.  
In summary, like the other APPs mentioned, CRP is described as a strong predictor for the development 
of T2D (40, 41, 286, 290, 291). Additionally, the role of CRP in the development of insulin resistance 




been described (287, 288, 292). However, the effect of CRP on other key nodes in the insulin signalling 
pathway, such as the IR, have not been researched to fully elucidate its role in insulin resistance.  
 
Table 1.6. Studies supporting the role of CRP in the development of insulin resistance and type-2 diabetes.  
Disease 
state 




Rat skeletal muscle (L6) cells 
treated with 10 mg/l CRP 
CRP induced insulin resistance in skeletal 
muscle cells by: 
• increasing serine phosphorylation of 
IRS-1  
• reducing activation of Akt 
• reducing glycogen synthesis 
• impairing glucose uptake 
Alessandris et 
al. 2007 (287) 
In vitro 
Mouse endothelial cells treated 
with recombinant CRP at 
various doses and times 
Overall CRP impaired insulin signalling in 
endothelial cells by: 
• increasing serine phosphorylation of 
IRS-1 
• decreasing activation of Akt 
Xu et al. 2007 
(288) 
In vitro 
Primary cultured rat 




Rats treated with CRP 
 
CRP induced hepatic insulin resistance both 
in vivo and in vitro by: 
•  reducing the activation of IRS-1 and 
Akt 
• impairing the association of IRS-1 with 
PI3K.  
• inducing the inhibition of IRS-1 
(through serine phosphorylation) 




Epidemiological study  
The IRAS study – measured 
CRP levels in non-diabetic 
patients in relation to incident 
diabetes within 5 years 
• Elevated CRP levels (>2.4 mg/l) was 
associated with incident T2D 
Festa et al. 
2002 (34) 
Epidemiological study  
Measured insulin sensitivity 
and CRP levels in the non-
diabetic population of the 
IRAS study  
• Elevated CRP levels (>3.53 mg/l) was 
strongly associated with components of 
insulin resistance and T2D 
Festa et al. 
2000 (39) 
Epidemiological study  
Women’s Health Study 
• High hsCRP levels were associated with 
increased risk for development of T2D 
Pradhan et al. 
2001 (40) 
Epidemiological study  
Cardiovascular Health Study 
• High baseline levels (2.8 mg/l) of CRP 
predicted T2D 





 Regulation of acute phase proteins 
Thus far it has been established that the APPs, PAI-1, SAA, and CRP are strongly associated with 
insulin resistance and T2D due to their elevated levels in these disease states. It is thus important to 
establish what signalling molecules regulate the levels of these APPs as this might provide insight into 
how and why APPs are associated with insulin resistance and T2D. For this reason, the regulation of 
the three APPs of interest will be discussed next.  
Studies investigating PAI-1 expression have shown that PAI-1 is regulated by a variety of factors 
including: insulin, TNF-α, IL-6, IL-1, GCs, glucose, epidermal growth factor (EGF), transforming 
growth factor-β (TGF-β) and very low density lipoproteins (VLDLs) (228), as summarised in Table 
1.7.  
The effect of insulin on PAI-1 regulation has been extensively studied (293–299). As discussed 
previously in section 1.5.2, PAI-1 levels is associated with hyperinsulinemia (248, 250). Several in vitro 
studies have shown that insulin stimulates PAI-1 transcription and protein synthesis in HepG2- (293, 
294), 3T3-L1 adipose- (298), and endothelial cells (299). Banfi et al., (294) demonstrated a possible 
mechanism through which insulin could regulate PAI-1 transcription in HepG2 cells. By using a 
tyrosine kinase inhibitor, the authors showed that tyrosine phosphorylation is required for PAI-1 
biosynthesis as well as interaction of insulin with its cognate receptor (294). Further investigations, 
using an inhibitor of a key protein in the insulin signalling pathway, PI3K, as well as a protein that 
regulates the pathway, PKC (as described in section 1.3.1.5), demonstrated that the presence of these 
inhibitors attenuated insulin stimulation of PAI-1 transcription and biosynthesis. Therefore, activation 
of PI3K, followed by PKC is required for insulin-induced biosynthesis of PAI-1 in HepG2 cells (294). 
However, the involvement of the PI3K pathway in the regulation of PAI-1 synthesis seems tissue-
specific, as Mukai and colleagues (299) demonstrated in vascular endothelial cells that treatment with 
PI3K inhibitors increased the TNF-α and insulin-induced expression of PAI-1. Finally, inhibition of 
MAPK and ERK (section 1.3.1.5) inhibited both basal and insulin-stimulated PAI-1 secretion and gene 
transcription (>75%) in HepG2 cells, thus suggesting that the MAPK pathway also regulates PAI-1 
expression in the liver (228, 294). Finally, the precursor of insulin, proinsulin, also increased the mRNA 
expression as well as activity of PAI-1 in HepG2 (295) and endothelial cells (296). The effect on PAI-1 
by proinsulin was mediated by the insulin receptor in HepG2 cells, whereas in endothelial cells it was 
not (295, 296). These studies suggest that insulin itself, through activation of its own signalling 
pathway, could upregulate PAI-1 synthesis in the liver. Furthermore, it was shown that even in an 
insulin-resistant state, PAI-1 continues to be induced to an even greater extent in comparison to control 
mice by insulin in diabetic mice (297). The effect of insulin on the regulation of SAA and CRP on the 
other hand, has not been investigated. Finally, PAI-1 can also be upregulated by metabolic disturbances 




In vitro studies in the hepatoma cell lines, AML-12 and HepG2, showed enhancement of PAI-1 
transcription by the pro-inflammatory cytokines, IL-6 and IL-1 (303, 304). Additionally, whereas IL-6 
only showed a modest effect on PAI-1 mRNA levels, IL-6 in combination with IL-1 showed a 
synergistic effect (303, 304). TNF-α seemed to affect PAI-1 mostly in adipose tissue, both in vitro and 
in vivo (298, 305, 306) by increasing mRNA levels in mice (305) as well as PAI-1 activity and protein 
expression in 3T3-L1 adipocytes (298, 306). Interestingly, the effect observed in 3T3-L1 adipocytes 
was enhanced in combination with insulin (298). These studies suggest that TNF-α (which is related to 
obesity) might be the key inducer of PAI-1 expression in adipose tissue in obesity-related insulin 
resistance. Additionally, TNF-α enhanced PAI-1 mRNA and protein expression in endothelial cells 
(299, 307). Furthermore, the anti-inflammatory GCs have also been shown to regulate PAI-1 expression 
(33, 254, 308–310). Using the synthetic GC, Dex, several studies have shown an increase in PAI-1 
mRNA and protein expression in response to Dex, in human visceral adipose tissue (308), primary 
hepatocytes (309), epithelial cells (33), and human bone marrow adipocytes (311). Interestingly, in 
epithelial cells, Kimura and colleagues (33) showed that Dex further enhanced the TNF-α induced 
mRNA expression of PAI-1. Thus, raising the question of whether these antagonizing mediators could 
work together to upregulate the expression of APPs, such as PAI-1? However, it is not yet known 
whether this combinational effect is observed in other cell types, or if Dex can enhance the effect of 
IL-6 and IL-1 on PAI-1 expression. Furthermore, corticosterone, the endogenous GC in mice, increased 
the mRNA as well as circulating level of PAI-1 in vivo (254). In addition to these pro- and anti-
inflammatory mediators, several growth factors have been shown to enhance the expression and activity 
of PAI-1 (310, 312), for example, EGF in HepG2 cells increased PAI-1 mRNA levels (310). Two 
additional growth factors, platelet-derived growth factor and TGF-β, have also been described as 
enhancing PAI-1 mRNA and protein expression in vascular smooth muscle cells (VSMC’s) (312).  
As markers of inflammation and major positive APPs, A-SAA and CRP expression are mainly regulated 
by the pro-inflammatory cytokines IL-6, IL-1, and TNF-α (summarised in Table 1.7). However, several 
in vitro studies investigating A-SAA and CRP mRNA and protein expression in hepatoma cell lines, 
show differential regulation by these aforementioned cytokines (Table 1.7). For instance, SAA mRNA 
expression is induced by all three cytokines (TNF-α, IL-1, and IL-6), however to different extents 
(26-28, 32, 278, 313–315). IL-1 was shown to be a strong inducer of SAA mRNA expression (32, 314), 
whilst IL-6 stimulates SAA mRNA expression to a lesser extent (315, 316). SAA mRNA was induced 
modestly by TNF-α and IL-6 alone in HepG2 cells, and this induction was enhanced when these 
cytokines were present in combination (28). Furthermore, TNF-α, IL-1, and IL-6 in combination were 
able to enhance the transcription of SAA in HepG2 cells to a greater extent compared to treatments with 
one cytokine alone (316). CRP synthesis, on the other hand, was shown to be mainly regulated by IL-6 
in the hepatoma cell lines, Hep3B and HepG2 (29, 278). Additionally, in primary human hepatocytes, 




argument that CRP levels are mainly upregulated by IL-6 in the liver (29). Interestingly, TNF-α alone, 
or in combination with IL-6, had no effect on CRP synthesis in Hep3B cells (26). 
The induction of SAA and CRP is not limited to the liver. CRP production was induced by IL-1 and 
IL-6, alone, and in combination in human adipocytes (279). The mRNA expression of SAA3, the SAA 
isoform mainly produced in adipose tissue, is increased, by TNF-α and IL-6 in 3T3-L1 adipocytes (317) 
as well as IL-1 (30). It was found that the positive effect on SAA3 mRNA expression induced by IL-6 
and IL-1 was mediated by JNK-2 and NFκB, respectively (30, 317). These two proteins are involved in 
the negative regulation of the insulin signalling pathway, as discussed in section 1.3.1.5. In addition, 
the adipokine, resistin, also induced CRP synthesis in adipocytes (279). 
Like PAI-1, the cytokine-driven production of SAA and CRP in hepatoma cell-lines can be enhanced 
by the GC, Dex (26–30). GCs were also able to increase SAA3 mRNA levels in 3T3-L1 adipocytes, 
suggesting this effect is not tissue specific (317). Interestingly, Dex treatment in combination with 
TNF-α, IL-1 or IL-6 increased SAA and CRP production to a greater extent in comparison to the 
respective cytokine alone (26, 27, 29). Depraetere et al., (29) showed that in HepG2 cells, pre-treatment 
with Dex primed the cells to be more responsive to IL-6. In addition to Dex, another synthetic GC, 
prednisolone, enhanced the cytokine-driven production of SAA in HepG2 cells, but not that of CRP 
(32).  
Overall, the APPs, PAI-1, SAA, and CRP are regulated by pro-inflammatory cytokines and anti-
inflammatory GCs. Both these signalling molecules are known to play a significant role in the 
development of T2D and the insulin resistant state (see section 1.4). It thus begs the question of whether 


















• Increased PAI-1 
mRNA and protein 
expression in both 
adipocytes (298, 
305) and endothelial 
cells (299, 307) 
Dex: 
• Increased PAI-1 
mRNA levels and 
secretion in 
adipose tissue 
(308, 311), primary 
hepatocytes (309) 
and epithelial cells 
(33) 
Insulin: 
• Stimulates PAI-1 
transcription and 
protein expression 
in HepG2 (293, 




• Stimulates PAI-1 
mRNA and activity 

















• Increased PAI-1 




growth factor and 
TGFβ: 
• Induce PAI-1 
mRNA and protein 
expression and 











• Modestly enhanced 
PAI-1 transcription 
in hepatocytes (303, 
304) 







• Increased PAI-1 






• Increases SAA 
mRNA in HepG2 
cells (28) and SAA3 
mRNA in 3T3-L1 
adipocytes (317) 





• Enhances the 
cytokine-induced 
production of SAA 
and CRP, in liver 
cells (26–30), and 
3T3-L1 adipocytes 
(317) 
• Has no effect on its 
own (192, 196, 200 
 
Unknown in the liver 
(no effect on SAA3 
mRNA expression in 
3T3-L1 adipocytes) 
(317) 












• Enhanced SAA 
production, 
induced by IL-1 in 





hepatoma cell lines 
(32, 314) 
• Increases SAA3 
mRNA in 3T3-L1 
adipocytes (30) 
• Induces CRP 
production in 
primary human 
hepatocytes (29) and 
human adipocytes 
(279) 
• No effect on CRP 
synthesis (32) 
IL-6: 
• Induces SAA to a 
lesser extent in 
hepatoma cells (313, 
315) 
• Increases SAA3 
mRNA in 3T3-L1 
adipocytes (317) 
• Strong inducer of 
CRP synthesis in 
hepatoma cells (29, 





• Dex enhanced 
SAA mRNA 
expression in 
Hep3B cells (26) 
Dex+IL-1+IL-6: 
• Dex enhanced the 
synthesis of SAA 
and CRP in Hep3B 
cells (26) and SAA 
gene expression in 
HepG2 cells (31) 
  
Combinatorial effect of 
the three cytokines: 
TNF-α+ IL-1+ IL-6: 
• Induces SAA 
synthesis in 
hepatoma cells (316) 
TNF-α+IL-6: 
• Increases SAA3 
mRNA in 3T3-L1 
adipocytes (317) 
IL-1+IL-6: 
• Increases CRP 
production in 
hepatoma cell lines 
(29) 





T2D is a state of heightened inflammation and although numerous factors contribute to the development 
of insulin resistance and subsequently T2D, such as obesity and stress, a common theme throughout the 
literature portrays inflammation as a key role player. APPs, which are markers of inflammation, have 
been closely associated with T2D as their serum levels are elevated in T2D patients (34, 35, 37–41, 
268, 272, 273). These include, PAI-1, SAA, and CRP, which all play different roles during the APR.  
Whether these APPs are more than just biological markers for T2D and actually influence the 
development of insulin resistance is still unclear. Some studies do support the possibility that PAI-1, 
SAA, and CRP impair insulin signalling (252–254, 271, 274, 287–289), whilst others believe APPs are 
only a by-product of T2D (67, 318–320). The major source of these APPs is the liver, a central target 
for insulin and believed to be the first peripheral tissue to become insulin resistant. The liver, when in 
an insulin resistant state, is an important contributor to hyperglycaemia, which contributes further to 
the systemic progression of insulin resistance. Very few studies have examined how APPs affect the 
ability of the liver to respond to insulin. Understanding whether these APPs play a role in insulin 
resistance and T2D progression could provide insight into novel mechanisms leading to the 
development of insulin resistance and towards the development of innovative drug targets. 
 
 Hypothesis and aims 
It is evident from the literature that the APPs, PAI-1, SAA and CRP are associated with insulin 
resistance and the development of T2D. However, the current knowledge regarding the role that these 
APPs may play in the development of insulin resistance is limited. Given that insulin resistance is 
caused by a defective insulin signalling pathway, and that insulin action in the liver plays an integral 
role in the progression to T2D, the main aim of this study was to investigate the effects of PAI-1, SAA, 
and CRP on hepatic insulin signalling. In this study we hypothesize that PAI-1, SAA, and CRP 
negatively affect the key proteins in the insulin signalling pathway, leading to deficient insulin action 
in the liver.  
Using a murine hepatoma and human liver carcinoma cell line, namely BWTG3- and HepG2 cells, 
respectively, as in vitro model systems to investigate hepatic insulin signalling, the aims of this study 
were as follows: 
(1) To establish optimal activation of the insulin signalling pathway. 
(2) Evaluate whether increasing concentrations of PAI-1, SAA, and CRP affect insulin-induced 




(3) To investigate if the length of exposure to PAI-1, SAA, and CRP affects insulin-induced 
activation of key proteins (IR, IRS-2 and Akt) in the insulin signalling pathway.  
(4) To determine if PAI-1, SAA, and CRP affect gluconeogenesis, a downstream target of insulin, 
through the transcriptional regulation of key gluconeogenic genes, G6Pase and PEPCK, as well 
as hepatic glucose production.  
 
The materials and methods used in this study will be described in detail in Chapter 2. The results of this 
study will be presented in Chapter 3 followed by the discussion in Chapter 4, which will place the 















 Test compounds  
Human insulin, human recombinant plasminogen activator inhibitor-1 (PAI-1) and C-reactive protein 
(CRP) were purchased from Sigma-Aldrich. Human recombinant apo-serum amyloid A (SAA) was 
purchased from PeproTech. A 10 mg/ml stock solution of insulin was prepared in milliQ water, filter 
sterilized, and further diluted to a final concentration of 1 mg/ml in low glucose (5 mM) Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(FBS). Working solutions were prepared with further dilutions in sterile nuclease-free water and stored 
at -20 °C. Lyophilized PAI-1 powder was reconstituted in sterile 100 µl ultrapure water to a stock 
concentration of 0.25 mg/ml. A working solution of 0.25 µg/ml was prepared using low glucose DMEM 
supplemented with 10% FBS and stored at -80 °C. Lyophilized SAA powder was dissolved to a stock 
concentration of 1 mg/ml and CRP was diluted to a working solution of 100 µg/ml in low glucose 
DMEM supplemented with 10% FBS, respectively. SAA was stored at -20 °C and CRP at 4 °C.   
 
 Mammalian cell culture 
2.2.1 Cell Growth and Maintenance 
 
Murine hepatoma (BWTG3) cells were obtained from the University of Gent, Belgium, and human 
liver carcinoma (HepG2) cells were purchased from Cellonex. Both BWTG3- and HepG2 cells were 
cultured and maintained in low glucose (5 mM) DMEM, containing 1 mM sodium pyruvate and 17.9 
mM sodium bicarbonate purchased from Sigma-Aldrich. In addition, the culture medium was 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Merck) and 1% (v/v) penicillin/streptomycin 
(Pen/Strep) (50 IU/ml penicillin and 50 µg/ml streptomycin) (Sigma-Aldrich). Both cell lines were 
maintained in 75 cm2 tissue culture flasks (Bio-Smart Scientific) and regularly tested for mycoplasma 
infection using Hoechst Staining (321) and only mycoplasma negative cells were used for further 
experiments (see Addendum A, Fig.A1). Cells were maintained at a temperature of 37 °C, 5% CO2 





2.2.2 Treatment Conditions 
For dose response experiments, BWTG3 and HepG2 cells were seeded, in culture medium, into 12-well 
plates (BioSmart Scientific) at a density of 2x105 cells/well and grown to a confluency of 70-80%. This 
was followed by serum starving the cells for 24 hours in un-supplemented culture medium. The serum 
starved cells were subsequently treated with PAI-1 (5, 10, and 20 ng/ml), SAA (5, 10, and 20 µg/ml), 
and CRP (2.5 and 4.5 µg/ml) for 24 hours. Treatments were prepared in unsupplemented culture 
medium. Because the test compounds were prepared in supplemented low glucose DMEM, the vehicle 
control for each experiment consisted of 0.1% of supplemented low glucose DMEM. Prior to cell lysis, 
the cells were treated with 100 ng/ml insulin for 30 minutes to stimulate the insulin signalling pathway. 
For time course experiments, BWTG3 and HepG2 cells were seeded into 6-well plates (BioSmart 
Scientific) at a density of 5x105 cells/well (BWTG3) and 1x106 cells/well (HepG2), respectively, 
followed by serum starving the cells for 24 hours in un-supplemented culture medium. Cells were 
treated with 10 ng/ml PAI-1, 10 µg/ml SAA, and 4.5 µg/ml CRP for 2, 24 and 48 hours, followed by a 
treatment with 100 ng/ml insulin for 30 minutes prior to cell lysis.   
 Total RNA extraction 
BWTG3 and HepG2 cells were maintained as described in section 2.2.1 and treated as described in 
2.2.2 for time course experiments. Total RNA was extracted using Tri-Reagent (Sigma-Aldrich) as per 
the manufacturer’s instructions. Briefly, the cells were lysed with 400 µl Tri-reagent and cell lysis was 
promoted by placing the cells at -20 °C overnight. The cells were then allowed to thaw, and the cell 
lysates were transferred into clean 1.5 ml microcentrifuge tubes followed by the addition of 80 µl 
chloroform to extract total RNA. The cells were vortexed for one minute, followed by centrifugation at 
14000 x g for 15 minutes at 4 °C. The aqueous phase containing the RNA was removed (130 µl) and 
transferred into a clean 1.5 ml microcentrifuge tube followed by the addition of 200 µl ice-cold 
isopropanol. The samples were vortexed for one minute and RNA precipitation was facilitated by 
placing the samples at -20 °C for 1-7 days. This was followed by centrifugation at 14 000 x g for 30 
minutes at 4 °C to pellet the RNA. The supernatant was removed, and the pellet was washed with 500 
µl ice-cold 70% EtOH (diluted in diethyl pyrocarbonate (DEPC) treated water) and vortexed for one 
minute followed by centrifugation at 14000 x g for 5 minutes at 4°C. This wash step was repeated at 
least once to ensure the removal of any contaminants. With the final wash step, the supernatant was 
removed, and the pellet air-dried for 10 minutes. RNA pellets were dissolved in 15 µl DEPC-treated 
water and incubated at 55 °C for 5 minutes. RNA samples were stored at -20 °C. The RNA concentration 
as well as purity was assessed using the NanoDrop (ND-100 Spectrophotometer). The integrity of the 
isolated RNA was confirmed by assessing the presence of intact 28S and 18S ribosomal RNA on a 1% 





 cDNA synthesis 
The cDNA was synthesized using the ImProm-II Reverse-Transcription kit (Promega) as per the 
manufacturer’s instructions. Briefly, 2 µg RNA was added into a thin-walled PCR tube followed by the 
addition of 50 µg/ml oligoDT primers. Nuclease-free water was then added to a final volume of 5 µl. 
This mixture was incubated at 70 °C for 5 minutes. Thereafter, a master mix containing the following 
reagents was added to each sample to a final volume of 20 µl: 7.6 µl of nuclease-free water, 4 µl 
ImProm-II 5X reaction buffer, 1.5 mM MgCl2, 0.67 mM dNTP’s, 20U of recombinant RNasin® 
ribonuclease inhibitor and 160U ImProm-II reverse transcriptase. This mixture was placed at 25 °C for 
5 minutes to allow annealing of the oligoDT primers, followed by an incubation step at 45 °C for 1 hour 
for extension. The final step involved placing the mixture at 70 °C for 15 minutes to inactivate the 
reverse transcriptase and placing the samples on ice for 5 minutes. The cDNA samples were stored at -
20 °C. 
 Quantitative real-time polymerase chain reaction (qPCR) 
Quantitative real-time PCR (qPCR) was performed using the Lightcycler 96 system (Roche Applied 
Science). For each cDNA sample,  a master mix containing the following reagents was prepared: 6.25 µl 
SYBR green (Kapa SYBR Fast qPCR mastermix, containing the DNA polymerase enzyme and 
necessary reagents for the PCR reaction, Roche Applied Science), 0.25 µM forward and reverse primers 
and 2.25 µl nuclease-free water to a final volume of 9 µl. Lightcycler multiwell plates were used (Celtic 
Molecular Diagnostics) for the qPCR reaction in which 9 µl of the mastermix was added to each well 
and 1 µl of the cDNA sample or nuclease-free H2O (for the non-template control). The details of the 
primer sets used in this study are shown in Table 2.1. LightCycler® 96 software (Roche Applied 
Science) was used to set the PCR conditions which were as follows: pre-incubation at 95 °C for 3 
seconds, followed with 45 cycles of amplification: 95 °C for 3 seconds, 60 °C (or 61 °C for the mouse 
PEPCK primer set) for 20 seconds and 72 °C for 3 seconds. This was followed with a melting step at 
95 °C for 10 seconds. The amplicon size was confirmed on a 2% (w/v) agarose denaturing gel 
(Addendum A, Fig.A3). GAPDH was used as an internal control for BWTG3 samples and 18S and β-
actin for HepG2 samples. The mRNA levels of the gene of interest was normalized relative to the 
respective internal control. Relative quantification of the target genes was performed using the 





Table 2.3. Details of primers used for real-time quantitative PCR analysis. 








































242 bp 60 °C 2.13 
CTCCTTAATGTCACGCACGAT Reverse 





 Western Blot analysis  
2.6.1  Preparation of protein lysates 
For western blot analysis, BWTG3 and HepG2 cells were treated as described in section 2.2.2 for dose 
response and time course experiments. Whole cell lysates were prepared: briefly, cells were washed 
with 1x ice-cold PBS, then lysed in 100 µl passive lysis buffer containing 0.09 M Tris pH 8.0, 0.5 M 
EDTA, 10% glycerol, 0.2% (v/v) TritonX-100, 0.125 M sodium fluoride (NaF), 50 mM sodium 
orthovanadate (Na3VO4), and 1% (v/v) phenylmethylsulphonyl fluoride (PMSF). Additionally, protease 
and phosphatase inhibitor tablets (both purchased from Roche Applied Science) were added. Cell lysis 
was promoted with an overnight freeze-thaw cycle, followed by the addition of 5x SDS-reducing lysis 
buffer (1 M Tris-HCl (pH 6.8), 10% SDS, 0.1% (w/v) bromophenol blue and 20% (v/v) glycerol). 
Protein lysates were boiled at 95°C for 15 minutes, to denature the proteins, and stored at -20 °C until 
further analysis. 
2.6.2 SDS-PAGE Electrophoresis and Western Blot 
For gel electrophoresis, protein lysates were separated on a 10% polyacrylamide gel at a constant 
voltage of 100 V for 15 minutes, and 200 V for 90 minutes, in 1X running buffer (3.03% (w/v) Tris, 
14.41% (w/v) glycine, 1% SDS). Proteins were transferred onto a HybondTM ECLTM nitrocellulose 
membrane (AEC Amersham) for 2 hours at a constant current of 0.18 A in cold 1X transfer buffer 
(3.03% (w/v) Tris, 14.41% (w/v) glycine, 1% SDS and 10% (v/v) methanol). Membranes were blocked 
in 5% (w/v) fat-free milk powder prepared in 1X Tris Buffered Saline (TBS) (0.05 M Tris, 0.15 M 
NaCl) containing 0.1% (v/v) Tween-20 (1X TBST), for 90 minutes at room temperature. Membranes 
were rinsed with 1X TBST and incubated with the primary antibodies overnight at 4 °C (Table 2.2), 
while agitating. Anti-phospho-insulin receptor (Tyr1150 & Tyr1151) (1:1000, cat# 81500, Santa Cruz 
Biotechnology), anti-phospho-insulin receptor substrate-2 (Ser731) (1:500, cat# ab3690, Abcam), anti-
phospho Akt (Ser473) (1:1000, cat# 4060, Cell Signalling Technology), anti-phospho Akt (Thr308) 
(1:700, cat# 13038, Cell Signalling Technology) were used to probe for phosphorylated proteins. Anti-
insulin receptor (1:500, cat# CT-1, ThermoFisher Scientific) and anti-AKT (1:1000, cat# 9272, Cell 
Signalling Technology) were used to probe for total proteins. Anti-EF-1α1 (1:1000, cat# 21758, Santa 
Cruz Biotechnology) and anti-Hsp90 (1:1000, cat# 7647, Santa Cruz Biotechnology) were used for 
loading controls to normalize for equal loading of proteins. All primary antibodies were prepared in 
1X TBST and stored at 4 °C. After incubating with the primary antibodies, the membranes were rinsed 
twice in 1X TBST for 5 minutes followed by one rinse with 1X TBS for 5 minutes, prior to incubation 
with the appropriate secondary antibody conjugated to HRP for 90 minutes at room temperature 
(Table 2.2). Goat anti-rabbit IgG-HRP (cat# ab6791) and rabbit anti-mouse IgG-HRP (cat# ab97046) 
were purchased from Abcam and goat anti-mouse IgG-HRP (cat# A9917) was purchased from Sigma-





with secondary antibodies, the membranes were washed as previously described and visualized using 
the Western ECL substrate (BioRad) for 5 minutes. Chemiluminescence was detected using the MyECL 
Imager (Thermo-Scientific). The MyImageAnalysis® software version 2.0 (Thermo-Scientific) was 
used to quantify all western blot images.  
 
Table 2.4. Specific antibodies and dilutions used for Western Blot analysis. 
Protein Primary (1°) antibody Secondary (2°C) antibody 
Phosphorylated insulin 
receptor 
1:1000 p-IR (Tyr1150 & 1151)1 1:2000 goat anti-mouse3 
Total insulin receptor 1:500 Total-IR2 1:2000 goat anti-mouse3 
Phosphorylated IRS-2 1:500 Phospho-IRS-2 (Ser731)4 
1:10 000 goat anti-rabbit4 
 
Phosphorylated Akt 
1:700 p-Akt (Thr308)5 
1:1000 p-Akt (Ser473)5 
Total Akt 1:1000 Total Akt5 
Hsp90 1:1000 Hsp901 
EF-1α1 1:1000 EF-1α11 1:10 000 rabbit anti-mouse4 









 Hepatic glucose production 
2.7.1 Induction of glucose production 
In order to measure hepatic glucose production, a protocol previously optimized for primary mouse 
hepatocytes was followed (323). BWTG3 and HepG2 cells were plated into 24-well plates at a density 
of 2x105 cells/well and grown to 70-80% confluency. Cells were serum-starved for 24-hours, followed 
with a pre-treatment with 10ng/ml PAI-1, 10 µg/ml SAA, and 4.5 µg/ml CRP for 48 hours. A one-hour 
pre-treatment with 100 ng/ml insulin was used as a negative control, as insulin is known to decrease 
de novo glucose synthesis. Cells were washed twice with pre-warmed sterile 1X PBS followed with an 
incubation in 250 µl glucose production buffer (consisting of phenol red free DMEM without glucose, 
2 mM L-glutamine, 15 mM HEPES, 20 mM sodium lactate and 2 mM sodium pyruvate as substrates 
for gluconeogenesis) for 6 hours in the presence of the test compounds (10 ng/ml PAI-1, 10 µg/ml SAA, 
and 4.5 µg/ml CRP), with or without 100 ng/ml insulin. The medium was collected, and extracellular 
glucose content was measured using a fluorometric glucose assay method based on the principles of the 
Amplex/Glucose Oxidase assay kit (ThermoFisher Scientific), discussed in detail in Addendum B. 
 
2.7.2 Glucose measurement assay 
To measure the extracellular glucose output, a fluorometric glucose detection method was utilised, 
which is based on the principle of the Amplex Red/Glucose oxidase kit (ThermoFisher Scientific). This 
assay is based on two reactions: 1) the conversion of glucose to D-gluconolactone and hydrogen 
peroxide (H2O2) by glucose oxidase and 2) the oxidation of a substrate by H2O2 catalysed by horseradish 
peroxidase (HRP). In this assay AmpliFlu (similar to Amplex Red) (Sigma-Aldrich, cat#90101) was 
used as a substrate for HRP to produce the red fluorescent product, resorufin (324, 325). After collection 
of 200 µl of the medium, 50 µl was added into each well of a 96-well microplate. A working reagent 
was freshly prepared each time before an experiment containing 10 µM AmpliFlu, 0.2 U/ml HRP 
(Sigma-Aldrich, cat#SRE0082) and 2 U/ml glucose oxidase (Sigma-Aldrich, cat#G7141) in glucose 
production buffer and 50 µl was added to each well. The microplate was incubated for 30 minutes at 
room temperature and protected from light (AmpliFlu is light sensitive). The fluorescence was 
measured at an excitation wavelength of 571 nm and emission wavelength of 585 nm (Addendum A, 
Fig.A4). A no-glucose containing control (glucose production buffer) was used to correct for 
background fluorescence. The relative fluorescence measured was normalized to total protein content 






 Protein determination  
To quantify the total protein content of the cell lysates, the PierceTM BCA (Bicinchoninic acid) protein 
assay (ThermoFisher Scientific) was utilised, which essentially measures the reduction of Cu2+ to Cu1+ 
by proteins in an alkaline solution, which is detected by bicinchoninic acid (326). Firstly, bovine serum 
albumin (BSA) standards were prepared by performing 8 serial dilutions of 1 ml BSA stock (2 mg/ml 
dissolved in H2O) in RIPA buffer (56 mM 1M Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA and 0.1% 
SDS) to concentrations ranging from 25-2000 µg/ml. Subsequently, the BCA working reagent was 
prepared: for each cell lysate, reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and reagent B (containing 4% cupric 
sulphate) was mixed in a 50:1 ratio. For the reaction in the 96-well microplate, 10 µl of cell lysate (in 
an appropriate dilution made in RIPA buffer) or the prepared standards was added to each well as well 
as 200 µl of working reagent. The microplate was incubated at 37 °C for 30 minutes and protected from 
light. The reaction forms a purple colour and the BCA/Cu1+ complex exhibits a strong absorbance at 
562 nm. The absorbance was measured at 562 nm and a standard curve was composed using GraphPad 
Prism® version 5 software. The protein concentration of each cell lysate was measured by interpolating 
the absorbance readings of each cell lysate into the standard curve and using the equation of the linear 
region, taking the Beer-lambert law into account.  
 
 Statistical analysis 
Visual representation of data and statistical analysis was conducted using GraphPad Prism® version 5 
software. For western blot analysis, specifically dose response experiments, a student t-test was used to 
compare the specific treatment to the vehicle and insulin control. For time course experiments, one-way 
ANOVA with Tukey’s Multiple Comparison’s post-test was used to compare between the different 
treatment times. Additionally, two-way ANOVA was used to compare the two data sets for the time 
course experiment. For real-time qPCR, one-way ANOVA with Tukey’s Multiple Comparison’s post-
test was used to compare the different treatment times with the vehicle and insulin control. Statistical 
significance was indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.0001, respectively. No 
statistical significance (ns) indicates p>0.05. All data shown represents two or three independent 
experiments, with the error bars indicating standard deviation (SD) for two independent experiments 

















3.1 Establishing an experimental model that displays maximal 
sensitivity to insulin 
Activation of the insulin signalling pathway is initiated when insulin binds to the insulin receptor (IR), 
initiating a phosphorylation cascade. Nodes within this phosphorylation cascade include the PI3K/Akt 
pathway, linked to the insulin receptor signalling via adaptor proteins, such as the insulin receptor 
substrates (IRSs) (Fig.3.1). Unperturbed insulin signalling eventually leads to the transcriptional 
regulation of various genes in addition to regulating the activity of various proteins involved in glucose 
metabolism via post-translational modifications. The ability of insulin to activate these key proteins in 
the pathway determines the cells responsiveness to insulin.  
Most studies use 100 nM insulin which correlates to 580 ng/ml to stimulate the insulin signalling 
pathway, irrespective of the tissue-or cell type (149, 260, 274, 287, 327). To confirm active insulin 
signalling in the murine hepatoma (BWTG3) cells, two insulin concentrations, 100 ng/ml and 500 ng/ml 
were used to determine the optimal conditions required for the activation of key proteins in the insulin 
signalling pathway. Additionally, whether a high glucose concentration, as found in traditional culture 
medium, could affect insulin signalling was also considered. Consistent exposure to high glucose levels 
are known to inhibit insulin signalling (328, 329). For this reason, a comparative study between the 
traditional culture medium, which contains 25 mM glucose (high glucose), and culture medium with 5 
mM glucose (low glucose) was included to further determine the optimal conditions for the activation 
of the insulin signalling pathway. More specifically, the phosphorylation status of the IR at 
Tyr1150 & 1151, Akt at Ser473, and IRS-2 at Ser731 was measured. The total Akt levels was also 
determined in response to insulin treatment.  
Firstly, western blot analysis showed that 100 ng/ml insulin was sufficient for maximal induction of IR 
-and Akt phosphorylation in the BWTG3 cells (Fig.3.2A & C). There was no significant difference 
(p>0.05) between the two insulin concentrations used, no matter the glucose concentration of the culture 
medium (Fig.3.2A, C & D). Lastly, high glucose culture medium affected the ability of insulin to 
optimally activate the IR and Akt (Fig.3.2A & C). For example, both insulin concentrations caused a 
greater increase in the phosphorylation of IR in low glucose medium (Fig3.2A). Additionally, culturing 
the cells in high glucose resulted in a significant (p<0.01) increase in IRS-2 Ser731 phosphorylation 
(4.2-fold) (Fig3.2B). Furthermore, whilst insulin at both concentrations used was unable to induce Akt 
phosphorylation at Ser473 in cells cultured in high glucose medium, insulin did significantly (p<0.001) 
increase Akt phosphorylation at Ser473 by 163-fold (Fig.3.2C) when cells were grown in low glucose 
culture medium as well as slightly decrease the phosphorylation of IRS-2 at Ser731 (Fig.3.2B), which 
was expected. As a result, going forward, the BWTG3- and HepG2 cells were maintained in low glucose 







Figure 3.1. Simplified illustration of key nodes in the insulin signalling pathway, specifically the PI3K/Akt pathway. Insulin 
binding to the IR results in autophosphorylation at its tyrosine residues and thus activation of the protein, leading to subsequent 
recruitment and activation of IRS-1 and 2. This results in the phosphorylation of the central protein, Akt, at its Thr308, by PDK1 
which involves the recruitment of various intermediate proteins (represented by the dotted arrow). Finally, mTORC2 
phosphorylates Akt at its Ser473 residue resulting in the full activation of the protein, resulting in the regulation of various 
downstream targets. Finally, the pathway can be regulated by phosphorylation of the IRS proteins at their serine residues, resulting 
in the inhibition of downstream targets which include the transcription of gluconeogenic genes, G6Pase and PEPCK. (A), (B) and 
(C), represents the three nodes that will be investigated in this study as well as (D) which represents the downstream target that 
will be investigated. These include (A) tyrosine phosphorylation of the IR at Tyr1150 & 1151, (B) phosphorylation of Akt at 
Thr308 and Ser473, (C) Ser731 phosphorylation of IRS-2 and (D) transcriptional regulation of G6Pase and PEPCK. IR = insulin 
receptor; IRS1/2 = insulin receptor substrates 1 and 2; PDK1= 3-phosphoinositide-dependent protein kinase 1; mTORC2 = 












Figure 3.2. An experimental model system that displays optimal activation of the insulin signalling pathway 
was established in murine hepatoma cells. BWTG3 cells were cultured and maintained in either traditional 
culture medium containing high glucose (25 mM) or culture medium containing low glucose (5 mM). Following 
serum-starving for 24 hours, the cells were treated with 100 ng/ml and 500 ng/ml insulin for 30 minutes prior to 
cell lysis. Phosphorylation of the insulin receptor (IR) at Tyr1150 & 1151 (A), insulin receptor substrate-2 (IRS) 
at Ser731 (B), Akt at Ser473 (C) as well as total Akt levels (D) were measured using western blot analysis and 
quantified relative to the loading control GAPDH and EF-1α1. Statistical analysis comparing the insulin treatment 
relative to the vehicle (*), which was set to 1 (represented as a dotted line), and the glucose concentrations to the 
insulin treatment (#) was performed using a two-tailed unpaired Student’s t-test (*/#p<0.05, **/##p<0.01, 
***p<0.001). 
 
3.2 Activation of the insulin signalling pathway 
Having established the model system for this study, the effect of the selected APPs on insulin signalling 
was investigated. As a control for each experiment, BWTG3 and HepG2 cells were treated with insulin 
in the absence of the APPs to confirm a functional insulin signalling pathway as determined by western 
blot analysis, which thus served as a positive control in all subsequent experiments. In BWTG3 cells, 
phosphorylation of the IR at Tyr1150 & 1151 significantly (p<0.01) increased by 8.6-fold upon 
100 ng/ml insulin treatment for 30 minutes (Fig.3.3A). A small (1.3-fold) but significant (p<0.05) 
increase was observed in total IR levels (Fig.3.3B). Further downstream activation of the pathway was 
confirmed as treatment with 100 ng/ml insulin significantly (p<0.001) increased Akt phosphorylation 
at Thr308 by 4.2-fold (Fig.3.3D) and at Ser473 by 81-fold (Fig.3.3E). The total Akt protein levels also 
significantly (p<0.05) increased by 1.7-fold (Fig.3.3F). The inhibitory phosphorylation site of IRS-2 at 
Ser731 was not affected by 100 ng/ml insulin treatment (Fig.3.3C). In HepG2 cells 100 ng/ml insulin, 
like in BWTG3 cells, slightly increased total IR levels (1.3-fold increase) (Fig.3.4A). Similarly, insulin, 
significantly (p<0.001), induced phosphorylation of Akt at Thr308 by 31-fold (Fig.3.4C) whilst a 
53-fold increase in phosphorylation of Akt at Ser473 (Fig.3.4D) was observed in HepG2 cells. Insulin 
treatment slightly increased total Akt protein levels (1.2-fold, Fig3.4E) in HepG2 cells albeit not 
significantly (p>0.05). Taken together, both cell lines responded to insulin treatment similarly albeit to 
different degrees. For example, Akt phosphorylation at Thr308 in the HepG2 cell model was more 
responsive to insulin (31-fold) when compared to the BWTG3 cell line (4.2-fold). In contrast, 
insulin-induced Akt phosphorylation at Ser473 was more pronounced in BWTG3 cells (81-fold) than 
HepG2 cells (53-fold) (Fig3.3E vs Fig3.4.D).                                                                                                                                                                                                                                                                                                                                                                                  
Finally, like in BWTG3 cells, phosphorylation of IRS-2 at Ser731 was not significantly (p>0.05) 
affected by the insulin treatment in HepG2 cells (Fig.3.4B). In summary 30-minute treatment with 
100 ng/ml insulin was able to successfully activate key proteins in the insulin signalling pathway, such 





It should be noted that phosphorylation of the IR could not be investigated in HepG2 cells due to 
difficulty experienced with the commercially obtained antibody used in this investigation, therefore 




Figure 3.3. Insulin successfully activates the phosphorylation of key regulatory proteins in the insulin signalling pathway 
in BWTG3 cells. Murine hepatoma (BWTG3) cells, grown in low glucose (5 mM) medium, were serum-starved for 24 hours 
followed with by a 100 ng/ml insulin treatment for 30 minutes prior to cell lysis. Phosphorylation of the insulin receptor (IR) at 
Tyr1150 & 1151 (A), insulin receptor substrate-2 (IRS-2) at Ser731 (C) and Akt at both the Thr308 and Ser473 site (D and E), as 
well as the total protein expression (B and F) was measured and quantified relative to the loading control, EF-1α1 or Hsp90 ( 
representative blots shown next to graphs). The vehicle was set to 1 and statistical analysis comparing the insulin treatment relative 







Figure 3.4. Insulin successfully activates key regulatory proteins in the insulin signalling pathway in human hepatoma cells. 
HepG2 cells, grown in low glucose (5 mM) medium were serum-starved for 24 hours. Cells were then treated with 100 ng/ml 
insulin for 30 minutes prior to cell lysis. Total insulin receptor (IR) (A) expression, as well as phosphorylation of insulin receptor 
substrate-2 (IRS-2) at Ser731 (B) and Akt at both Thr308 (C) and Ser473 (D) in addition to total Akt (E) expression was measured 
and quantified relative to the loading control, EF-1α1 or Hsp90 (representative blots are shown next to graph). The vehicle was 
set to 1 and statistical analysis comparing the insulin treatment relative to the vehicle control was done using a two-tailed unpaired 






3.3 The effects of selected acute phase proteins, PAI-1, SAA, and 
CRP on insulin-induced activation of the insulin signalling 
pathway  
The central focus of this study was to investigate the effect of three different acute phase proteins 
(APPs), plasminogen activator inhibitor-1 (PAI-1), serum amyloid A (SAA), and C-reactive protein 
(CRP) on insulin-induced activation of key nodes in the insulin signalling pathway. Systematic 
evaluation of the insulin signalling pathway was investigated starting with the insulin receptor, followed 
by IRS-2, and lastly Akt (Fig.3.1). Activation of the proteins via phosphorylation and total protein levels 
were examined using western blot analysis. Finally, interference of factors, other than the chosen APPs, 
on the insulin signalling pathway were limited by culturing the cells in medium containing low glucose 
concentrations (5 mM) and serum-starving for 24 hours prior to APP treatment. Additionally, the insulin 
concentration used to activate the insulin signalling pathway was optimised as described in section 3.1.  
  
3.3.1 Activation of the insulin receptor is differentially regulated by 
PAI-1, SAA, and CRP 
As previously described, phosphorylation of the IR at tyrosine residues is important for downstream 
signalling to elicit a biological response, indicative of a receptor tyrosine kinase. Therefore, western 
blot analysis was performed to investigate the effect of the APPs, PAI-1, SAA, and CRP on insulin-
induced phosphorylation of the IR at Tyr1150 & 1151 in BWTG3 cells. As shown previously 
(Fig.3.3A), insulin alone increased the phosphorylation of IR at Tyr1150 & 1151 in the murine 
hepatoma cells. This increase in phosphorylation was set to 1 as well as the effect of insulin on total IR 
levels when compared to the effect of the APPs on the insulin-induced effect (Fig.3.5). Pre-treatment 
with 5 ng/ml PAI-1 significantly (p<0.01) reduced the insulin-induced phosphorylation of the IR by 
23% (Fig.3.5A). In contrast, higher PAI-1 concentrations of 10 and 20 ng/ml caused a slight increase 
in the insulin-induced phosphorylation of the IR, by 1.2- and 24%, respectively (Fig.3.5A). The total 
IR protein levels, however, were not significantly (p>0.05) affected by PAI-1, at any of the three 
concentrations used (Fig.3.5B). Like PAI-1, SAA pre-treatment for 24 hours showed a similar effect 
regarding insulin-induced phosphorylation of the IR, with 5 µg/ml SAA causing a 18% decrease in the 
insulin-induced phosphorylation, and 10 and 20 µg/ml causing a 9- and 25% increase, respectively 
(Fig.3.5C). Furthermore, SAA was the only selected APP that decreased the total IR protein levels at 
all three concentrations, by 50%, 32% and 19%, respectively (Fig.3.2D). Interestingly, CRP treatment 





with 2.5 and 4.5 µg/ml CRP decreasing phosphorylation by 31- and 20%, respectively (Fig.3.5E). CRP 
at both concentrations used however had no significant effect (p>0.05) on the total IR levels (Fig.3.5F).  
When investigating the effect of the selected APPs on the total IR expression in HepG2 cells (Fig.3.6), 
different responses were observed in comparison to the BWTG3 cells. Whilst in BWTG3 cells 
pre-treatment with PAI-1 at all the concentrations tested had no significant effect on total IR protein 
levels (Fig3.5B) this was not the case with total IR protein levels in HepG2 cells in response to PAI-1 
treatment (Fig.3.6A). The total IR protein levels in HepG2 cells were increased to a similar extent by 
the different PAI-1 concentrations used, with 5 ng/ml resulting in a 1.4-fold increase (p<0.001) and 
10 ng/ml and 20 ng/ml causing a 1.6-fold (p<0.01) increase (Fig.3.6A). SAA pre-treatment in HepG2 
cells showed differential effects on the total IR protein levels, depending on the concentration used. 
Like PAI-1, pre-treatment with 5 µg/ml SAA caused a significant (p<0.05) increase of 1.4-fold, while 
10 and 20 µg/ml significantly (p<0.001) decreased total IR levels 25- and 53%, respectively (Fig.3.6B). 
Pre-treatment with both concentrations of CRP, 2.5 and 4.5 µg/ml, significantly (p<0.05 and p<0.01 
respectively) decreased total IR levels by 36- and 43%, respectively, in contrast to what was observed 








Figure 3.5. The APPs, PAI-1, SAA, and CRP differentially regulate phosphorylation of the insulin receptor as well as 
its total receptor levels in the mouse hepatoma cell line, BWTG3. BWTG3 cells were serum-starved for 24 hours and 
treated with physiological concentrations of PAI-1 (5-20 ng/ml) (A & B), SAA (5-20 µg/ml) (C & D) and CRP (2.5 and 4.5 
µg/ml) (E & F) for 24 hours followed by a 30 minute treatment with 100 ng/ml insulin to stimulate the insulin signalling 
pathway prior to cell lysis. Phosphorylation of the insulin receptor (IR) at Tyr1150 & 1151 (A, C, E) and total insulin receptor 
expression (B, D, F) was measured and quantified relative to the loading control, EF-1α1 (G shows a representative blot). 
The response of the APPs used were normalised relative to the insulin control which was set to 1 and represented by the 
dotted line. Data shown represents three independent experiments. Statistical analysis comparing the relative APP treatments 






Figure 3.6. The APPs, PAI-1, SAA and CRP differentially regulate expression of the total insulin receptor levels in the human 
hepatoma cell line, HepG2. HepG2 cells were serum-starved for 24 hours and pre-treated with physiological concentrations of 
PAI-1 (5-20 ng/ml) (A), SAA (5-10 µg/ml) (B), CRP (2.5 and 4.5 µg/ml) (C) for 24 hours followed by a 30 minute treatment with 
100 ng/ml insulin to stimulate the insulin signalling pathway prior to cell lysis. Total IR protein levels were measured and quantified 
relative to the loading control, EF-1α1 (D shows the representative blot). The response of the APPs used were normalised relative 
to the insulin control which was set to 1 and represented by the dotted line. Data shown represents three independent experiments. 
Statistical analysis comparing the relative APP treatments to the insulin control was performed using a two-tailed unpaired Student’s 






3.3.2 The inhibition of IRS-2 is differentially affected by the APPs, 
PAI-1, SAA, and CRP 
Following activation of the IR, IRS-2 is recruited and binds to the IR and is subsequently activated 
through phosphorylation at its tyrosine residues (Fig.3.1). However, the ability of the IRS to bind to the 
IR is reduced when certain serine residues are phosphorylated, thereby preventing the IRS-2 from 
undergoing tyrosine phosphorylation and thus inhibiting its activity (145, 330). It is for this reason that 
phosphorylation of IRS-2 at Ser731 was investigated in response to the APPs using western blot 
analysis. Firstly, 100 ng/ml insulin treatment for 30 minutes had no significant (p>0.05) effect on the 
phosphorylation of IRS-2 at Ser731 site in both BWTG3 cells (Fig.3.3C) and HepG2 cells (Fig.3.4B). 
Subsequently, in BWTG3 cells treatment with PAI-1 for 24 hours prior to insulin exposure showed 
differential effects, with 5 ng/ml significantly (p<0.01) reducing phosphorylation of IRS-2 (35%), while 
10 ng/ml caused a slight, although not significant, increase (13%) and 20 ng/ml PAI-1 had no effect 
(Fig.3.7A). The effect of SAA on Ser731 phosphorylation of IRS-2 was also dependent on the 
concentration. The lowest concentration SAA (5 µg/ml) used resulted in a 20% decrease although not 
significant (p>0.05), whilst 10 and 20 µg/ml SAA both increased phosphorylation of IRS-2 at Ser731 
by 8%, although only 20 µg/ml SAA showed statistical significance (p<0.01) (Fig.3.7B). In contrast to 
PAI-1 and SAA, CRP at 2.5 and 4.5 µg/ml significantly (p<0.01 and p<0.001, respectively) reduced 
the phosphorylation of IRS-2 at Ser731 by 28- and 44%, respectively (Fig.3.7C), which suggest 
unhindered binding to the IR.  
In HepG2 cells treatment with 5 ng/ml PAI-1 for 24 hours prior to insulin exposure caused a significant 
(p<0.01) increase in phosphorylation of IRS-2 at Ser731 (1.2-fold), while 10 and 20 ng/ml had no 
significant effect (Fig.3.8A). Additionally, the effect of SAA treatment on Ser731 phosphorylation of 
IRS-2 was independent of concentration, with 5 µg/ml causing a 28% decrease, although not significant, 
and 10 and 20 µg/ml SAA treatment caused a significant (p<0.05 and p<0.01, respectively) decrease in 
IRS-2 phosphorylation of 29- and 34%, respectively (Fig.3.8B). Similarly, to what was observed in 
BWTG3 cells, CRP at the two concentrations tested, 2.5 and 4.5 µg/ml, significantly (p<0.001 and 
p<0.05, respectively) decreased the phosphorylation of IRS-2 at Ser731 by 36% and 34%, respectively 
(Fig.3.8C).  
In summation, these results show that in both the murine and human liver cell models, the APPs, PAI-1, 







Figure 3.7. The APPs, PAI-1, SAA and CRP regulate the inhibition of the insulin receptor substrate-2 via Ser731 
phosphorylation in the mouse hepatoma cell line, BWTG3. BWTG3 cells were serum-starved for 24 hours and pre-treated with 
physiological concentrations of PAI-1 (5-20 ng/ml) (A), SAA (5-20 µg/ml) (B), and CRP (2.5 and 4.5 µg/ml) (C) for 24 hours 
followed by a 30 minute treatment with 100 ng/ml insulin to stimulate the insulin signalling pathway prior to cell lysis. 
Phosphorylation of the insulin receptor substrate-2 (IRS-2) at Ser731 was measured and quantified relative to the loading control, 
Hsp90 (D shows the representative blot). The response of the APPs used were normalised relative to the insulin control which was 
set to 1 and represented by the dotted line. Data shown represents three independent experiments. Statistical analysis comparing the 






Figure 3.8. The APPs, PAI-1, SAA and CRP regulate the inhibition of the insulin receptor substrate-2 via Ser731 
phosphorylation in the human hepatoma cell line, HepG2. BWTG3 cells were serum-starved for 24 hours and pre-treated with 
physiological concentrations of PAI-1 (5-20 ng/ml) (A), SAA (5-20 µg/ml) (B), and CRP (2.5 and 4.5 µg/ml) (C) for 24 hours 
followed by a 30 minute treatment with 100 ng/ml insulin to stimulate the insulin signalling pathway prior to cell lysis. 
Phosphorylation of the insulin receptor substrate-2 (IRS-2) at Ser731 was measured and quantified relative to the loading control, 
Hsp90 (D shows the representative blot). The APPs used were normalised relative to the insulin control which was set to 1. Data 
shown represents three to four (for SAA) independent experiments. Statistical analysis comparing the relative APP treatments to the 






3.3.3 Insulin-induced activation of Akt at both Thr308 and Ser473 is 
differentially affected by PAI-1, SAA, and CRP 
Activation of the central protein of the insulin signalling pathway, Akt, is required for downstream 
signalling, which regulates energy homeostasis, and more specifically lipid and glucose metabolism in 
the liver. Phosphorylation of Akt at Thr308 and Ser473 is required for maximum activity (121, 123–
125). As mentioned earlier (section 3.2) insulin alone increased phosphorylation of Akt at Thr308 and 
Ser473 in both the murine (Fig.3.3D and E) and human hepatoma cells (Fig.3.4C and D). Disruption of 
the insulin-induced phosphorylation at these sites plays an important role in the development of insulin 
resistance (160, 162). Therefore, the possible effect of the selected APPs on insulin-induced Akt 
phosphorylation was of interest. Firstly, in BWTG3 cells, treatment with increasing concentrations of 
PAI-1 (5-20 ng/ml) for 24 hours before insulin exposure significantly (p<0.001) reduced insulin-
stimulated phosphorylation of Akt at Thr308. The percentage inhibition for 5 ng/ml, 10 ng/ml, and 
20 ng/ml was 30%, 41%, and 49% respectively. (Fig.3.9A). In contrast, insulin-induced 
phosphorylation of Akt at Ser473 was differentially regulated by the concentrations of PAI-1 used 
(Fig.3.9B). Pre-treatment with 5 ng/ml PAI-1 resulted in a slight but significant (p<0.05) decrease in 
insulin-induced Akt phosphorylation at Ser473, whilst 20 ng/ml PAI-1 significantly (p<0.001) 
increased insulin-induced phosphorylation at this site by 1.4-fold (Fig.3.9B). In contrast, 10 ng/ml PAI-
1 had no significant effect on insulin-induced phosphorylation of Akt at Ser473 (Fig.3.9B). SAA, unlike 
PAI-1, had no significant (p<0.05) effect on the insulin-induced phosphorylation of Akt at Thr308 
(Fig.3.9C), but significantly (p<0.01) attenuated insulin-induced phosphorylation of Akt at Ser473 at 
all concentrations used (Fig.3.9D). Similar to PAI-1, pre-treatment with CRP, specifically 4.5 µg/ml 
CRP, significantly (p<0.01) reduced insulin-induced Akt phosphorylation at Thr308 by 18% (Fig.3.9E). 
Both concentrations of CRP used had no significant (p>0.05) effect on the insulin-induced 
phosphorylation of Akt at Ser473 (Fig.3.9F). 
Total Akt protein levels were also differentially regulated by the APPs in BWTG3 cells. Firstly, PAI-1 
at all the concentrations used had no effect on total Akt protein levels (Fig.3.10A). In contrast, both 
SAA and CRP affected Akt protein levels albeit dependant on the concentration used. The lowest 
concentration of SAA (5 µg/ml) used, significantly (p<0.01) decreased total Akt levels, whilst 20 µg/ml 
significantly (p<0.001) increased Akt protein levels (Fig.3.10B). Similarly, the lowest concentration of 
CRP (2.5 µg/ml) used, significantly (p<0.001) inhibited total Akt levels, whilst the highest 
concentration (4.5 µg/ml) used, increased Akt protein levels (Fig.3.10C).  
In HepG2 cells, only the highest concentration tested for PAI-1 (20 ng/ml) had a significant effect on 
insulin-induced phosphorylation of Akt at both Thr308 and Ser473 (Fig.3.11A & B). Treatment with 
20 ng/ml PAI-1 resulted in a 20% significant (p<0.01) decrease in insulin-induced Akt phosphorylation 





Ser473 by 26% (p<0.05) (Fig.3.11B). SAA, unlike PAI-1, at all the concentrations tested, significantly 
(p<0.001) reduced insulin-induced Akt phosphorylation at Thr308 (Fig.3.11C). The percentage 
inhibition for 5, 10, and 20 µg/ml was 49%, 52%, and 61%, respectively. Similarly, SAA at 5 and 10 
µg/ml was able to significantly (p<0.001 and p<0.01 respectively) inhibit insulin-induced 
phosphorylation at Ser473 by 39% and 34%, respectively (Fig3.11D). Although a slight inhibition was 
observed for 20 µg/ml SAA no significance could be established (p>0.05). Furthermore, pre-treatment 
with both concentrations used for CRP attenuated insulin-induced activation of Akt at Thr308. CRP 
was able to significantly (p<0.01) reduce insulin-stimulated phosphorylation of Akt at Thr308 by 50% 
and 59% for at 2.5 and 4.5 µg/ml CRP, respectively (Fig.3.11E). Insulin-induced Akt phosphorylation 
at Ser473 phosphorylation was also significantly inhibited by 26% (p<0.05) and 22% (p<0.01) when 
pre-treated with 2.5 and 4.5 µg/ml CRP, respectively (Fig.3.11F). PAI-1 also had no significant 
(p>0.05) effect on the total Akt levels in HepG2 cells, except at the highest concentration (20 ng/ml), 
which caused a slight but significant (p<0.05) increase of 1.2-fold (Fig3.12A). The lowest concentration 
of SAA (5 µg/ml) significantly (p<0.05) decreased total Akt levels by 36% (Fig.3.12B), while 10 and 
20 µg/ml SAA, along with both concentrations of CRP (Fig.3.12C) had no significant (p>0.05) effect 










Figure 3.9. The APPs, PAI-1, SAA and CRP regulate the phosphorylation of Akt at Thr308 and Ser473 in the mouse 
hepatoma cell line, BWTG3. BWTG3 cells were serum-starved for 24 hours and pre-treated with physiological concentrations of 
PAI-1 (5-20 ng/ml) (A & B), SAA (5-20 µg/ml) (C & D), and CRP (2.5 and 4.5 µg/ml) (E & F) for 24 hours followed with a 
30 minute treatment with 100 ng/ml insulin to stimulate the insulin signalling pathway prior to cell lysis. Phosphorylation of the Akt 
at Thr308 (A, C, E) and Ser473 (B, D, F) was measured and quantified relative to the loading control, Hsp90 (for Thr308) and 
EF-1α1 (for Ser473) (G & H show the respective representative blots). The response of the APPs used were normalised relative to 
the insulin control which was set to 1 and represented by the dotted line. Data shown represents three independent experiments. 
Statistical analysis comparing the relative APP treatments to the insulin control was performed using a two-tailed unpaired Student’s 








Figure 3.10. The APPs, PAI-1, SAA and CRP differentially regulate Akt in the mouse hepatoma cell line, BWTG3. BWTG3 
cells were serum-starved for 24 hours and pre-treated with physiological concentrations of PAI-1 (5-20 ng/ml) (A), SAA 
(5-20 µg/ml) (B) and CRP (2.5 and 4.5 µg/ml) (C) for 24 hours followed with a 30 minute treatment with 100 ng/ml insulin to 
stimulate the insulin signalling pathway prior to cell lysis. Total Akt expression was measured and quantified relative to the loading 
control, EF-1α1 (D shows the representative blot). The response of the APPs used were normalised relative to the insulin control 
which was set to 1 and represented by the dotted line. Data shown represents three independent experiments. Statistical analysis 








Figure 3.11. The APPs PAI-1, SAA and CRP differentially effect the phosphorylation of Akt at Thr308 and Ser473 in the 
human hepatoma cell line, HepG2. HepG2 cells were serum-starved for 24 hours and pre-treated with physiological concentrations 
of PAI-1 (5-20 ng/ml) (A & B), SAA (5-20 µg/ml) (C & D) and CRP (2.5 and 4.5 µg/ml) (E & F) for 24 hours followed with a 
30 minute treatment with 100 ng/ml insulin to stimulate the insulin signalling pathway prior to cell lysis. Phosphorylation of the Akt 
at Thr308 (A-E) and Ser473 (C-F) was measured and quantified relative to the loading control, Hsp90 (for Thr308) and EF-1α1 (for 
Ser473) (G & H show the respective representative blot). The response of the APPs used were normalised relative to the insulin 
control which was set to 1 and represented by the dotted line. Data shown represents three independent experiments. Statistical 
analysis comparing the relative APP treatments to the insulin control was performed using a two-tailed unpaired Student’s t-test 







Figure 3.12. The APPs, PAI-1, SAA and CRP differentially effect Akt in the human hepatoma cell line, HepG2. HepG2 cells 
were serum starved for 24 hours and pre-treated with physiological concentrations of PAI-1 (5-20 ng/ml) (A), SAA (5-20 µg/ml) 
(B) and CRP (2.5 and 4.5 µg/ml) (C) for 24 hours followed with a 30 minute treatment with 100 ng/ml insulin to stimulate the 
insulin signalling pathway prior to cell lysis. Total Akt expression was measured and quantified relative to the loading control, 
EF-1α1 (D shows the representative blot). The response of the APPs used were normalised relative to the insulin control which was 
set to 1 and represented by the dotted line. Data shown represents two to three independent experiments. Statistical analysis 







3.4 Pro-longed exposure to acute phase proteins, PAI-1, SAA, 
and CRP increased their inhibitory effect on the insulin 
signalling pathway 
Chronic inflammation is directly, and indirectly, linked to insulin resistance, more specifically obesity-
related insulin resistance (20, 166, 183, 202, 203). This is characterized by chronic exposure to pro-
inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), and 
inflammatory markers such as SAA and CRP (263, 271, 331). Additionally, PAI-1 is considered an 
adipokine and marker of obesity (234, 243, 247) as it is increased in response to inflammation in 
adipocytes. This too is associated with chronic inflammation, which plays a role in the development of 
insulin resistance (242, 245, 246, 252). Furthermore, the normal acute phase response in the liver is 
considered rapid and peaks at 24-48 hours (209), but can last up to days (209, 215). Therefore, we 
decided to investigate whether the length of treatment could play a role in the effect that these APPs, 
PAI-1, SAA, and CRP, have on the insulin signalling pathway, by looking at what is defined as an 
“acute” and “chronic” (or pro-longed) exposure. Physiologically relevant concentrations of these APPs 
were chosen as indicated by the literature (35, 219, 236). Additionally, the dose response results (in 
section 3.3) were also taken into consideration. Consequently, a concentration of 10 ng/ml PAI-1, 
10 µg/ml SAA, and 4.5 µg/ml CRP was chosen, and a time-course was performed by pre-treating 
murine (BWTG3) and human hepatoma (HepG2) cells with these APPs for 2, 24, and 48 hours followed 
by 30 minutes insulin exposure. Regulation of the insulin signalling pathway was investigated using 
western blot analysis. 
 
3.4.1. PAI-1 and CRP similarly affect the activation of the insulin 
receptor, while SAA has no statistical effect 
As shown in section 3.2, in BWTG3 cells, treatment with 100 ng/ml insulin for 30 minute induced the 
phosphorylation of the IR (Fig.3.3A), while increasing the amount of total receptor (Fig.3.3B), which 
was subsequently set as 1 as previously mentioned. The time course suggests that PAI-1 and CRP affect 
insulin-induced phosphorylation of the IR to a similar extent as shown in Fig.3.13A. Pre-treatment for 
2 hours caused an initial increase in the insulin-induced phosphorylation, which subsequently decreased 
significantly (p<0.05) at 24 hours, reaching a maximum significant (p<0.01) inhibition at 48 hours of 
55% and 72% (p<0.001) for PAI-1 and CRP, respectively. In contrast to PAI-1 and CRP, SAA 
potentiated the insulin-induced phosphorylation of the IR over time, reaching a maximum significant 
(p<0.05) increase of 1.5-fold at 24 hours. This effect remained constant at 48 hours. Furthermore, PAI-1 





CRP already at 24 hours significantly (p<0.05) decreased total IR protein levels, reaching a maximum 
significant decrease of 63% at 48 hours (p<0.001) (Fig.3.13B). In contrast, SAA, had no significant 
(p>0.05) effect on the total IR levels although a slight but not significant (p>0.05) decrease of 18% at 
48 hours was observed. This result suggests that pro-longed exposure to PAI-1 and CRP, in BWTG3 
cells, is sufficient to attenuate the ability of insulin to increase its cognate receptor levels, which is the 
initial site of the insulin signalling pathway.  
In HepG2 cells, the selected APPs had no significant (p>0.05) effect on the total IR levels except for 
PAI-1 at 24 hours, which caused a significant (p<0.05) increase (Fig.3.13D). In contrast, PAI-1 and 
CRP decreased total IR protein levels to a similar extent at 48 hours by 46 and 57%, respectively, 
although significance could not be established (p>0.05).  Furthermore, a two-way ANOVA analysis 
indicated that the IR phosphorylation in BWTG3 cells and total IR expression in HepG2 cells are 
significantly (p<0.001) dependent on the APP used and the length of exposure (Fig.3.13A & D, 
respectively). However, this dependence on length of exposure and APP used, with regards to total IR 







Figure 3.13. The APPs, PAI-1, SAA and CRP decrease the phosphorylation of the insulin receptor as well the total receptor 
levels over time in both the mouse and human hepatoma cell lines, BWTG3 & HepG2. BWTG3 and HepG2 cells were serum-
starved for 24 hours followed with a treatment with 10 ng/ml PAI-1, 10 µg/ml SAA and 4.5 µg/ml CRP for 2, 24 and 48 hours (acute 
versus chronic exposure). The cells were treated with 100 ng/ml insulin for 30 minutes prior to cell lysis, to activate the insulin 
signalling pathway. Phosphorylation of the insulin receptor at Tyr1150 & 1511 (A) as well as the total receptor expression (B & D) 
was measured and quantified relative to loading control, EF-1α1 (C & E show the respective representative blots). The response of 
the APPs used were normalised relative to the insulin control, which was set to 1, and is represented by the dotted line. Data shown 
represents two independent experiments. Statistical analysis comparing the time treatments relative to the insulin control was 
performed using one-way ANOVA with Tukey’s Multiple Comparison’s Test (*p<0.05, **p<0.01, ***p<0.001). Additionally, the 
interaction between the time of treatment and the APP on the effect of the insulin receptor was analysed using a two-way ANOVA 





3.4.2. The phosphorylation of IRS-2 at Ser731 is differentially 
regulated by PAI-1 and CRP with different lengths of exposure 
In section 3.3.2 it was shown that, in the BWTG3 cells, the phosphorylation of IRS-2 at Ser731 is 
differentially affected by the different concentrations of PAI-1, SAA, and CRP used, when treated for 
24 hours. In agreement with this, as shown in Fig.3.14A, 10 ng/ml PAI-1, 10 µg/ml SAA, and 4.5 µg/ml 
CRP affect the phosphorylation of IRS-2 at Ser731 differentially in a time-dependent manner. PAI-1 
significantly (p<0.01) decreased the phosphorylation of IRS-2 at Ser731 at 2 hours by 25%, which was 
the maximum observed. This remained unchanged as the time of exposure increased, reaching a similar 
inhibition of 25% at 48 hours. In contrast, SAA had no significant (p>0.05) effect on the 
phosphorylation of IRS-2 at Ser731, although a 1.6-fold increase was observed at 2 hours, albeit not 
significant (p<0.05), while CRP, although initially increasing the phosphorylation of IRS-2 at Ser731 
at 2 hours, it subsequently significantly decreased at 24 and 48 hours (p<0.01 and p<0.001, 
respectively), reaching 59% maximal inhibition.  
In accordance with the BWTG3 results, the different concentrations of PAI-1, SAA, and CRP 
differentially affected the phosphorylation of IRS-2 at Ser731 in section 3.3.2. However, when exposed 
for different time periods, these APPs had no significant (p>0.05) effect on the phosphorylation of 
IRS-2 as shown in Fig.3.14B. Although not significant, pro-longed exposure to SAA and CRP for 
48 hours decreased phosphorylation of IRS-2 by 29% and 14%, respectively.  
Moreover, a two-way ANOVA analysis indicated that Ser731 phosphorylation of IRS-2 in BWTG3 and 
HepG2 cells is significantly (p<0.0001 and p<0.05, respectively) dependent on the two variables i.e. 
the APP used (PAI-1, SAA, and CRP) and the exposure time (Fig3.14 A & B, respectively). 
 
3.4.3 The activation of Akt at Thr308 is similarly affected by PAI-1 
and CRP with different lengths of exposure  
As previously shown (Fig.3.3C), in BWTG3 cells, treatment with 100 ng/ml insulin for 30 minutes 
significantly (p<0.001) increased the phosphorylation of Akt at Thr308, which was subsequently set as 
1 for further analysis as depicted in Fig.3.15A. Insulin-stimulated phosphorylation of Akt at Thr308 
was already inhibited by 10 ng/ml PAI-1 at 2 hours treatment although no significance could be 
established (p<0.05). This inhibition however became more pronounced over time, reaching a 
maximum inhibition of 41% at 48 hours (p<0.001). Like PAI-1, CRP significantly (p<0.01) attenuated 
insulin-stimulated phosphorylation of Akt at Thr308 at 2 hours, which over time gradually reached 
maximal inhibition of 59% at 48 hours. Thus, indicating that acute as well as chronic exposure to 





the Thr308 site. In contrast, SAA had no significant effect on the insulin-induced Akt phosphorylation 
at Thr308, although an inhibition of 61% at 2 hours was observed (Fig.3.15A).  
In HepG2 cells, as previously shown, insulin treatment resulted in a greater increase in Akt 
phosphorylation at Thr308 (Fig.3.4C), which was subsequently set as 1. Treatment with SAA and CRP 
inhibited insulin-induced phosphorylation of Akt at Thr308, with a significant decrease already 
demonstrated for both at 2 hours (Fig.3.15C). SAA caused a significant (p<0.01) decrease of 36% at 
2 hours, which was the maximum inhibition observed. CRP however, significantly (p<0.05) decreased 
phosphorylation over the time period investigated, resulting in a 51% decrease at 2 hours which 
continued to decrease, reaching 58% inhibition at 48 hours. In contrast to SAA and CRP, PAI-1 was 
unable to significantly affect insulin-induced phosphorylation of Akt at Thr308 (p>0.05) in HepG2 
cells. Two-way ANOVA analysis indicated that in both BWTG3 (Fig.3.15A) and HepG2 (Fig.3.15D) 
cells, phosphorylation of Akt at Thr308 is significantly (p<0.001 and p<0.01, respectively) dependent 














Figure 3.14. The APPs, PAI-1, SAA and CRP differentially regulate the phosphorylation of IRS-2 at Ser731 
over time in both the mouse and human hepatoma cell lines, BWTG3 & HepG2. BWTG3 (A & C) and HepG2 
(B & D) cells were serum-starved for 24 hours followed by PAI-1, SAA or CRP treatment for 2, 24 and 48 hours 
(acute versus chronic exposure). The cells were treated with 100 ng/ml insulin for 30 minutes prior to cell lysis, 
to activate the insulin signalling pathway. Phosphorylation of IRS-2 at Ser731 was measured and quantified 
relative to the loading control, Hsp90 (C & D show the respective representative blots). The response of the APPs 
used were normalised relative to the insulin control, which was set to 1, and is represented by the dotted line. Data 
shown represents two independent experiments. Statistical analysis comparing the time treatments relative to the 
insulin control was performed using one-way ANOVA with Tukey’s Multiple Comparison’s Test 
(*p<0.05, **p<0.01, ***p<0.001). Additionally, the interaction between the time of treatment and the APP on the 
effect of IRS-2 was analysed using a two-way ANOVA (#p<0.05 and ###p<0.001). 
 
3.4.4 PAI-1 and CRP show a similar trend at the Ser473 
phosphorylation of Akt and total Akt protein levels  
As with prior experiments the insulin-induced effect on both phosphorylation of Akt significantly 
(p<0.001) Ser473 and total Akt protein levels were set to 1 to evaluate the role of the APPs on insulin-
induced signalling.  
In BWTG3 cells, pre-treatment with 10 ng/ml PAI-1 for 2 hours reduced the insulin-stimulated 
phosphorylation of Akt at Ser473 as well as the total Akt levels albeit no significance could be 
established. This inhibition by PAI-1 remains constant at 24 hours and then decrease at 48 hours. 
Phosphorylation status of Akt at Ser473 and total Akt protein levels are maximally reduced by 64% 
(p<0.001) and 53% (p<0.001), respectively at 48 hours by PAI-1 (Fig.3.15B and C). Unlike PAI-1, 
CRP at the initial time points measured, namely 2- and 24-hours, slightly potentiated insulin-induced 
phosphorylation of Akt at Ser473 although significance could not be established (Fig.3.15B). 
Subsequently, at 48 hours, CRP significantly (p<0.001) inhibited insulin-induced phosphorylation of 
Akt at Ser473 by 54%. Similarly, CRP pre-treatment only had a significant (p<0.001) effect on total 
Akt protein levels at 48 hours by inhibiting its levels by 53% when compared to insulin treatment alone 
(Fig.3.15C). Finally, SAA had no significant (p>0.05) effect on Akt phosphorylation at Ser473 
(Fig.3.15B). However, the total Akt protein levels were significantly (p<0.05) decreased, by 56%, when 
BWTG3 cells were pre-treated for 48 hours with SAA before insulin exposure (Fig3.15C).  
As shown in Fig.3.15E, HepG2 cells pre-treated with PAI-1 caused a slight (1.3-fold) increase in the 
insulin-induced phosphorylation of Akt at Ser473 at 24 hours. This modest potentiation of PAI-1 was 
diminished at 48 hours, resulting in a significant (p<0.05) inhibition of insulin-induced phosphorylation 
by 25%. Unlike PAI-1, CRP attenuated insulin-induced Ser473 phosphorylation of Akt significantly 
(p<0.01) by 23% at 24 hours, which reached a maximum inhibition at 48 hours (40%) (p<0.001). In 
contrast, SAA was unable to affect the ability of insulin to induce Akt phosphorylation at Ser473 





(Fig.3.15F), although at 2 hours SAA and CRP did cause a slight increase, which decreased over time 
resulting in a similar effect in comparison to the insulin control.  
Finally, two-way ANOVA indicated that phosphorylation of Akt at Ser473 in BWTG3 (p<0.01) and 
HepG2 (p<0.001) cells as well as the total Akt levels in BWTG3 cells (p<0.05), but not HepG2 cells, 
are significantly dependent on both the selected APPs (PAI-1, SAA, and CRP) and the time of treatment.   
Taken together, these results indicate that an increase in exposure time to these APPs, especially PAI-1 











Figure 3.15. The APPs, PAI-1, CRP and SAA, decrease the phosphorylation of Akt at both Thr308 and 
Ser473 as well the total Akt protein levels over time in both the mouse (BWTG3) and human (HepG2) 
hepatoma cell lines. BWTG3 and HepG2 cells were serum-starved for 24 hours followed by 10 ng/ml PAI-1, 10 
µg/ml SAA and 4.5 µg/ml CRP treatment for 2, 24 and 48 hours (acute versus chronic exposure). The cells were 
treated with 100 ng/ml insulin for 30 minutes prior to cell lysis, to activate the insulin signalling pathway. 
Phosphorylation of Akt at Thr308 (A & D) and Ser473 (B & E) as well as total Akt protein expression (C & F) 
was measured and quantified relative to the loading control, EF-1α1 and Hsp90. The response of the APPs used 
was normalised relative to the insulin control, which was set to 1, and is represented as a dotted line. Data shown 
represents two independent experiments. Statistical analysis comparing the time treatments relative to the insulin 
control was performed using one-way ANOVA with Tukey’s Multiple Comparison’s Test 
(*p<0.05, **p<0.01, ***p<0.001). Additionally, the interaction between the time of treatment and the APP on the 
effect of the insulin receptor was analysed using a two-way ANOVA (#p<0.05, ##p<0.01, ###p<0.001). 
 
3.5 Pro-longed exposure to acute phase proteins, PAI-1, SAA 
and CRP regulate the mRNA expression of G6Pase and 
PEPCK 
De novo glucose synthesis (also known as gluconeogenesis) is a key process in the liver that is crucial 
for glucose metabolism. It is known that insulin inhibits this process in response to increased plasma 
glucose levels, in order to maintain homeostasis. A mechanism through which this occurs is the 
transcriptional regulation of two key gluconeogenic enzymes, G6Pase and PEPCK. Therefore, real-time 
PCR (qPCR) was performed to investigate the mRNA expression of the genes encoding these enzymes. 
In accordance with the previous section, which showed that the effects of the selected APPs, PAI-1, 
SAA, and CRP, are influenced by the length of exposure, mRNA expression levels were measured over 
time using the same chosen concentrations: 10 ng/ml PAI-1, 10 µg/ml SAA, and 4.5 µg/ml CRP. The 
same insulin treatment optimised upstream of the insulin signalling pathway was utilised. It should be 
noted that the mRNA expression of G6Pase could not be investigated in HepG2 cells due to difficulty 
experienced with the human G6Pase primers in this investigation, therefore due to limited time, G6Pase 
mRNA expression could only be investigated in BWTG3 cells. 
As expected for such a short treatment time, 100 ng/ml insulin exposure for 30 minutes had no 
significant (p>0.05) effect on G6Pase mRNA expression in BWTG3 cells (Fig3.16). Pre-treatment with 
PAI-1 significantly (p<0.05) increased the mRNA levels of this gene at all the time points investigated 
(Fig.3.16A). PAI-1 treatment for 2 hours was able to increase G6Pase mRNA levels by 3-fold. This 
fold increase of mRNA levels was maintained and kept relatively constant over time. In contrast, SAA 
and CRP was only able to induce G6Pase mRNA expression in BWTG3 cells when treated for 48 hours. 
SAA and CRP resulted in a 3.5-fold and 4.8-fold increase in G6Pase mRNA expression, respectively, 
at 48 hours treatment (Fig.3.16B and C).  
Although insulin had no effect on G6Pase mRNA expression in BWTG3 cells, 30 minutes exposure to 





relatively short exposure time to insulin in BWTG3 cells resulted in a 10-fold decrease in PEPCK 
mRNA levels (Fig.3.17A-C). PAI-1 and CRP could only attenuate the insulin-induced repression of 
PEPCK mRNA expression when pre-treated for 48 hours in BWTG3 cells (Fig3.17 A & C). The degree 
of attenuation at 48 hours between the two APPs differ, however. Treatment with PAI-1 for 48 hours 
resulted in a significant (p<0.001) 12.9-fold increase (Fig.3.17A) compared to insulin control, while 
CRP greatly inhibited insulin-induced repression of PEPCK mRNA expression by up to 225-fold 
(p<0.001) (Fig.3.17C). In contrast to PAI-1 and CRP, SAA at 2 hours already was able to attenuate the 
ability of insulin to inhibit PEPCK mRNA expression by 14-fold (p<0.001). This inhibition of insulin 
by CRP was, however, short lived as no significant difference (p>0.05) was observed between CRP 
pre-treatment and insulin alone (Fig.3.17B) at later time points.  
Furthermore, in HepG2 cells, 100 ng/ml insulin significantly (p<0.001) decreased PEPCK mRNA 
expression by 4-fold and pre-treatment with the selected APPs showed differential effects. Firstly, 
PAI-1 significantly (p<0.05) attenuated insulin-induced inhibition of PEPCK mRNA expression at 
24 hours (2.5-fold). Attenuation of insulin by PAI-1 was not observed at the other time points measured 
(Fig.3.17D). In contrast, SAA was unable to significantly affect insulin-induced inhibition of PEPCK 
mRNA expression (p<0.05) at any of the time points measured (Fig.3.17E). CRP, however, was able to 
attenuate (p<0.05) insulin-induced inhibition of PEPCK mRNA expression at all the time points 
measured. A maximal response was observed at 24-hours (13-fold), whereas 2 and 48 hours showed a 








Figure 3.16. The APPs, PAI-1, SAA and CRP, regulate the mRNA expression of the gluconeogenic gene, G6Pase, over time in the mouse hepatoma cell line, BWTG3. 
BWTG3 cells were serum-starved for 24 hours followed by a treatment with 10 ng/ml PAI-1 (A), 10 µg/ml SAA (B), and 4.5 µg/ml CRP (C) for 2, 24, and 48 hours (acute versus 
pro-longed exposure). The cells were treated with 100 ng/ml insulin for 30 minutes prior to cell lysis, to activate the insulin signalling pathway. The mRNA expression of the 
gluconeogenic gene, G6Pase, was measured using real-time qPCR and quantified relative to the housekeeping gene, GAPDH. The response of insulin was normalized to the 
vehicle which was set to 1 and is represented as a dotted line. The response of the APPs used was normalized to insulin. Data shown represents two independent experiments. 
Statistical analysis comparing insulin to the vehicle (p>0.05 = not significant) and the time treatments relative to the insulin control was performed using one-way ANOVA with 






Figure 3.17. The APPs, PAI-1, SAA and CRP, regulate the mRNA expression of the gluconeogenic gene, PEPCK, over 
time in both the murine and human hepatoma cell lines, BWTG3 and HepG2. BWTG3 and HepG2 cells were serum-starved 
for 24 hours followed by a treatment with 10 ng/ml PAI-1 (A & D), 10 µg/ml SAA (B & E) and 4.5 µg/ml CRP (C & F) for 2, 
24, and 48 hours (acute versus chronic exposure). The cells were treated with 100 ng/ml insulin for 30 minutes prior to cell lysis, 
to activate the insulin signalling pathway. mRNA expression of the gluconeogenic gene, PEPCK, was measured using real-time 
qPCR and quantified relative to the housekeeping gene, GAPDH (for BWTG3) and 18S and β-actin (for HepG2). The response 
of insulin was normalized to the vehicle which was set to 1 and is represented as a dotted line. The response of the APPs used 
was normalized to insulin. Data shown represents two independent experiments. Statistical analysis comparing insulin to the 
vehicle (***p<0.001) and the time treatments relative to the insulin control was performed using one-way ANOVA with Tukey’s 





3.6 Preliminary results show the effect of PAI-1, SAA and CRP 
on hepatic glucose production in BWTG3 & HepG2 cells 
In order to correlate the observed effect of PAI-1, SAA, and CRP on the transcriptional regulation of 
G6Pase and PEPCK, with hepatic glucose production (HGP), a fluororimetric assay was utilized to 
measure the extracellular glucose concentrations in the medium of BWTG3 and HepG2 cells, pre-
treated with 10ng/ml PAI-1, 10µg/ml SAA, and 4.5 µg/ml CRP for 48 hours. However, this assay 
needed to be setup and optimized in the research laboratory, which was done by the candidate (see 
Addendum B). As described in section 2.7, HGP was promoted in BWTG3 and HepG2 cells, by 
incubating the cells for 6 hours in medium (without glucose) containing gluconeogenic substrates, 
pyruvate and lactate. Preliminary results show that this 6 hour incubation induced the production of 
glucose as shown by the increase in extracellular glucose concentrations in the medium of the vehicle, 
previously lacking glucose, of BWTG3 and HepG2 cells (Table 3.1). Additionally, pre-treatment with 
the selected APPs had no significant effect on the ability of BWTG3 cells to synthesize de novo glucose, 
in comparison to the control (Table 3.1). In HepG2 cells, however, pre-treatment with 4.5 µg/ml CRP 
increased the extracellular glucose concentrations by 7.6-fold in comparison to the control (8.4- vs 
1.1 µM) although significance could not be established. This was not observed in the presence of 
10 ng/ml PAI-1 or 10 µg/ml SAA (Table 3.1).  
 
Table 5.1 Extracellular glucose concentrations measured in the medium of cultured BWTG3 and HepG2 
cells pre-treated with PAI-1, SAA and CRP for 48 hours.  
Glucose concentrations (µM±SD; n=2) 
 
BWTG3 HepG2 
Vehicle 3.8 ± 1.8 µM 1.1 ± 0.9 µM 
10 ng/ml PAI-1 4.0 ± 0.9 µM 1.6 ± 1.2 µM 
10 µg/ml SAA* 3.4 µM*  1.2 µM* 
4.5 µg/ml CRP 4.5 ± 0.7 µM 8.4 ± 3.2 µM 

















T2D affects 451 million people worldwide (2, 4) and is the second most important cause of death in 
South African adults (8, 9). As insulin resistance is the main risk factor for the development of T2D, it 
is thus important to investigate the molecular mechanisms that contribute to an insulin-resistant state. 
Herein, the peripheral target tissues (including the liver, skeletal muscle, and adipose tissue) is unable 
to respond normally to the physiological concentrations of insulin, leading to deficient insulin action in 
these tissues (67, 71). Thus, blood glucose concentrations rise, as insulin is unable to inhibit HGP and 
increase glucose uptake in adipose tissue and skeletal muscle. This leads to the characteristic 
hyperglycemia observed in T2D, as well as the compensatory hyperinsulinemia (154–156). These 
aforementioned effects occur as a result of an imbalance between the activation of key proteins or nodes 
in the insulin signalling pathway, which include the IR, IRS proteins, and Akt, and the negative 
regulation of the pathway which involves mainly the phosphorylation of the IRS proteins at their 
Ser/Thr residues (68, 154).  
It is well recognized that a chronic inflammatory state plays an important role in the development of 
insulin resistance (202, 203). Additionally, obesity, which is a known contributor to the development 
of insulin resistance, is described as a chronic inflammatory condition, therefore it is evident that 
chronic inflammation plays a role in the development of insulin resistance. A mechanism through which 
this may occur is via APPs, specifically PAI-1, SAA, and CRP as they are associated with chronic 
inflammation and are additionally used as biological markers for T2D (39, 206, 207). Although many 
human studies have shown that circulating levels of PAI-1, SAA, and CRP are elevated and also 
associated with T2D development (34, 35, 273, 36–38, 40, 41, 261, 268, 272), little research is available 
regarding the mechanism through which these APPs may contribute to the disease state. Additionally, 
as the liver plays an important role in the development of hyperglycemia and progression to T2D, an 
understanding of the molecular mechanism of hepatic insulin resistance, and how APPs may play a role 
in the development thereof, would be beneficial. Therefore, the main focus of this study was to elucidate 
whether PAI-1, SAA, and CRP could lead to the development of hepatic insulin resistance, specifically 
by inhibiting the activation of key nodes in the insulin signalling pathway. These include tyrosine 
phosphorylation and total expression of the IR and phosphorylation of Akt at both Thr308 and Ser473. 
Additionally, the role of these APPs in the negative regulation of the insulin signalling pathway was 
also investigated via the phosphorylation of IRS-2 at Ser731. The regulation of key gluconeogenic 
enzymes namely, PECK and G6Pase, responsible for HGP was also investigated to determine if the 





4.2 Validating the experimental model of insulin stimulation  
The activation of the insulin signalling pathway is initiated when insulin binds to its cognate receptor, 
the IR, resulting in the autophosphorylation of the receptor at its tyrosine residues (77, 80, 97, 332). An 
activated IR recruits IRS proteins, which become phosphorylated at their tyrosine residues and 
subsequently recruits PI3K. This eventually results in the activation of the central protein Akt via 
phosphorylation at both its Thr308 and Ser473 residue, by PDK-1 and mTORC2, respectively (Fig.3.1), 
resulting in full activation of the protein. Akt regulates glucose metabolism in the liver by regulating 
downstream targets, which include attenuating the transcription of key gluconeogenic enzymes, G6Pase 
and PEPCK, via the protein FoxO1. In contrast, phosphorylation of the IRS proteins at their serine 
residues inhibits the ability of the protein to bind to the IR thereby losing its ability to become activated 
and initiate further downstream signal transduction (149). Perturbations in the activation of IR, IRS, 
and Akt could lead to cells becoming resistant to insulin, which was of particular interest to this study, 
especially in regard to hepatic insulin resistance.  
HepG2 cells, a well-known cell line, has previously been described as a suitable cell model to 
investigate hepatic insulin signalling (333). However, to the best of our knowledge, insulin signalling, 
and its modulation has never been investigated using the BWTG3 cell line. It is for this reason that we 
had to optimise and validate our experimental model. Firstly, we were able to show that culturing 
BWTG3 cells in the traditional culture medium, containing 25 mM glucose (6 times higher than what 
is observed in serum (261) can negatively influence insulin signalling (Fig.3.2) as described by others 
in the literature (172, 328, 329). Culturing the cells in 5 mM glucose was found to be the most optimal 
in regard to the insulin sensitivity of the cells (Fig 3.2). Additionally, it was established that using 
100 ng/ml (~17 nM) insulin was sufficient for optimal activation of the insulin signalling pathway when 
compared to 500 ng/ml (~86 nM) insulin, which is similar to the 100 nM more commonly used in the 
literature (149, 260, 274, 287, 327) (Fig.3.2).  
Activation of the insulin signalling pathway was induced in both cell lines albeit to different degrees. 
For example, phosphorylation of Akt at Thr308 was 7 times less responsive to insulin in BWTG3 cells 
compared to the HepG2 cell line (Table 4.1), whilst Ser473 phosphorylation of Akt was slightly more 
pronounced in the BWTG3 cells. This could suggest that PDK1, responsible for Akt phosphorylation 
at Thr308, is more active in HepG2 cells, whereas mTORC2, which causes phosphorylation of Akt at 
Ser473 might be more effective in the BWTG3 cell line (Fig.3.1). Furthermore, PEPCK mRNA levels 
were downregulated to a greater extent in BWTG3 cells compared to the HepG2 cell line upon insulin 
treatment for 30 minutes, most probably due to the more pronounced Ser473 phosphorylation of Akt in 
the murine hepatoma cells (Table 4.1). Although, a rapid decline in mRNA transcript levels of PEPCK 
has been previously documented (129, 334, 335), to the best of our knowledge a 10-fold decrease in 





levels in BWTG3 cells, which suggest that this effect may require a longer insulin treatment in order to 
observe a significant response, which has been previously shown in rat hepatoma cells treated for 4 
hours with insulin (336).  
Table 6.1. Summary table of the insulin-stimulated response on key proteins in the insulin 
signalling pathway observed in BWTG3 and HepG2 cells 
 
 
In summary, we could establish an optimal treatment regime allowing us to investigate insulin 
signalling in liver cell models. Both BWTG3 and HepG2 cells were significantly responsive to insulin 
and allowed us to examine how APPs would affect insulin signalling. 
4.3 Effects of APPs on hepatic insulin signalling   
The insulin signalling pathway is a complex signalling cascade consisting of various nodes. These nodes 
affect each other as well as other signalling proteins and molecules. Disruption of any of these nodes 
could negatively affect downstream effects induced by insulin. Insulin resistance is defined as the 
disruption of peripheral insulin signalling (13) and the inhibition of Akt, a central node in the insulin 
signalling pathway, is described by many researchers as indicative of an insulin resistant state (128, 
337), although many other downstream nodes exist, which include GSK, FoxO1, and mTORC1, that 
could be modulated to induce insulin resistance. Nonetheless, for the purpose of this study and to omit 
confusion insulin resistance induced by the APPs is presumed when activation of Akt is impaired. Thus, 
having established the experimental model system for optimal insulin signalling activation in the two 
liver cell lines: BWTG3 and HepG2, the next step involved investigating how APPs, specifically PAI-1, 
SAA, and CRP, influence critical nodes in the insulin signalling pathway. As previously mentioned, 





levels reflect a state of inflammation, play a role in the development of insulin resistance and 
subsequently T2D is not well defined in the literature, especially in regard to hepatic insulin resistance. 
Many believe increased APP levels is due to an already established insulin resistance state (67), and 
thus information on how these APPs affect the progression of insulin resistance is limited. This study 
aimed to add to the body of knowledge regarding the role that these biological markers of T2D play in 
establishing an insulin resistant state. In the previous chapter (Chapter 3) we show that the selected 
APPs differentially regulate various key nodes in the insulin signalling pathway, which correlates with 
the regulation of important gluconeogenic enzymes that could affect hepatic de novo glucose 
production. Here we will focus on how this conclusion was reached and how these results compare to 
the literature. 
4.3.1 PAI-1 differentially affects hepatic insulin signalling in a dose- 
and time-dependent manner 
PAI-1 is a strong predictor of T2D development as described by Festa and colleagues (34, 35). This 
APP is increased moderately during the APR, in response to inflammatory stimuli and is known to play 
a role in tissue remodelling as well as blood clot formation (213, 226). The role of PAI-1 in general 
biology ties into its association with various disease states, such as obesity and cardiovascular disease 
(234). For instance, it has been well established that PAI-1 plays a role in the development of obesity 
by modulating adipocyte differentiation (242–244), which may be facilitated by its ability to inhibit the 
degradation of extracellular matrix components (an important process during adipocyte differentiation). 
As obesity is a known contributor to the development of insulin resistance and T2D, it is therefore 
deemed important to investigate the role of PAI-1 in the development of insulin resistance. It has 
previously been established that elevated PAI-1 levels is a core feature of insulin resistance and 
numerous studies have linked PAI-1 to its development, as described in Chapter 1 (Table 1.4). For 
example, PAI-1 is associated with altered glucose metabolism and hyperglycemia in mice (173, 245, 
246, 252, 254). However, little is known about how or if it contributes to the development of the disease 
state, in addition to the possible molecular mechanism involved.  
A wide range of PAI-1 concentrations have been reported in healthy individuals as well as T2D patients. 
In healthy individuals, PAI-1 levels ranging between 9.4 ng/ml-34 ng/ml (34, 35, 235, 236, 251) have 
been reported, whilst PAI-1 levels of ±24 ng/ml have been described in T2D patients (34). Furthermore, 
mice fed a high-fat diet showed elevated PAI-1 levels of up to 6.92 ng/ml (252). Taking into 
consideration that both a mouse and human liver cell line was utilized in this study, a concentration 
range of 5, 10, and 20 ng/ml was chosen. In addition, we were also guided by the literature to 
use10 ng/ml PAI-1 as it has been used previously in an in vitro study investigating the effect of PAI-1 





range found in circulation and could thus demonstrate the effects of PAI-1 levels in normal circulation 
on the insulin signalling pathway.  
PAI-1 in the current study, was able to induce insulin resistance in both liver cell lines although to 
different extents. The murine liver cell line was more sensitive to PAI-1-induced inhibition of the insulin 
signalling pathway (Table 4.2 & 4.3), although the highest concentration used (20 ng/ml) potentiated 
insulin-induced phosphorylation of Akt at Ser473, probably as a result of the increase in IR 
phosphorylation observed at this concentration (Fig.3.5A). The HepG2 cell line was less sensitive to 
PAI-1, with only 20 ng/ml, the highest concentration used, able to attenuate insulin signalling at 
24 hours. Similarly, Tamura et al., (254) reported decreased phosphorylation of Akt at Ser473 by PAI-1 
in HepG2 cells at 24 hours using 860 ng/ml PAI-1, 43 times more concentrated than what was used in 
the current study, suggesting that this cell line is less responsive to PAI-1. Nonetheless, the degree of 
Akt attenuation by PAI-1 increased over time (Table 4.4), reaching maximum inhibition at 48 hours in 
both liver cell lines (Fig.3.15B & E & Table 4.4). Indeed, treatment with 10 ng/ml PAI-1 for 48 hours 
attenuated all markers investigated, in BWTG3 cells (Table 4.5). However, Akt phosphorylation at 
Thr308 was not much affected by longer PAI-1 exposure in HepG2 cells (Fig.3.15), suggesting that 
PAI-1 might target Akt Ser473 specific phosphatases like PHLPP (see Chapter 1), thus preventing Akt 
from becoming fully activated. Future studies could investigate whether PAI-1 affects the protein levels 
and activity of Akt Ser473 phosphatases. Nonetheless, the inhibition of Akt by PAI-1 correlates with 
the increase in mRNA levels of the gluconeogenic enzymes, G6Pase and PEPCK in response to PAI-1 
treatment (Table.4.4), as shown by Tamura and colleagues (254). It is therefore surprising that in this 
study PAI-1 was not able to induce HGP in both liver cell lines used (Table 3.1). However, the increase 
in glucose production was consistently higher than the control, albeit very small, which might indicate 
that longer exposure to PAI-1 could significantly affect HGP as suggested by the late attenuation of 
insulin-induced repression of PEPCK mRNA expression by PAI-1 in both liver cells used (Fig. 3.17). 
And although PAI-1 could not affect HGP, possibly due to the length of PAI-1 exposure, these results 
suggest that PAI-1 could influence the development of hepatic insulin resistance by disrupting the 
insulin signalling pathway.     
4.3.2 SAA differentially affects hepatic insulin signalling in a 
concentration- and cell-line-dependent manner 
SAA is a major APP that is increased rapidly in response to inflammation during the APR, and is thus 
a sensitive marker of inflammation (217, 219). Additionally, this protein is also a biological marker of 
T2D as well as a marker of obesity, like PAI-1. Indeed, SAA was reported to play a role in the 
development of obesity by modulating adipocyte differentiation (260, 269). It has also been questioned 
whether SAA may link the APR to obesity and insulin resistance (269). The role of SAA in the 





effect of SAA on the development of hepatic insulin resistance (Chapter 1, Table 1.5). SAA has been 
shown to decrease GLUT4 mRNA expression in 3T3-L1 adipocytes (263, 274) and chronic exposure 
to 5-20 µg/ml SAA decreased glucose uptake in these cells (260, 274). Physiological levels as well as 
the concentrations used in previous in vitro studies was considered when choosing the SAA 
concentrations used in this study. The normal physiological levels of SAA range between 1-5 µg/ml, 
and elevated levels range between 2.1-24 µg/ml in obese and T2D individuals (37, 38, 263, 267, 268, 
272, 273). Additionally, taking into consideration that previous in vitro studies utilized SAA 
concentrations ranging between 1-30 µg/ml (260, 269, 271, 274), concentrations of 5, 10 and 20 µg/ml 
was decided upon.  
The results in this study showed that SAA was able to decrease the activation of the insulin signalling 
pathway in both murine and human liver cell models, however this effect was variable and dependent 
on the node investigated in the insulin signalling pathway (Table 4.2 & 4.3). The phosphorylation of 
Akt at either Thr308 or Ser473 generally coincides with the inhibition of either the IR or IRS, suggesting 
that the decrease in Akt could be attributed to the modulation of upstream signalling proteins. This 
modulation entails either decreasing total protein levels or inhibiting its activation. For example, in 
BWTG3 cells, decreased Akt phosphorylation at Ser473 by 20 µg/ml SAA correlates with increased 
IRS-2 phosphorylation at Ser731 indicative of its deactivation even though an increase in IR activation 
(phosphorylation at Tyr1150 &1151) was observed (Table 4.2).  
Unfortunately, 10 µg/ml SAA was unable to attenuate insulin signalling over time (Table 4.4) in both 
cell lines used, in contrast to the dose response experiment in which the cells were exposed to SAA for 
24 hours. G6Pase mRNA expression did however increase in response to 48 hours SAA treatment, 
whilst the repression of PEPCK mRNA levels by insulin was attenuated at 2 hours only. The variability 
of the SAA time course, however, brings into question its reliability. Because the time course 
experiments were performed after the dose response studies, we speculate that the stock SAA used 
might have degraded and became less effective over time, even when kept stored in aliquots at -20°C. 
The degraded SAA could also have affected HGP as SAA was unable to stimulate de novo glucose 
production (Table 3.1). Further experiments using freshly prepared SAA will be required to validate 
this hypothesis.  
Nonetheless, the dose response experiments did establish that SAA has the ability to induce hepatic 
insulin resistance (Table 4.2 & 4.3). This is the first study, to the best of our knowledge, to investigate 
the effect of SAA on hepatic insulin signalling, as well as on the activation of the IR and Akt. Previous 
studies have shown that SAA decreased the mRNA expression (271) as well as tyrosine phosphorylation 
of IRS-1 (274) in 3T3-L1 adipocytes. In addition, Ye et al., has shown in 3T3-L1 adipocytes that 
treatment with 20 µg/ml SAA for 48 hours increased the phosphorylation and thus activation of JNK, a 





the increase in IRS-2 phosphorylation at Ser731 in the BWTG3 cells treated with 20 µg/ml SAA (Fig 
3.7B & Table 4.2). Future studies should include the effect of SAA on JNK activation in addition to 
other MAPKs. We could conclude from these results that SAA modulates insulin signalling in liver cell 
models, which might influence the development of hepatic insulin resistance and that caution should be 
exercised when working with SAA as it appears to degrade in solution over time.  
 
Table 4.2. Summary table of the effect of a 24-hour treatment with PAI-1, SAA, CRP on 
insulin-stimulated activation of key proteins in the pathway in BWTG3 cells (Data from Figs 
3.5, 3.7, 3.9 & 3.10).  
 
 
Table 4.3. Summary table of the effect of a 24-hour treatment with PAI-1, SAA, CRP on 
insulin-stimulated activation of key proteins in the pathway in HepG2 cells (Data from Figs 






4.3.3 CRP is the most effective APP in inhibiting hepatic insulin 
signalling 
CRP, a major APP, is increased rapidly in response to inflammatory stimuli during the APR. It is a 
sensitive marker of inflammation as well as an indicator for T2D (39, 338) with the progression to T2D 
connected to increased CRP levels. The increased levels of CRP observed in T2D patients (34, 36, 39–
41, 268, 273), played a role in the experimental design of this study. The serum concentrations of CRP 
reported in patients with T2D varies, with levels ranging from 2.4 µg/ml-6.1 µg/ml (34, 36, 39, 41, 268, 
273). CRP levels between 2 and 10 µg/ml are also seen in metabolic inflammatory states (219), thus 
concentrations in this range was considered suitable for this investigation. It should however be noted, 
that these concentrations indicate a median range and thus does not reflect true concentrations observed 
in these disease states. Nonetheless, concentrations of 2.5 and 4.5 µg/ml CRP was chosen in this 
investigation to determine whether CRP could contribute to the development of insulin resistance in 
two liver cell lines.  
CRP is shown to significantly inhibit the insulin signalling pathway in this study, by mainly affecting 
both the IR and Akt in both murine and human liver cell models. Generally, CRP acted similarly in both 
cell lines used with some differences observed. In BWTG3 cells, treatment with both concentrations of 
CRP for 24 hours, decreased the insulin-induced phosphorylation of the IR at Tyr1150 & 1151, while 
having no effect on the total IR levels as well as the Ser473 phosphorylation of Akt (Table 4.2). Only, 
4.5 µg/ml CRP decreased the Thr308 phosphorylation of Akt, while increasing the total Akt levels 
(Table 4.2). In HepG2 cells, both concentrations of CRP decreased the insulin-induced activation of all 
of the nodes investigated which include, total IR expression as well as phosphorylation of Akt at both 
Thr308 and Ser473, while having no effect on total Akt levels (Table 4.3). The decrease in Akt 
phosphorylation could be attributed to the decrease in the upstream activation of the IR as observed in 
BWTG3 cells or the decrease in total IR expression as shown in HepG2 cells (Table 4.2 & 4.3). 
Although demonstrating slight species specific differences, these results are in agreement with a report 
by Xi et al., (289) who concluded that CRP plays a significant role in the development of hepatic insulin 
resistance both in vivo (in rats) and in vitro (in primary cultured rat hepatocytes). However the authors 
only observed a decrease in Akt phosphorylation at Ser473 in response to CRP, while Thr308 was 
unaffected as well as total Akt levels (289), which is in contrast to the results observed in the current 
study (Table 4.2 and 4.3). These authors did however treat with a higher concentration of CRP 
(30 µg/ml) for a shorter period (150 minutes), which may explain the differences observed between 
studies. Furthermore, CRP was also shown to decrease the phosphorylation of Akt at both residues in 
rat skeletal muscle cells and bovine aortic endothelial cells (287, 288), which is in agreement with the 
results observed in the current study and suggests that the effect by CRP on the insulin signalling 





As previously mentioned, IRS phosphorylation at its serine residues is believed to inactivate this adaptor 
protein, disrupting any further downstream signal including the activation of Akt. And although CRP 
was able to inhibit insulin-induced phosphorylation of Akt, both concentrations of CRP decreased the 
phosphorylation of IRS-2 at Ser731 in both liver cell lines, which is surprising as CRP has been shown 
to induce the phosphorylation and thus activation of, JNK and ERK1/2 (287–289). These kinase 
proteins are known to induce the serine phosphorylation of the IRS proteins (144, 148). Previous studies 
have also reported that CRP increased the phosphorylation of IRS-1 at Ser307 and Ser612 in L6 
myotubes (rat skeletal muscle) (287), primary cultured rat hepatocytes (289), and bovine aortic 
endothelial cells (288). However, it could be postulated that the observed decrease in the Ser731 
phosphorylation of IRS-2 may be due to a decrease in total IRS-2 expression. This could however not 
be confirmed at protein level, due to difficulty experienced with the commercially available antibody, 
but qPCR analysis revealed that, over time, in both BWTG3 and HepG2 cells, IRS-2 mRNA levels 
increased in response to CRP treatment (Addendum A, Fig.A5). And although CRP was unable to 
deactivate IRS-2, it appears not to have affected the ability of CRP to inhibit Akt phosphorylation (Table 
4.2 & 4.3).  
The inflammatory state associated with insulin resistance and T2D is considered to be chronic. For this 
reason, we wanted to investigate how longer exposure to the APPs affect the ability of the liver cell 
models to become insulin resistant. “Acute” exposure was considered to be 2 hours treatment, whilst 
48 hours were considered “chronic”. The ability of CRP to attenuate the insulin signalling pathway is 
shown to be time-dependent as pro-longed (chronic) exposure to CRP decreased the insulin-induced 
activation of all the nodes investigated as well as their total protein levels in both BWTG3 cells, 
specifically, and Akt in HepG2 cells (Table 4.4 and 4.5). The decrease in insulin-induced 
phosphorylation of Akt at both residues observed in BWTG3 cells in response to chronic CRP treatment 
may be due to the 53% decrease in total Akt levels in addition to a significant decrease in total IR 
(Table 4.5). However, at 2 hours treatment with CRP in HepG2 cells, decreased Akt phosphorylation 
at Thr308 was already observed, which only became more pronounced over time (Fig.3.15D). The 
decrease in Akt phosphorylation at Thr308 in HepG2 cells was subsequently followed by a decrease in 
Ser473 Akt phosphorylation although no significant effect on total IR and Ser731 IRS-2 
phosphorylation was observed (Table 4.4). This would suggest that Akt inhibition in the HepG2 cells 
does not involve these upstream signalling proteins. Directly upstream from Akt is PI3K, which might 
be inhibited by CRP resulting in decreased Akt activation as total Akt levels were unaffected by CRP 
in HepG2 cells (Fig.3.15F & Table 4.5). In addition, CRP might affect PTEN or SHIP2, phosphatases 
responsible for converting PIP3 to its precursor PIP2 thereby antagonising PI3K signalling and 
subsequently Akt activation (64, 82) in HepG2 cells. Furthermore, phosphatases which directly affects 
Akt phosphorylation, such as PHLPP and PP2A, could be influenced by CRP. Future studies should 





This attenuation of the insulin signalling pathway culminated in the increase in PEPCK mRNA levels 
(Fig.3.17E & F). In addition to increasing PEPCK mRNA levels in both BWTG3 and HepG2 cells 
(Table 4.4 & 4.5), pro-longed exposure to CRP also increased G6Pase mRNA expression in the BWTG3 
cell line. Although chronic exposure to CRP increased PEPCK mRNA levels to a greater extent in 
BWTG3 vs HepG2 cells (Table 4.5), an increase in HGP was only observed in HepG2 cells (Table 3.1). 
Further HGP experiments, however, need to be conducted due to the assay not being fully optimised 
due to time constraints. In summary, chronic exposure to CRP induced hepatic insulin resistance in both 
BWTG3 and HepG2 cells, by causing an overall decrease in the ability of insulin to activate key proteins 
in the insulin signalling pathway, such as the IR and Akt, which correlates with the ability of CRP to 
upregulate G6Pase mRNA levels and attenuate insulin induced inhibition of PEPCK (Fig.3.16 & 3.17).   
Of all the APPs examined, CRP was the most effective in attenuating insulin signalling over time as 
summarised in Table 4.5 in the liver cell models. This strengthens the findings by the Women’s Healthy 
Study (40), which associated increased CRP levels in healthy women with the development of future 
T2D. In addition, this highlights the role of CRP as beyond that of just biological marker for T2D, but 
also as a possible causative agent of the disease.  
 
Table 4.4. Summary of the overall effects of PAI-1, SAA and CRP over time on insulin-stimulated activation of key proteins 
in the insulin signalling pathway as well as downstream regulation of G6Pase and PEPCK mRNA, in BWTG3 and HepG2 











4.4 Conclusions and Future work 
To conclude, all three APPs investigated affected insulin signalling albeit to different degrees depending 
on the dose and length of exposure (Tables 4.2, 4.3 & 4.4) in the liver cell models. Generally longer 
exposure to the APPs appeared to be most effective in establishing hepatic insulin resistance except for 
SAA (Table 4.4). The modulating effect of the APPs on critical nodes of the insulin signalling pathway 
corresponds to the ability of the APPs to increase G6Pase mRNA levels and inhibit insulin-induced 
repression of PEPCK mRNA. These results imply that PAI-1, SAA, and CRP are capable of establishing 
an insulin resistant state affecting HGP that could result in hyperglycaemia, a characteristic of T2D. 
Thus, our hypothesis that PAI-1, SAA and CRP negatively affect the insulin signalling pathway, leading 
to deficient insulin action is accepted. To the best of our knowledge, this study is the first to show the 
direct effects of PAI-1, SAA and CRP on the activation of the insulin signalling pathway in hepatoma 
cell lines, thus establishing their role in the development of hepatic insulin resistance. Additionally, this 
study highlights the differences between these APPs in terms of their inhibitory effects on hepatic 
insulin signalling.  
In order to improve our understanding of the role of PAI-1, SAA and CRP in the development of hepatic 
insulin resistance, this study can be extended to investigating the possible mechanisms of the observed 





pathway, such as JNK and ERK1/2, which is known to induce the serine phosphorylation of the IRS 
proteins (64, 82, 118, 144, 148). As well as tyrosine phosphatases such as PTP1B, which is an essential 
component inhibiting the insulin receptor (82, 131). Furthermore, investigating the effects of PAI-1, 
SAA and CRP on PDK-1 and mTORC2 can provide insight into the regulation of Akt activation at 
Thr308 and Ser473 by these APPs as observed in Chapter 3. Finally, as the insulin-induced suppression 
of gluconeogenesis is mediated by the transcription factor FoxO1, future studies could aim to 
investigate the effect of  PAI-1, SAA and CRP on the phosphorylation, and thus inhibition, of FoxO1, 
which could provide context to the observed attenuation of insulin’s inhibition of G6Pase and PEPCK.  
Factors influencing APP levels such as obesity, inflammation, and stress are known to cause insulin 
resistance and the development of T2D (22, 23, 179, 180, 185, 186, 194, 204, 205, 24, 25, 167, 170–
172, 175, 176). This study raises the question of whether these physiological conditions affect insulin 
signalling via the production of APPs such as PAI-1, SAA, and CRP. It would explain why pro-
inflammatory cytokines and GCs, known antagonists of each other’s activity, are associated with insulin 
resistance as they have been reported to co-operatively upregulate APP expression (26, 28–33). Future 
work should thus entail linking pro-inflammatory cytokines- and GC-induced insulin resistance to the 
APPs, providing insight into a possible novel mechanism explaining the development of this disease in 
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A1. BWTG3 and HepG2 cells used in this study were mycoplasma negative.
 
Figure A1. Mycoplasma negative BWTG3 (A) and HepG2 (B) cells. Cells were fixed with methanol and glacial acetic acid 
in a 3:1 ratio before staining with the DNA Hoechst 33258 dye (Sigma-Aldrich, SA). The Hoechst-dye only stain DNA-
containing nuclei. Fluorescent images were obtained using the Olympus XI81 inverted fluorescent microscope. 
 
A2. RNA isolated from BWTG3 and HepG2 cells were intact.
 
Figure A2. Representative 1% denaturing agarose gel indicating intact RNA isolated from BWTG3 and HepG2 cells. 
Total RNA was isolated from BWTG3 (A) and HepG2 (B) cells treated with either vehicle (DMEM-full) (Lane 1), 100 ng/ml 
insulin (Lanes 2 & 3), 10 ng/ml PAI-1 (Lanes 4-6), 10 µg/ml SAA (Lanes 7-9) and 4.5 µg/ml CRP (Lanes 10-12) for 2, 24 and 
48 hours. RNA was isolated using Tri-reagent as described in Chapter 2, section 2.3. A total of 1 µg RNA was loaded onto the 






 A3. The correct qPCR products were confirmed with agarose gel electrophoresis. 
 
Figure A3. Representative agarose gels indicating qPCR products of mouse (A-D) and human genes (E-H) used in this study. 
PCR products were subjected to agarose (2% w/v) gel electrophoresis and visualised with Nancy-520 nucleic acid stain. M: 
O’GeneRuler 1kB (B & G) or 100bp (A, C-F, H) DNA ladder (ThermoFisher Scientific, USA); S: sample treated with vehicle 





A4. Fluorescence measured of the fluorescent product, resorufin, in the medium of 
the BWTG3 and HepG2 cells pre-treated with PAI-1, SAA and CRP for 48 hours. 
 
Figure A4. Fold increase in fluorescence measured of the fluorescent product, 
resorufin, in the medium of BWTG3 and HepG2 cells. BWTG3 and HepG2 cells were 
serum-starved for 24 hours, followed with a pre-treatment with 10 ng/ml, 10 µg/ml SAA 
and 4.5 µg/ml CRP for 48 hours. In the final hour of the APP pre-treatment, the cells were 
treated with 100 ng/ml insulin for 1 hour. The cells were washed twice with 1X pre-warmed 
PBS and incubated with glucose production buffer (containing 20 mM sodium lactate and 
2 mM sodium pyruvate as substrates for gluconeogenesis) for 6 hours, in the presence of 
the test compounds (10 ng/ml, 10 µg/ml SAA and 4.5 µg/ml CRP) as well as 100 ng/ml 






A5. IRS-2 mRNA expression in BWTG3 and HepG2 cells showing effects of selected APPs, PAI-1, SAA 
and CRP at different lengths of exposure.
 
Figure A5. IRS-2 mRNA expression measured in BWTG3 and HepG2 cells using qPCR analysis, showing effects of 
selected APPs at different treatment times. BWTG3 and HepG2 cells were serum-starved for 24 hours followed with a 
treatment with 10 ng/ml PAI-1, 10 µg/ml SAA and 4.5 µg/ml for 2, 24 and 48 hours (acute versus chronic exposure). The cells 
were treated with 100 ng/ml insulin for 30 minutes prior to cell lysis, to activate the insulin signalling pathway. mRNA 
expression of the IRS-2 gene was measured using real-time qPCR and quantified relative to the housekeeping gene, GAPDH 
(for BWTG3) and 18S and β-actin (for HepG2). Data shown represents two to three independent experiments, except (E) which 
shows one independent experiment. Statistical analysis comparing insulin to the vehicle (*p<0.05) and the time treatments 













OPTIMISING A TECHNIQUE TO MEASURE 
EXTRACELLULAR GLUCOSE CONTENT OF 





Glucose detection method: AmpliFlu/Glucose oxidase assay 
In order to measure and quantify the extracellular glucose content in the medium of BWTG3 and HepG2 
cells, the principles of the Amplex Red/Glucose oxidase kit (ThermoFisher Scientific) was followed. This 
kit makes use of two enzymes: glucose oxidase (GOD) and peroxidase (POD) to convert the available 
glucose in the medium to a detectable product. For this, two reactions occurs: firstly, glucose oxidase 
catalyzes the conversion of glucose to D-gluconolactone and H2O2. Secondly, the oxidation of the 
substrate Amplex Red, by H2O2 to the fluorescent product resorufin, is catalyzed by horse radish 
peroxidase (HRP) (324, 325). Resorufin has a fluorescence excitation and emission maxima at 571 nm 
and 585 nm, respectively, which is measured with a fluorescence microplate reader.  
In order to optimize a method in the research laboratory that is based on these principles, the limitations 
of this reaction had to be considered. For instance, the absorption and fluorescence of resorufin is pH-
dependant, and a pH of 7.4 is recommended. As the Amplex/Red Glucose oxidase kit made use of a 50 
mM sodium phosphate buffer (pH 7.4), we decided to test using PBS (pH 7.34) and the glucose production 
buffer (pH 7.3) as diluents. The background fluorescence of these solutions was additionally monitored. 
The glucose production buffer produced a consistent background whereas the background fluorescence 
of the PBS was variable between experiments. Therefore, the glucose production buffer was used as a 
diluent for the preparation of the working reagent which contains the AmpliFlu, GOD and HRP, in 
subsequent experiments. Additionally, although the difference between AmpliFlu and Amplex Red was 
not defined in literature, a paper by Csepregi et al. (339) optimized a method of detecting resorufin, 
following the principles of the Amplex Red/Glucose oxidase kit using AmpliFlu. In this paper, the authors 
prepared a working reagent with 16 µM AmpliFlu, 4.5 µU/ml GOD and 0.13 µU/ml POD. Herein, they 
measured the intracellular glucose content of HepG2 cells, in which glucose uptake was inhibited. 
However, when we tested these concentrations of the reagents to measure the extracellular glucose 
content of BWTG3 and HepG2 cells, inconsistent results were produced with no change between the no-
glucose control and the glucose containing medium/samples. Therefore, we decided to test the 
concentrations used in the Amplex Red/Glucose oxidase kit. A working reagent was prepared in glucose 
production buffer containing: 10 µM AmpliFlu, 2U/ml GOD and 0.2 U/ml HRP. Prior to testing the 
BWTG3 and HepG2 samples, we prepared glucose standards in a concentration range of 4-40 µM, in 
glucose production buffer. 50 µl of these standards were added to a 96-well microplate with 50 µl of the 
aforementioned working reagent (1:1 ratio), which produced a glucose concentration range between 2-20 
µM. These concentrations of ᴅ-glucose were chosen as the GOD-POD reaction can detect as little as 3 
µM glucose as described in the Amplex Red/Glucose oxidase kit and by Csepregi et al. (339). A glucose 
standard curve was produced (Fig.B1), with glucose concentrations ranging between 2-20 µM, and 





B1. Standard curve of ᴅ-glucose in a concentration range of 2-20 µM.   
 
Figure B1. Standard curve produced using glucose concentrations ranging from 2-20 
µM. ᴅ-Glucose in concentrations 4-40 µM was incubated with 10 µM AmpliFlu, 2 U/ml 
GOD and 0.2 U/ml HRP, in glucose production buffer, in a 1:1 ratio, at room temperature for 
30 minutes. Fluorescence of the reaction product, resorufin, was measured at an excitation of 
571 nm and emission of 585 nm Background fluorescence, determined for a no-glucose 
control reaction, was subtracted from each value. The black line represents the standard curve 
produced and the red line represents the non-linear fit of the curve.   
 
The standard curve produced indicated that concentrations of the reagents, used in the Amplex 
Red/Glucose oxidase kit, was conducive to detect glucose concentrations in this range. Therefore, 10 µM 
AmpliFlu, 2 U/ml GOD and 0.2 U/ml HRP was used to detect the glucose content in the medium of 
BWTG3 and HepG2 in following experiments (Fig.A4). The glucose concentrations in each BWTG3 and 
HepG2 sample was measured by interpolating the fluorescence readings of each sample (Fig.A4) in to 
the standard curve produced (Fig.B1), using the GraphPad Prism® version 5 software.   
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